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ABSTRACT 
Nathan D. Pfeifer:  Impact of Hepatic Transporter Multiplicity and Loss-of-Function on  
Hepatocellular Distribution and Excretion of Drugs 
(Under the direction of Kim L.R. Brouwer) 
 
 The objective of this research project was to develop preclinical and clinical tools to assess 
hepatocellular exposure and multiplicity of transport.  A variety of model systems were employed, 
including membrane vesicles, sandwich-cultured hepatocytes (SCH), rat isolated perfused livers (IPLs), 
and in vivo human studies; a truly translational approach.  This research focused primarily on three drugs 
to evaluate transporter function: 99mTechnetium-mebrofenin (MEB), ritonavir (RTV), and rosuvastatin 
(RSV).  A semi-physiologically-based pharmacokinetic (semi-PBPK) modeling and in vitro systems 
translational approach suggested a transporter-mediated drug-drug interaction (DDI) between MEB and 
RTV at both hepatic and extrahepatic sites of MEB distribution, observed using a novel clinical protocol.  
Rather than a specific multidrug resistance-associated protein (MRP) 2 probe, this clinical study 
demonstrated the utility of MEB as a model organic anion to evaluate DDIs in overall (uptake and efflux) 
transporter-mediated hepatobiliary clearance.  A novel application of classic approaches to determine 
whole tissue distribution (differential centrifugation, equilibrium dialysis) was investigated with a set of 
probe drugs in the SCH model system, highlighting the finding that total tissue accumulation and 
intracellular unbound concentrations can be predicted using SCH, including the relative contribution of 
active transport vs. binding/sequestration as potential mechanisms of hepatocellular accumulation.  A 
novel uptake and efflux protocol in SCH, coupled with pharmacokinetic modeling, was developed in 
order to elucidate the relative contribution of basolateral and biliary efflux to the hepatocellular 
elimination of RSV.  This approach, along with IPL data, revealed that basolateral and biliary efflux 
represent alternative pathways with a quantitatively similar contribution to total hepatocellular excretion 
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of RSV; the role of basolateral efflux in the hepatocellular disposition of RSV has not been investigated 
previously.  RSV transport was evaluated in human SCH and membrane vesicles prepared from MRP3- 
and MRP4-overexpressing cells, demonstrating that RSV is an efficient MRP4 substrate.  This research 
resulted in a number of important and novel contributions to the preclinical and clinical “toolkit” 
available to study hepatic drug disposition.  These developments will significantly enhance the ability to 
assess and predict altered hepatobiliary drug disposition due to DDIs, genetic variation and/or disease 
states, and will ultimately lead to improved safety and efficacy of medications. 
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CHAPTER 1 
 
Introduction 
 
Role of Hepatic Efflux Transporters in Regulating Systemic 
and Hepatocyte Exposure to Xenobiotics 
Introduction 
The liver is arguably the single most important organ for drug disposition, serving as the primary 
site of drug metabolism in the body, providing a “gatekeeper” function for systemic exposure following 
first-pass of portal blood, and being one of the major routes for final elimination of substances from the 
body.   Compounds are presented to hepatocytes via sinusoidal blood, and gain access to the intracellular 
space by passive diffusion and/or active uptake mediated by transport proteins expressed on the 
basolateral membrane.  The propensity and relative contribution of these mechanisms depends largely on 
physicochemical properties of the compound.  Once inside hepatocytes, the fate of compounds depends 
on susceptibility to the diverse strategies available for the cell to regulate concentrations of useful and 
potentially harmful chemicals constantly present in the cellular milieu.  This includes subcellular 
sequestration and mechanisms of elimination, such as biotransformation (metabolism) and/or excretion.  
It has become clear that transport proteins are responsible for the hepatocellular disposition of highly 
polar or charged drugs and metabolites, which cannot exit hepatocytes at a sufficient rate without the aid 
of an active efflux mechanism. 
This review provides a summary of transporter-mediated efflux of drugs and metabolites from 
 
 
This work will be published, in part, in Annual Review of Pharmacology and Toxicology (ARPT) 
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hepatocytes into sinusoidal blood and/or bile.  The impact of altered transport function, resulting from 
drug-drug interactions (DDIs), genetic variation and disease states, on systemic and hepatic exposure is 
discussed.  Related issues including multiplicity of transporters, interplay of metabolism and transport, 
and model systems used to elucidate the role of hepatic efflux on drug disposition are addressed and 
updated with recent contributions to this area of active research. 
Canalicular Efflux  
Canalicular efflux transporters include several well-known drug transporters such as ABCB1 (P-
gp; MDR1), ABCC2 (MRP2), and ABCG2 (BCRP); in addition, ABCB11 (BSEP), ABCB4 (MDR3), 
ABCG5/G8, and SLC47A (MATE1) are responsible for bile acid, phosphatidylcholine, and sterol 
excretion(1-3). MRP2, BCRP, and P-gp are important determinants of biliary excretion of organic anions, 
organic cations, and Phase II xenobiotic products including glutathione, glucuronide, and sulfate 
conjugates. 
MRP2 is responsible for the bile acid-independent portion of bile flow via secretion of reduced 
glutathione(1; 4). Additionally, MRP2 is responsible for biliary excretion of organic anions and sulfate-, 
glucuronide-, and glutathione-conjugates such as methotrexate, etoposide, and acetaminophen-glucuronide, 
as well as glucuronide and sulfate bile acid conjugates(4-6). Perhaps more importantly, MRP2 transports 
bilirubin conjugates into bile.  Deleterious polymorphisms in the ABCC2 gene lead to the condition known 
as Dubin-Johnson Syndrome, which is characterized by hyperbilirubinemia despite normal secretion of bile 
acids via BSEP(5; 6). BCRP is a half transporter containing six transmembrane domains and one ATP-
binding cassette in contrast to the common twelve transmembrane domains and two ATP-binding cassettes 
that comprise other ABC transporters(7; 8). Studies have shown that in order to be functional, BCRP most 
likely needs to homodimerize or oligomerize(7; 8). BCRP mediates the biliary excretion of sulfate and 
glucuronide conjugates and bile acids(4; 9). Additionally, BCRP appears to be responsible for the partial 
compensatory excretion of such conjugates in scenarios of diminished MRP2 function(6). P-gp transports 
a wide variety of substrates including immunosuppressants, antibiotics, steroids, anticonvulsants, and Ca2+ 
channel blockers, among others.(10) Although it is postulated that P-gp does not normally play a primary 
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role in biliary excretion of drug conjugates, it is one of the major determinants of cation excretion into 
bile(6; 10). Unlike MRP2 and BCRP, P-gp is not considered as having a major role in the formation of bile 
flow(4).  
Due to their wide substrate specificity, canalicular efflux transporters play a central role in limiting 
systemic exposure to xenobiotics and their conjugates. In the classic view, xenobiotics and conjugates are 
excreted into bile by canalicular transporters for delivery to the intestine and removal from the body via 
fecal excretion. However, some xenobiotics and conjugates that undergo biliary excretion evade fecal 
elimination, at least in part, by reabsorption in the intestine and re-delivery to the liver. This process, which 
may occur numerous times for a given compound, is known as enterohepatic recirculation (ER).  ER can 
lead to a prolonged half-life of compound in the systemic circulation, and frequently is manifested by 
multiple peaks in the plasma concentration-time profile.(11; 12)  ER often involves cleavage of phase II 
conjugates in the gut and reabsorption of parent drug, a process that can be facilitated by intestinal 
microflora.(12; 13)  Drugs (or their metabolites) that are known to undergo ER to a significant extent 
include mycofenolic acid(14), glycyrrhizic acid(15), morphine(12), warfarin(12), amlodipine(16), 
indomethacin(17; 18), spironolactone(12), sulindac(12), sorafenib(19), valproic acid(20), and the irinotecan 
metabolite, SN-38(21). 
Enterohepatic recirculation is an important process for the regulation of bile acid synthesis in the 
liver, thus any event leading to perturbation of normal biliary secretion has implications not only for 
xenobiotic excretion, but also for the circulating bile acid pool and hepatocellular homeostasis(22). BSEP 
dominates bile acid and bile acid conjugate excretion into bile; however, the affinity and capacity of BSEP 
for individual bile acid conjugates differs between species, necessitating caution in the interpretation of 
mechanistic rodent studies(2; 4). Mutations in the ABCB11 gene can result in the lack of protein expression, 
improper localization of the transporter in the canalicular membrane, or overall decreased expression(2). 
Such mutations lead to the accumulation of bile acids within hepatocytes and subsequently, hepatocellular 
damage and cholestasis(2). This condition, which is known as progressive familial intrahepatic cholestasis 
(PFIC), is a collection of cholestatic disorders resulting from mutations in ABCB11 (PFIC2), ATP8B1 
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(PFIC1), or ABCB4 (PFIC3). On the other hand, xenobiotic inhibition of BSEP can result in an acquired 
cholestatic condition, which may also lead to severe hepatocellular damage, toxicity, and liver failure, 
known as drug-induced liver injury (DILI), which will be discussed below(2; 23). 
Basolateral/Sinusoidal Efflux 
Basolateral efflux commonly is regarded as a compensatory route of elimination to protect 
hepatocytes in the setting of cholestasis or otherwise impaired biliary excretion, by mediating excretion of 
endo- and xenobiotics from hepatocytes into the sinusoidal blood.  Transport proteins that have been 
shown to mediate basolateral efflux of drugs are limited primarily to MRP3 and MRP4.  These 
transporters serve also to facilitate systemic exposure and resulting efficacy, toxicity and/or non-hepatic 
(e.g., renal) elimination of metabolites that are formed in the liver.  This is particularly true of phase II 
metabolites such as sulfate, glucuronide and glutathione conjugates(6).  A classic example is 
acetaminophen, which undergoes extensive conversion to glucuronide and sulfate conjugates that are 
recovered largely in urine, and are known to be substrates for MRP3 and/or MRP4(6).  Another example 
is enalaprilat, the dicarboxylic acid and active metabolite of enalapril, which is formed primarily in the 
liver and relies on active transport for efflux into the systemic circulation(24).  Additionally, increased 
systemic concentrations of the pharmacologically active phase II metabolite, ezetimibe-glucuronide, 
correlated with increased expression of Mrp3 and altered localization (internalization) of Mrp2 in a rodent 
model of NASH(25).  This shift from biliary excretion to plasma by basolateral efflux transporters diverts 
the active ezetimibe-glucuronide metabolite away from the site of action in the intestine, and illustrates a 
mechanism of altered efficacy as a result of disrupted hepatobiliary efflux.  Basolateral efflux transporters 
also may play a role in the disposition of parent drugs, such as fexofenadine.  The loss of Abcc3 (but not 
Abcc4) in mice reduced outflow perfusate recovery in the isolated perfused liver system(26).  Another 
example is methotrexate, which will be discussed under Interplay of Multiple Hepatic Efflux Systems 
(below). 
The importance of basolateral efflux in regulating systemic versus hepatocyte exposure, routes of 
drug elimination, and the detoxification function of the liver has been described recently for bilirubin 
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glucuronides by Schinkel and colleagues(27).  The interplay of Oatp-mediated hepatic uptake and efflux 
by Mrp2 and Mrp3 was investigated by observing alterations in the disposition of bilirubin glucuronides 
in single- and multiple-knockout mice(27-29).  These studies elegantly challenged the prevailing 
perception that extensive biliary excretion of bilirubin glucuronides results from efficient vectorial 
transport from sinusoidal blood to bile on the level of an individual hepatocyte.  The relative contribution 
of basolateral vs. canalicular excretion may be much greater than previously thought.  Rather than 
efficient excretion from the cellular space into bile, it is possible that multiple rounds of less efficient 
cycling, or “hepatocyte hopping,” along the length of the liver sinusoid result in extensive biliary 
excretion.  In this way, basolateral efflux was suggested to be a major contributor to the efficiency of the 
liver as a “flexible and robust” organ of detoxification, “potentially distributing the biliary excretion load 
over all hepatocytes within the liver lobule”(27).   
A number of other efflux transporters are known to be expressed on the basolateral/sinusoidal 
membrane of hepatocytes, including ABCC5 (MRP5) and ABCC6 (MRP6).  Although expression levels 
are generally low in healthy individuals, there is evidence of upregulation in disease states(30; 31), 
suggesting that these proteins may play an important compensatory role in the setting of impaired biliary 
excretion pathways, or otherwise compromised hepatocellular function.  Although a number of drugs and 
endogenous compounds have been identified as substrates and/or inhibitors in isolated expression 
systems(32), there are no known examples where these transport proteins play a significant role in the 
disposition of compounds in vivo.  It may be that these proteins are responsible (in part or in whole) for 
the significant “residual” basolateral efflux of sulfate and glucuronide conjugates observed in Abcc3-/-, 
Abcc4-/- and Abcc3-/-/Abcc4-/- animals(33). 
In addition to the unidirectional, ATP-driven ABC family transporters, a number of facilitated 
diffusion mechanisms exist that can participate in uptake or efflux depending on the electrochemical 
gradient of substrates and co-substrates.  One example is SLC51 (polyspecific organic solute carrier, 
OSTα/β), which is thought to be involved in bile acid and sterol reabsorption under normal 
circumstances, but displays bidirectional transport in vitro(34-37).  The substrate specificity of OSTα/β is 
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limited currently to bile acids, steroid conjugates and eicosanoids, but the ability to transport digoxin 
suggests that further characterization of potential drug substrates is needed.  It has been suggested that the 
SLC isoforms (OATPs, OATs and OCTs) are capable of bidirectional transport under certain 
conditions(38; 39), which would open the door to a large number of well-known substrate drugs, 
including the statins.  However, the role of bi-directional transport by OATPs and other SLC family 
members is controversial and has not been shown definitively to play a role for drug molecules. 
 
Functional Impairment Mechanisms 
Drug Interactions Involving Hepatic Efflux Transport 
Inhibition of hepatocellular efflux activity affects normal hepatic function, including excretion of 
endogenous substances such as glutathione, bile acids and bilirubin, and can alter the pharmacokinetic 
profile of drugs(40).  Therefore, affinity of drug candidates for hepatic efflux transporters may represent a 
liability to serve as victims and/or perpetrators of drug interactions(40).  For example, clinically-
significant differences in mycophenolic acid (MPA) pharmacokinetics are observed when this medication 
is co-administered with the calceiunurin inhibitors tacrolimus or cyclosporine A (CsA) for maintenance of 
immunosuppression following solid organ transplant(14; 41).  MPA is metabolized primarily to the 
inactive phenolic glucuronide conjugate, MPAG, which is excreted into bile via MRP2, hydrolyzed back 
to MPA in the gut, and undergoes ER(14; 41; 42).   Inhibition of MRP2-mediated biliary excretion and 
decreased ER explains some of the ~50% decrease in MPA trough concentrations in patients co-
administered CsA(14; 41).   One challenge in distinguishing biliary excretion as the definitive mechanism 
responsible for DDIs and altered pharmacokinetics is that many of the same transport proteins are present 
at the apical border of the intestine and kidney(6; 40; 43-46).   In the absence of mechanistic information, 
such as bile-duct cannulated animals, it can be difficult to deconvolute the relative contribution of 
impaired canalicular versus intestinal or renal excretion(47; 48).  Definitive examples of reduced biliary 
clearance in the presence of inhibitors remain limited.  Erythromycin decreased the biliary excretion of 
fexofenadine in rat isolated perfused livers(49), while elacridar (GF120918, an BCRP and P-gp inhibitor) 
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decreased the biliary excretion of DPDPE (a metabolically stable opioid peptide) in isolated perfused 
livers from Abcc2-/Mrp2-deficient TR- rats(50).   P-gp inhibition may contribute to other DDIs, such as 
the reduced biliary excretion of colchicine, doxorubicin and digoxin by erythromycin or ketoconazole(44; 
45).  The role of Mrp2 and Bcrp as the primary mechanisms for biliary excretion of rosuvastatin was 
confirmed in rat livers from wild-type and TR- rats in the presence and absence of GF120918, which had 
been suggested previously using in vitro systems and single knockout animals.(51; 52)  A number of 
drugs have been shown to inhibit biliary excretion of conjugated bile salts mediated by BSEP, which can 
result in DILI, as demonstrated by several cases of drug withdrawals or black-box warnings (e.g., 
troglitazone, bosentan, erythromycin, nefazodone)(53-58).  In addition to BSEP, MRP3 and MRP4 also 
are involved in the export of bile acids and drugs/metabolites.  Recent studies suggest that inhibition of 
MRP4 is a risk factor for the development of DILI; considering the potential for drug candidates to inhibit 
MRP4, in addition to BSEP, could aid in predicting compounds with liability for DILI at an earlier stage 
in drug development(59).  
For lists of compounds that inhibit hepatic efflux transporters, the reader is directed to a number 
of excellent reviews that have collated available data for individual ABC family transport proteins: 
MRP2(5; 32; 60), BCRP(7; 60-62), P-gp(60; 63), BSEP(64), MRP3(6; 32) and MRP4(6; 32).  These 
reviews typically include information such as the model system that was used to generate inhibition data, 
the probe substrate, and a mathematical value corresponding to the inhibitory potential of the compound 
of interest, such as a percent inhibition at a given concentration, IC50 or Ki.  These data tend to be 
collected from reports of individual or small sets of inhibitors generated in different experimental 
systems/conditions.  As such, it can be difficult to compare the relative inhibitory potential of compounds 
from different sources.  In addition to these reviews, several large-scale, public, web-based efforts are 
underway to curate the historic and growing body of experimental data reporting interactions between 
chemicals and transport proteins. These databases include “TP-Search” (www.tp-search.jp)(65), the 
Transporter Classification Database (TCDB; www.tcdb.org)(66), TransporterDB 
(www.membranetransport.org)(67) and the UCSF pharmacogenetics database 
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(pharmacogenetics.ucsf.edu)(68). A large-scale QSAR modeling effort was reported recently by Tropsha 
and colleagues, which included automated curation of the aforementioned databases and literature 
sources, resulting in the largest known repository of transporter inhibition data(69).   
Mechanisms of DDIs Involving Hepatic Efflux Transporters 
The vast majority of data describing transporter DDIs suggest a competitive inhibition 
mechanism, resulting from the aforementioned wide and overlapping substrate specificity of transport 
proteins.  However, drugs may interact with transport proteins by a variety of mechanisms and, therefore, 
cis-inhibition as well as mechanism-based and trans-inhibition, allosteric-induced modulation and 
induction of transport function may be important mechanisms of transporter-mediated DDIs(70).  For 
example, trans-inhibition of BSEP has been demonstrated for estrogens, possibly contributing to 
cholestasis of pregnancy(71; 72).  Time-dependent inhibition of hepatic uptake transporters has been 
shown with cyclosporine A(73; 74).  Of the multiple binding sites proposed for P-gp, some are reported to 
interact in a positive cooperative manner, resulting in mutual stimulation of P-gp-mediated transport of 
several substrates, including rhodamine 123, anthracyclines, some flavonoids, and the p53 inhibitors 
QB102 and QB11(75). Similarly, in 2003, two groups independently reported potentiation of estradiol-
17-β-D-glucuronide transport by MRP2, which was followed by additional reports from large-scale 
screening approaches(76).  Another classic mechanism leading to increased transport activity is induction.  
Treatment of cultured primary rat hepatocytes with the chemical carcinogen 2-acetylaminofluorene (2-
AAF), the antineoplastic drug cisplatin, and the protein-synthesis inhibitor cycloheximide led to a dose-
dependent and time-dependent increase in gene expression of Mrp2, with corresponding plasma 
membrane localization(77).  Although this effect is likely to be of relevance mostly for the acquisition of 
multidrug resistance during chemotherapy, potential implications exist for the hepatobiliary disposition of 
drugs and metabolites.  P-gp also is induced by a number of drugs, including ritonavir(78).  In the case of 
P-gp, many drugs overlap in their ability to interact with CYP3A and P-gp (as substrates, inhibitors 
and/or inducers).  Due to the often sequential detoxification chain represented by these mechanisms, the 
effect of inducers or inhibitors can be synergistic, thereby resulting in extreme changes in xenobiotic 
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elimination(45).  Although many of these atypical mechanisms have been observed only in in vitro 
systems, it is clear that competitive inhibition should not be regarded as the only mechanism of DDIs 
resulting in modulation of transporter function/activity. 
Effect of Genetic Polymorphisms on Transporter Expression and Function 
Several studies have investigated the impact of transporter polymorphisms on drug 
pharmacokinetics; however, difficulty exists in demonstrating reproducible functional effects in vitro with 
successful clinical translation. A brief description of selected polymorphisms in specific efflux 
transporters, and some of the controversies surrounding them, will be discussed. For a more detailed 
review of transporter pharmacogenetics, the reader is directed elsewhere.(5; 10; 79-81) 
ABCC2/MRP2 
ABCC2, next to ABCB1, is one of the most illustrious of the efflux transporters with regard to 
pharmacokinetics. Several polymorphisms in the ABCC2 gene locus have been associated with the 
hyperbilirubinemic disorder known as Dubin-Johnson Syndrome including the R412G, I1173F, 
R1392del, and M1393del protein variants(5). Of those associated with Dubin-Johnson Syndrome, the 
I1173F, R1392del, and M1392del variants lead to improper trafficking of MRP2 protein to the apical 
membrane of hepatocytes and loss of transport function(82; 83).  Two independent groups identified the 
2366C>T (S789F) and 4348G>A (A1450T) alleles as conferring decreased ATPase and transport activity, 
along with altered membrane localization(84; 85). In contrast, the 1249G>A (V417I) allele was shown to 
decrease affinity(85), or have little effect on transport function in vitro.(84) Additional in vitro 
experiments discovered a reduction in transport activity for the K324A, K483A, R1210A, and R1257A 
MRP2 protein variants as well as diminished protein expression of the K578A variant(86). The 4544G>A 
allele has been associated with susceptibility to nonalcoholic fatty liver and cholestatic liver diseases, 
resulting in decreased ATPase activity and diminished transport of lopinavir, calcein, and 
carboxydichlorofluorescien diacetate(87; 88).  ABCC2 promoter variants and haplotypes have been 
associated with susceptibility to hepatotoxicity(89). Haplotypes containing the -1774Gdel variant have 
been linked to cholestatic and mixed-type hepatotoxicity in a Korean population, while the -1774Gdel/-
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1549G>A/-24C>T haplotype appears to reduce promoter activity(89). In contrast, the -24C>T allele alone 
and within the -24C>T/-1019A>G/-1549G>A haplotype leads to an increase in promoter activity(90). 
Additional ABCC2 haplotype studies investigating the -24C>T, 1249G>A, and 3972C>T alleles 
identified the -24C/1249A/3972C haplotype as conferring an increase in MRP2 protein levels, which 
corresponded to transport activity in vitro and altered bioavailability of talinolol in vivo(91). In contrast, 
the -24C/1249G/3972T, -24T/1249G/3972C, and -24T/1249G/3972T haplotypes resulted in diminished 
protein expression in vitro(91). Still others have shown a preference for transcription of the 3972C allele 
in comparison to 3972T, which did not correlate with hepatic or renal MRP2 expression(90).  
ABCC3/MRP3 
In 2004, Lang and colleagues determined that homo- and heterozygous carriers of the -211C>T 
variant exhibited decreased hepatic mRNA expression of ABCC3, and that this promoter variant affected 
binding of transcription factors(92). The investigators concluded that the -211C>T allele affected hepatic 
expression of the transporter, although this effect has been controversial(93).  Additional studies using 
reporter gene activity experiments discovered that the length of the promoter, rather than the -211C>T 
variant affected gene expression(94).  A later study discovered improper post-translational processing and 
localization of the MRP3 R1381S protein variant in vitro(95).  Additionally, investigators identified the 
MRP3 S346F and S407N protein variants to confer decreased transport activity in Sf9 membrane 
vesicles, the three polymorphisms were postulated to be possible risk factors for hepatotoxicity(95).  In an 
effort to translate in vitro polymorphism studies to in vivo pharmacokinetics, Sasaki, et al., utilized a 
reporter gene assay to identify decreased transcriptional activity of the -1767A>G allele(96). However, 
the -1767A>G variant did not appear to affect human hepatic ABCC3 mRNA expression, nor was it 
associated with 4-methylumbelliferone-glucuronide pharmacokinetics(96). 
ABCC4/MRP4 
Experiments utilizing site-directed mutagenesis and transfected HEK293 cells identified a 
decrease in the transport of azidothymidine and adefovir for the MRP4 G187W and G487E protein 
variants(97). Additionally, the G187W variant was associated with decreased expression in the 
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transfected cell system(97); however, the clinical significance of these variants has not been determined. 
Others identified the -1393T>C allele to be associated with improved event-free survival and decreased 
methotrexate plasma concentrations in pediatric acute lymphoblastic leukemia as opposed to an 
association between the 934A>C allele with decreased event-free survival and increased toxicity(98). In 
contrast, a later study tested the results of Ansari, et al., in adult ALL patients and found no association 
between event-free survival and genotype(99). The impact of age of disease-onset and the discrepancies 
in these two findings have not been determined.  
ABCB1/P-gp 
The majority of the >100 ABCB1 polymorphisms have been studied in the context of gut 
expression of P-gp protein and altered bioavailability of drugs such as digoxin, talinolol, and 
fexofenadine(10; 100). However, Elens, et al., investigated ABCB1 polymorphisms in ~150 liver donors 
and their subsequent effects on blood and hepatic tacrolimus concentrations(101). This study found that 
ABCB1 polymorphisms, specifically the 1199G>A and 2677G>T/A alleles, independently exerted a 
significant effect on tacrolimus liver, but not plasma concentrations, the primary endpoint used for 
therapeutic monitoring(101). Owen, et al., when investigating the 3435C>T and 2677T>G alleles 
determined that the large variation observed in human hepatic ABCB1 mRNA and P-gp protein 
expression could not be attributed to genetic variation alone(102). In contrast, Song, et al., identified an 
increase in hepatic ABCB1 mRNA for homozygous carriers of the 3435C allele, and a decrease in those 
homozygous for the 2677T allele(103). 
ABCG2/BCRP 
Of the polymorphisms identified in the ABCG2 gene, the 421C>A allele resulting in the Q141K 
amino acid substitution appears to be the most important for adverse drug events(104). The ABCG2 
421C>A allele appears to decrease BCRP-associated ATPase activity and cause alterations in 
diflomotecan, imatinib, sulfasalazine, atorvastatin, rosuvastatin, nitrofurantoin, lamuvidine, and 
pitavastatin pharmacokinetics, among others(104; 105). Additionally, the 34G>A allele resulted in the 
V12M amino acid substitution, which results in the improper processing and cellular localization of 
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BCRP protein in vitro(105). The Q141K variant also has been implicated in improper membrane 
localization of BCRP protein(106). 
Despite major advances in the field of molecular biology and pharmacogenomics, the ability to 
translate in vitro polymorphic effects on transporter expression and function to the clinic remains a 
daunting task. 
Expression of Hepatic Efflux Transporters in Disease States 
Historically, investigations to determine the effect of liver disease on efflux transporter 
expression have sought to provide insight to disease pathogenesis. However, alterations in the expression 
of efflux drug transporters can have significant effects on the elimination of xenobiotics and endogenous 
molecules. It has been proposed that upregulation of efflux transporters may serve as an adaptive 
mechanism to limit cellular exposure to hepatotoxicants(107); however, systematic, comprehensive 
investigations of efflux transporter expression are severely limited for several disease states. The 
following will provide a brief overview of efflux transporter expression in human liver tissue from 
selected liver diseases. A summary of the effects discussed is provided in Table 1 below to aid in 
comparisons among diseases. 
Primary Biliary Cirrhosis 
Primary biliary cirrhosis (PBC) arises from inflammation and irritation of bile ducts leading to 
stasis of bile flow (cholestasis) which can severely damage hepatocytes and ultimately lead to cirrhosis. 
Much work has been done to understand the effects of cholestasis on transporter expression and function. 
ABCC2 mRNA remains largely unchanged in PBC compared to normal liver(107-109). While some have 
reported no change in ABCC4 mRNA(110), others have discovered an increase in ABCC4 mRNA in 
cholestasis(111). There is overall agreement that MRP3 and MRP4 protein are elevated in 
cholestasis(107; 111). Additionally, ABCB1 and ABCC1 mRNA levels appear to be elevated compared 
to normal liver(109). 
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Nonalcoholic Fatty Liver Disease & Nonalcoholic Steatohepatitis 
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) represent a 
spectrum of liver damage that has emerged recently as a prevalent condition due to its association with 
the obesity epidemic. It is characterized by the accumulation of lipids within hepatocytes, termed simple 
steatosis. NAFLD progresses via inflammation, oxidative stress, and increased lipid accumulation to 
NASH, which also may incorporate fibrosis and eventual cirrhosis(31). ABCC1, ABCC3, ABCC4, 
ABCB1, and ABCG2 mRNA levels are increased with progression of NAFLD from simple steatosis to 
NASH, while ABCC2 mRNA levels remain unchanged(31). Protein levels of all efflux transporters 
appear to be increased with disease progression, although the localization of MRP2 most likely shifts to 
the subapical region, away from the plasma membrane(31).  
Hepatitis C Virus 
Hepatitis C virus (HCV) induces several response pathways in hepatocytes including oxidative 
and endoplasmic reticulum stress(112). Chronic HCV infection can lead to fibrosis and development of 
severe cirrhosis, propagating hepatocellular injury with potential for numerous alterations in gene 
expression patterns(113). In comparisons of HCV-positive tissue with HCV-negative, ABCC1, ABCC3, 
ABCC4, and ABCB1 mRNA are elevated in non-cirrhotic tissue(113; 114). ABCG2 and ABCC2 mRNA 
expression is diminished in HCC(113; 114) with ABCC2 mRNA decreasing as fibrosis severity 
increases(112). Studies comparing mRNA expression in cirrhotic HCV tissue with HCV-negative, 
noncirrhotic tissue are in agreement with those comparing HCV-positive to noncirrhotic, HCV-negative 
tissue, suggesting that the changes in gene expression are driven primarily by infection status.  ABCB1, 
ABCC1, ABCC4 mRNA is elevated, while ABCC2 and ABCG2 levels are decreased(114). Additionally, 
ABCC2 mRNA has been demonstrated to be reduced in HCV/HCC-positive tissues compared to 
HCC/HCV-negative tissues(115). Comparisons of protein levels in this disease are limited; however, 
MRP4 protein is elevated in HCV-positive tissue versus noncirrhotic, HCV-negative tissue(114). 
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Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is a common form of cancer that arises from cirrhosis due to 
chronic liver disease(116). Studies have shown an increase in mRNA levels of several efflux transporters 
including ABCC1, ABCC2, ABCC4, and ABCB1(116; 117). ABCG2 mRNA remains unchanged in 
comparison to healthy adjacent tissue(116). However, ABCC3 mRNA increased(116) or remain 
unaltered(117). Information regarding protein levels of efflux transporters in HCC as compared to normal 
tissue remains limited. 
Progressive Familial Intrahepatic Cholestasis. 
Progressive familial intrahepatic cholestasis (PFIC) refers to a group of autosomal recessive 
disorders affecting biliary membrane proteins including ATP8B1, BSEP, and MDR3, referred to as 
PFIC1, 2, and 3, respectively. The resultant dysfunction in each generally culminates in disrupted 
formation of bile. Investigations assessing the expression of efflux transporters in PFIC are limited to 
small groups of patients. Keitel, et al., determined mRNA levels in PFIC 2 and 3 for a number of efflux 
transporters and discovered an increase in ABCC4 mRNA in both PFIC2 and 3, while protein was 
increased in PFIC3(118). ABCC1 and ABCB1 mRNA was increased in PFIC3 as well(118). ABCC2 
mRNA was unaltered in PFIC2 and 3, but protein may be decreased in PFIC3(118). ABCC3 mRNA was 
unaltered in both PFIC2 and PFIC3(118). Unfortunately, due to low patient numbers (n=4-5) and thus low 
statistical power, generalizations on efflux transporter expression due to PFIC are tentative at best. 
Though systematic studies including both mRNA and protein data for efflux transporters are 
minimal, a significant obstacle in the application of findings from such studies remains the ability to 
absolutely quantify transporter protein. Understanding the absolute expression level of one specific efflux 
transporter compared to another may provide better insight regarding which transporters may exert a more 
dominant function in various disease states and enable better prediction of drug response. 
Trafficking of Hepatic Efflux Transporters 
An important concept in transporter regulation is that of intracellular pools from which membrane 
transporters can be swiftly recruited and inserted into the membrane as a result of xenobiotic treatment or 
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physiological demand(119). It has been postulated that these intracellular reservoirs of transporters serve 
as a means of increasing transporter expression in the membrane, and thus transport activity, without 
initiating the energetically expensive processes of transcription and translation(120).  In contrast, other 
studies have demonstrated the endocytic retrieval of transporters from the membrane as a consequence of 
xenobiotic treatment or disease states.  Whether changes involve transporter delivery to, or internalization 
from, the membrane, the net result is alteration of the steady-state levels of efflux transporters residing in 
the membrane, and thus modulation of their transport function. However, the majority of such studies 
have focused on canalicular efflux transporters including P-gp and MRP2, with less attention directed 
towards sinusoidal efflux transporters. 
Much work has been done to determine the mechanisms governing P-gp trafficking from large 
intracellular pools to the canalicular membrane. Administration of cAMP or taurocholate to rats results in 
increased levels of hepatic P-gp in the membrane(120-122).  Furthermore, in vivo pulse-chase 
experiments revealed that newly-synthesized P-gp is targeted directly from the Golgi apparatus to the 
canalicular membrane rather than progressing through the transcytotic pathway via temporary insertion in 
the sinusoidal membrane(123).  Additional studies in HepG2 cells revealed the involvement of protein 
kinase A (PKA)-RIIα, which can be activated by cAMP, in the trafficking of newly-synthesized P-gp to 
the membrane(124).  Interestingly, the basal rate of P-gp delivery to the membrane in HepG2 cells 
differed from that of MRP2(124).  Non-hepatic cell lines have provided further insight into the proteins 
responsible for regulating the insertion into and endocytic retrieval of ABCB1/P-gp from the membrane 
via perimembranous pools. Concomitant overexpression of green fluorescent-tagged P-gp in HeLa cells 
with constitutively-active forms of the small GTPases Rab5 or RalA resulted in an increase in 
intracellular P-gp localization, which correlated with increased intracellular accumulation of the 
fluorescent P-gp substrate, daunorubicin(125).  However, whether Rab5 and RalA were involved in the 
process of exocytic insertion, or endocytic retrieval of P-gp from the membrane is unclear. A recent study 
involving membrane expression of P-gp in K562 cells identified the small GTPase Rab4 as a negative 
regulator in the exocytic insertion of P-gp in the membrane(126).  Similar to studies in transfected HeLa 
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cells, Rab4-mediated retrieval of P-gp correlated with increased intracellular levels (reduced efflux) of an 
P-gp substrate(126). 
Extensive investigations have focused on the dynamic regulation of MRP2 in the canalicular 
membrane. Several experimental cholestatic and oxidative stress-inducing conditions such as bile duct 
ligation or treatment with estradiol-17β-D-glucuronide, lipopolysaccharide, phalloidin, ethacrynic acid, or 
buthionine sulfoximine, are known to induce endocytic retrieval of Mrp2 from the canalicular membrane 
in rats(127-129). Additionally, disrupted canalicular localization of MRP2 has been demonstrated in 
primary biliary cirrhosis, drug-induced liver injury, poorly drained obstructive jaundice, autoimmune 
hepatitis, sclerosing cholangitis, and nonalcoholic steatohepatitis patients(31; 130; 131).  The specific 
mechanisms governing the endocytic retrieval and exocytic insertion ofMRP2 in the canalicular 
membrane are convoluted and involve multiple kinases. Ethacrynic acid-induced oxidative stress resulting 
in depletion of glutathione leads to rapid internalization of Mrp2 which can be rescued by subsequent 
glutathione treatment(127; 132). Estradiol-17β-D-glucuronide-induced cholestasis also causes 
internalization of Mrp2 resulting in diminished biliary excretion of Mrp2 substrates; however, this 
process is reversed by cAMP administration(133). The endocytic retrieval of Mrp2 from the membrane is 
largely a microtubule-independent process involving activation of Ca2+-dependent protein kinase C 
(PKC), and de-phosphorylation of radixin, which is responsible for tethering actin filaments to membrane 
proteins(128; 134-137). De-phosphorylation of radixin destabilizes its interaction with Mrp2 leading to 
their dissociation and movement away from the membrane(134; 136).  Once internalized, 
phosphatidylinositol 3-kinase (PI3K) has been proposed to regulate Mrp2 retention within the cell via 
interactions with extracellular signal-regulated kinases 1 and 2(137; 138). Furthermore, sustained 
buthionine sulfoximine-induced oxidative stress has been shown to lead to not only internalization of 
Mrp2, but increased ubiquitination and subsequent degradation of the protein(129). Conversely, 
reinsertion of Mrp2 into the membrane is a microtubule-dependent process that is sensitive to colchicine 
treatment and stimulated by cAMP, taurocholate, tauroursodeoxycholate, and hypoosmotic buffer(128; 
133). Protein kinase A (PKA) may be involved in the phosphorylation of radixin; however, PKC isoforms 
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also have been implicated in the exocytic reinsertion of Mrp2 in the membrane through signaling events 
involving p38 mitogen activated protein kinase(132; 134; 138; 139). 
Glycosylation has been implicated as an additional factor affecting the membrane localization of 
efflux transporters. N-linked glycosylation of BCRP has been implicated as a possible mechanism 
affecting protein stabilization, proper routing of the transporter to the membrane, and functional 
activity(140-142). Others have shown full glycosylation of MRP2 to be necessary for proper localization 
within the membrane and effective transport activity(143; 144). The interconnection of glycosylation 
pathways regulating transporter routing to the membrane and kinase pathways involved in the dynamic 
localization of efflux transporters remains to be determined. 
Localization studies investigating sinusoidal efflux transporters are beginning to emerge; 
however, there is a substantial gap between the breadth of knowledge of canalicular efflux transporter 
trafficking and that of sinusoidal efflux transporters. Recent studies have identified Na+/H+ exchanger 
regulatory factor 1 (NHERF1) and nexin 27 as binding partners of MRP4 necessary for internalization of 
the transporter(145; 146). Further studies are necessary to determine the pathways involved and clinically 
relevant states of MRP4 internalization. Nonetheless, whether reduced membrane expression of efflux 
transporters is the result of improper post-translational processing and trafficking to the membrane or 
endocytic retrieval and intracellular sequestration, the net result is diminished extrusion of substrates out 
of the hepatocyte. 
 
Interplay Between Multiple Hepatic Efflux Systems 
As one of the main eliminating organs of the body, the liver has evolved to excrete a wide range 
of endo- and xenobiotics.  In order to perform this essential excretory function, an array of transport 
proteins with overlapping substrate specificity exist to handle a wide range of endo- and xenobiotics 
(Figure 1.1).  This includes multiple complimentary proteins on the same membrane transporting in the 
same direction, as well as proteins on the opposite, or alternative, membrane.  Due to the potential 
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involvement of multiple transporters, it can be challenging to predict the impact of altered function of one 
or more transport proteins on hepatic and systemic exposure of a given substrate. 
The quantitative impact of excretory transport modulation on the hepatic, systemic, and biliary 
exposure to xenobiotics and derived metabolites was formalized recently by Zamek-Gliszyznski based on 
work conducted in our laboratory(147).  Experimental data and theoretical relationships indicated that the 
fold change in exposure is governed by the relationship, 1/(1 – fe), where fe is the fraction excreted by a 
particular transport protein.  Loss-of-function of a transport pathway associated with a fe < 0.5 will have 
minimal consequences on exposure, but exponential changes can be expected in response to loss-of-
function of one or more transport pathways with fe > 0.5.  It should be noted that the impact of fe on 
exposure depends on the compartment of interest (systemic, hepatic or bile), the directionality of the 
impaired pathway (canalicular or sinusoidal), and the existence of an alternative route of excretion.  For 
example, when a transport protein is impaired, the increased excretion in the alternative direction is a 
function of the fraction of total hepatocellular clearance mediated by the impaired pathway.  The resulting 
increase in excretion over the alternative membrane is caused by the decrease in total excretory clearance, 
which produces elevated cellular concentrations that serve as a driving force for increased excretion by 
the remaining available pathways.  The relationship between exposure and fe also can be extended to 
partial inhibition scenarios by modifying the equation with the ratio of inhibitor concentration and 
inhibition constant ([I]/Ki).  Figure 1.2 depicts the relationship between exposure and fe, including the 
effect of partial inhibition(147). 
Fold change in exposure ൌ	 1fe
(1 +[I] Ki
൘ )
 + (1 - fe)
   (1) 
  In a series of reports, Vlaming and colleagues characterized the role of multiple hepatic efflux 
transporters in the elimination of methotrexate and its main toxic metabolite, 7-hydroxymethotrexate, in 
vivo using single and multiple knockout mouse models(148-150).  Biliary excretion of methotrexate and 
the 7-hydroxy metabolite were reduced ~20-fold in Abcc2:Abcg2-/- mice, indicating that these proteins 
are the main determinants of canalicular efflux(149).   The role of Mrp3 in compensatory excretion of 
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methotrexate and 7-hydroxymethotrexate from the liver into sinusoidal blood was demonstrated by 
increased plasma concentrations and urinary excretion in the absence of Mrp2 and/or Bcrp, which was 
reversible in Abcc2:Abcc3-/- mice(150).  Mrp3 appeared to be required for increased plasma 
concentrations in the absence of Bcrp(148).  Despite initial hepatic accumulation of methotrexate in the 
absence of one or two proteins, the mass recovered in was similar to wild-type by 2 hours.  However, in 
the absence of all three proteins, hepatic accumulation was further increased and prolonged in 
Abcc2:Abcg2:Abcc3-/- mice (7- and 90-fold increase for parent and metabolite at 2 h)(148).  Also in 
Abcc2:Abcg2:Abcc3-/- mice, 7-hydroxymethotrexate still exited the liver, resulting in a 10-fold increase 
in plasma exposure, potentially due to up-regulation of Mrp4.  The role of multiple efflux transporters in 
the enterohepatic circulation and related efficacy of ezetimibe and its glucuronide conjugate was explored 
using a variety of model systems, demonstrating that enterohepatic circulation strongly depends on the 
joint function of Mrp3, Mrp2 and Bcrp(151).  Although biliary excretion of ezetimibe glucuronide was 
minimally altered in Abcg2-/- mice, Bcrp clearly functions to compensate for loss of Mrp2, as 
demonstrated in Abcc2:Abcg2-/-(151).  Interestingly, the role of Mrp3 in absorption of ezetimibe from the 
intestine was shown in Abcc3-/- mice, which displayed greatly reduced enterohepatic circulation(151).  
The overlapping function of P-gp, MRP2 and MRP3 in protection against trabectedin-mediated 
hepatotoxicity by clearing harmful metabolites formed by CYP3A was shown using a combination of 
single- and multiple-knockout animals with translation to humans using MRP2- and MRP3-transfected 
MDCK cells(152; 153).  Multiple efforts to characterize the hepatobiliary disposition of fexofenadine 
have shown the overlapping roles of P-gp, BSEP and MRP2, but not BCRP in facilitating biliary 
excretion, and the significant contribution of MRP3 but not MRP4 in the sinusoidal efflux from liver into 
blood(26; 154-156).  Using a combination of Mrp2-deficient TR- rats and chemical “knockdown” of 
Abcb1/P-gp by elacridar (GF120918),  Mrp2 was identified as the primary mechanism for biliary 
excretion of the metabolically stable opioid peptide, DPDPE, in rats, with P-gp facilitating biliary 
excretion only in the absence of Mrp2(45; 50).  These studies also suggested that GF120918 inhibited a 
basolateral excretion mechanism for DPDPE.  Using chemical inhibitors alone, increased hepatocyte 
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concentrations of valproate glucuronide were observed in isolated perfused rat livers following 
probenecid and valproate co-administration.(157)  Mathematical modeling of the data revealed that 
probenecid inhibited both the basolateral and canalicular excretion of generated valproate glucuronide. 
For most drugs where multiple pathways are available for hepatocellular egress into bile or blood, 
the safety is maintained when only one pathway is impaired.  However, as demonstrated by the fe concept 
and various experimental models used to study multiple transporters, significant changes begin to occur 
as more pathways are impaired and the hepatoprotective effect of transporter multiplicity is diminished.  
That is why it is important to characterize the multiplicity and relative contribution of transport pathways 
for new chemical entities (NCEs), as a way to asses risk in the setting of impaired function of one or more 
transporters, whether due to DDIs (with NCE as victim and/or perpetrator), disease states or genetic 
variation.  
 
Relationship Between Hepatic Efflux Transport and Intracellular Unbound Concentrations  
Measurement of unbound blood or plasma concentrations is convenient and may correlate with 
unbound tissue/cellular concentrations for compounds with sufficient passive permeability.  However, for 
compounds that are poorly permeable or otherwise violate the assumption of rapid equilibration, the ratio 
of intracellular to extracellular (blood or plasma) Cunbound (Kpu,u) may be highly disparate.  Since the liver 
is frequently a primary site of drug elimination from the body, hepatocellular Cunbound greatly influences 
drug efficacy and toxicity on a systemic as well as local level.  As such, predictions of clinical efficacy, 
toxicity and drug-drug interactions (DDIs) could be improved by accounting for Cunbound in vitro and in 
vivo, as well as between cell-free and whole cell in vitro systems used to assess mechanisms/targets of 
efficacy, toxicity and drug disposition, including transporter activity. 
Altered function of efflux mechanisms described in this review can influence hepatocellular 
exposure of drugs, with implications for altered efficacy, toxicity and DDI potential.  This includes the 
effect of interplay between drug transport and metabolizing enzymes, in which intracellular Cunbound drives 
elimination of parent drug; however, metabolic/elimination pathway “switching” can occur in the setting 
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of impaired efflux, leading to increases in hepatic and/or systemic metabolite exposure.(6; 147; 158-161)  
In contrast, subcellular binding/sequestration can limit access of drugs to mechanisms of elimination and 
constrain the ability of efflux and/or metabolism to “clear” drug from the hepatocytes.  It is assumed that 
only the Cunbound within the cell is available for elimination.   
Although hepatocellular Cunbound is assumed to be the relevant concentration driving elimination, a 
number of exceptions exist, particularly in the case of efflux transport.  A preponderance of evidence 
suggests that ABCB1/P-gp has multiple binding sites, including the ability to remove compounds from 
the inner leaflet of the plasma membrane and function as a “membrane vacuum” for compounds that 
partition into the lipid bilayer.(162; 163)  An elegant piece of pharmacokinetic modeling by Korzekwa, et 
al., supports this mechanism, and suggests that a portion of the ABCB1/P-gp-mediated efflux process is 
driven by drug accumulation and concentration within the membrane, although this would not be 
regarded as a component of Cunbound within the cell.(164)  As integral membrane proteins, transporters are 
transferred to the plasma membrane following synthesis through dynamic and complex vesicle trafficking 
pathways.(123; 165-168)  Likewise, plasma membrane regions and their contents are continuously cycled 
on and off the membrane, leading to pools of transporter-containing vesicles.(122; 169)  As a result, 
substrates for efflux transporters are constantly accumulating within these vesicles, as has been shown 
with fluorescent ABCC2/MRP2 substrates, demonstrating characteristic punctate vesicular structures, 
which are absent in Abcc2-/Mrp2-deficient cells and sensitive to known inhibitors, such as cyclosporine 
A.(169-171)  Although the initial transport into these vesicles is presumed to be driven by intracellular 
Cunbound, the terminal release (efflux) of accumulated drug results from fusion of the vesicles with the 
plasma membrane, which may occur at a very different rate compared to direct efflux across the plasma 
(canalicular or basolateral) membrane.(169; 172)  This vesicular fusion pathway offers yet another level 
of complexity to hepatic efflux that is subject to altered function, as vesicle trafficking in hepatocytes is 
known to be altered by a number of disease states (see above). 
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Model Systems for Evaluating the Role of Hepatic Efflux 
 For a comprehensive list of experimental models used to measure transporter activity in general, 
the reader is referred to a recent review by the International Transporter Consortium(173).  While vesicle 
systems and transfected systems are useful to determine whether a transporter may be involved for a 
particular substrate, the more challenging aspect is to determine the role of a particular transporter in the 
presence of other competing transporters and pathways of cellular elimination.  The only cells that truly 
express all of the relevant transporters of interest are primary cells from the organ of interest. 
Primary Hepatocytes 
Freshly isolated or cryopreserved primary hepatocytes are not polarized and require long-term culture in a 
sandwich configuration to recapitulate polarized architecture, including formation of bile networks and 
appropriate expression and localization of efflux transporters on the respective apical (canalicular) and 
basolateral membrane domains.(174)  Sandwich-cultured hepatocytes (SCH) typically are used to 
evaluate vectorial transport into bile and differentiate the roles of active uptake and biliary excretion.  
This is accomplished by modulating tight junctions in the presence (cells+bile) or absence (cells) of 
divalent cations (Ca2+ and Mg2+) in the experimental buffer system (B-CLEAR® technology, Qualyst 
Transporter Solutions, Research Triangle, NC).  These studies are performed routinely by applying 
substrates in the presence or absence of inhibitors for a period of 10 min, and a number of 
pharmacokinetic parameters can be calculated from the resulting data, including the total accumulation in 
cells+bile and cells, biliary excretion index (BEI) and in vitro clearance values for uptake and/or biliary 
excretion, which can be scaled to predict in vivo clearance values based on scaling factors such as protein 
content and hepatocellularity(174). 
The SCH model has many advantages including expression of relevant transport mechanisms, 
which enables accurate prediction/assessment of efflux processes, since the panoply of mechanisms 
mediating hepatocellular entry and egress are represented.  However, it should be noted that transporter 
expression may be altered compared to whole tissue, depending on the culture conditions, as shown for 
rat SCH with (~5-fold) downregulation of SLCO/OATP expression and 5-fold increase in expression of 
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efflux transporters such as P-gp and Mrps(175-178).  Presently, estimation/prediction of transport 
processes may be improved by taking these changes into account upon scaling of data from in vitro to in 
vivo(179; 180). Less frequently, the SCH model has been used to assess efflux by various strategies of 
preloading the cells with substrates (± inhibitors), followed by a brief wash and application of “blank” 
buffer for an efflux phase, which may involve sampling/observation of substrate in cells+bile, cells and/or 
appearance in buffer(181; 182).  However, the SCH system remains to be characterized under these 
conditions. 
In a “simplified” conception of the SCH system, maintenance of tight junctions in the presence of 
Ca2+ would completely seal the bile networks, and appearance in buffer during an efflux experiment 
would reflect only basolateral efflux.  Efflux in the absence of Ca2+ with disrupted tight junctions would 
reflect basolateral plus biliary efflux, and would be greater than that in +Ca2+ conditions.  In reality, the 
SCH model is dynamic, with regular and extensive “pulsing” of the bile canaliculi, similar to reports in 
hepatocyte couplets and cultured hepatocytes(183; 184) (video: 
http://www.pharmacy.unc.edu/research/labs/kim-brouwer-lab/bile-canalicular-contractions-in-sandwich-
cultured-rat-hepatocytes)  This means that appearance of substrate in buffer in the +Ca2+ condition 
reflects basolateral efflux plus the flux of accumulated substrate within the bile spaces.  In order to 
deconvolute these data and elucidate the relative contribution of basolateral versus biliary efflux, one can 
apply a pharmacokinetic modeling approach to the SCH data(161; 185-188). 
At least two potential schemes exist for the design of efflux studies in SCH (Figure 1.3). One is to pre-
incubate and/or perform the uptake phase exclusively in standard (+Ca2+) Hanks’ Balanced Salt Solution 
(HBSS), followed by a brief wash and efflux in ±Ca2+ HBSS [Fig. 1.3, (A)](181; 182). A potential 
limitation of this approach is that substrate accumulation in the bile networks during the uptake phase 
may not be washed away completely before initiating the efflux phase in -Ca2+ HBSS.   The time required 
for “complete” opening of bile networks is unclear, although disappearance of carboxydichlorofluorescein 
(CDF) fluorescence intensity in bile networks suggests a time frame of ~5-6 min (Figure 1.4).  Prior to 
this time, efflux in the -Ca2+ condition in part reflects dumping of bile networks.  A potential solution is to 
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incubate in ±Ca2+ HBSS long enough to complete opening/dumping of bile spaces in -Ca2+ (~5-6 min), 
and then replace buffer again and observe efflux.  However, it may be difficult to detect cellular content 
for compounds that are rapidly excreted (e.g. taurocholate)(186).   Another potential experimental design 
for efflux studies in SCH involves maintaining tight junction modulation throughout the study period by 
pre-incubating in ±Ca2+ HBSS, then performing an uptake phase in +Ca2+ HBSS (<30 min) to provide 
relief from -Ca2+/EGTA , followed by a brief wash and efflux in ±Ca2+ HBSS [Fig. 1.3, (B)].  A limitation 
with this method is potential re-sealing of the tight junctions during Ca2+ repletion in the uptake phase.  
This has been characterized previously(186), and is of concern for compounds with extensive biliary 
excretion (BEI), such as taurocholate(186).  However, imaging with CDF suggests that re-sealing of the 
tight junctions allowing substrate accumulation in the bile networks is minimal over a 20-min 
loading/uptake phase (Figure 1.4).  Another potential issue relates to cell integrity in prolonged and 
repeated -Ca2+ conditions; this does not appear to be an issue in rat SCH as judged by LDH release (<5% 
of total cellular content over the study period).  The advantages and limitations associated with these two 
approaches suggest that maintaining tight junction modulation throughout the study period [Fig. 1.3, (B)] 
is the most appropriate method for conducting efflux studies in the SCH system. It should be noted that a 
modeling and simulation approach to data analysis is required in order to differentiate basolateral and 
biliary efflux from flux out of bile spaces in +Ca2+ conditions.  Using this approach, it is possible to 
elucidate the relative contribution of basolateral and biliary efflux to the total hepatocellular elimination 
of probe drugs. 
Whole Tissue and Animal Models 
Isolated perfused livers (IPLs) are considered the “gold standard” for studying the hepatobiliary 
system in isolation, without the influence of extrahepatic components(189).  Single-pass and recirculating 
configurations are possible, both offering direct sampling of bile and determination of biliary excretion.  
A useful feature of the single-pass method in the context of hepatic efflux is that it allows continuous 
sampling of outflow perfusate.  When coupled with a protocol in which drug is added to the perfusate 
(“loading” phase) and then switched over to blank buffer (“efflux” phase), the single-pass method is an 
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established approach to measure basolateral efflux directly(26; 190).  However, when coupled with an 
appropriate experimental design and pharmacokinetic modeling of generated data, recirculating and 
single-pass IPLs are both useful for investigating hepatobiliary transport.  In theory, liver tissue can be 
used from any species or strain, including those with natural or targeted disruption of genes encoding 
transport proteins, as described in further detail below. 
A common paradigm for evaluating the role of transport proteins in the hepatobiliary disposition 
of drugs is to use a combination of single- and multiple-knockout animal models, as discussed above.  
Although there exist a number of naturally-occurring mutant animal strains in which transporter genes are 
disrupted, such as Abcc2-/Mrp2-deficient rats (TR- Wistar or EHBR Sprague-Dawley), targeted knockout 
of transporter genes has been limited primarily to mice.  A recent development has been the application 
and marketing of zinc-finger nuclease technology, allowing efficient, targeted editing of the genome in a 
variety of preclinical species.  This technology is offered from Sigma (St. Louis, MO) under the SAGE 
(Sigma Advanced Genetic Engineering) line of products.  These models have been adopted for a variety 
of biomedical research applications, including ADME and drug transport, with various single- and 
multiple-knockout models available.  Abcb1-/-, Abcg2-/- and Abcc2-/- SAGE rat models were characterized 
recently using loperamide, paclitaxel, sulfasalazine and carboxydichlorofluorescein.(191)  One limitation 
to knockout animal models is that compensatory regulation of other transport mechanisms may confound 
the interpretation of generated data.  Another challenge in distinguishing the role of hepatic excretion in 
vivo as the definitive mechanism responsible for DDIs and altered pharmacokinetics is that many of the 
same transport proteins are present at other epithelial barriers, most notably the apical border of the 
intestine and kidney.  For example, Abcb1-/- and Abcg2-/- rats, along with chemical inhibitors (GF-
120918) and bile-duct cannulation were used to differentiate the role of Abcb1/P-gp and Abcg2/Bcrp in 
the biliary excretion/enterohepatic recirculation versus direct excretion from the circulation into the 
intestinal lumen of intravenously-administered apixaban, a Factor Xa inhibitor.(192)  Similarly, the 
biliary excretion of nitrofurantoin, sulfasalazine and a proprietary compound were decreased 70-90% in 
Bcrp knockout rats, with differential effects on systemic clearance, urinary excretion and oral absorption 
36 
 
depending on clearance pathways and compound properties.(193)  These studies highlight the fact that 
transport proteins contributing to hepatocellular efflux exist in other tissues, and altered function may be 
global (germline genetic variation) or local (DDIs, tissue-specific disease states or epigenetic regulation), 
with implications for hepatic or systemic exposure and alternative clearance pathways.  In addition, since 
transport proteins are responsible for the disposition of many endogenous and exogenous substances, and 
vectorial transport from blood to bile is often a result of overlapping substrate specificity and reliance on 
multiple mechanisms, a complex network of cellular regulation is often perturbed along with transport 
function, leading to compensatory/additional changes in disposition mechanisms. 
General Strategies 
While animal models are useful and convenient for evaluating transporter activity, translating these data 
to humans can be challenging and must be done with caution, due to potential species differences in 
substrate and/or inhibitor affinity.  A common strategy for strengthening the extrapolation of animal data 
to human conditions is to perform studies in systems (e.g., membrane vesicles, transfected cell lines) 
containing the human-specific homologues/isoforms that were shown to be important in animals(151; 
152).  A common paradigm for exploring the involvement of multiple transporters is a combination of 
genetic knockout and chemical “knockdown” in cultured hepatocytes, isolated livers and whole animals.  
Perhaps the most common application is the use of naturally-occurring Abcc2-/Mrp2-deficient rats (TR- 
Wistar or EHBR Sprague-Dawley), combined with an inhibitor, such as GF120918 (elacridar) for 
modulation of Abcb1/P-gp and/or Abcg2/Bcrp.(50; 52; 192)   In this way, one can elucidate the role of 
some of the most common transporters involved in the biliary excretion of drugs.  The only major biliary 
excretion mechanism excluded in this paradigm is Abcb11/Bsep.  Chemical inhibition is used commonly 
with the intention to assess the impact of individual transport pathways on the pharmacokinetics of drugs.  
However, when inhibitors are used in complex systems such as intact organs and whole animals, they 
often interact with multiple transport pathways.  Thus, the use of chemical inhibitors intended to disrupt 
single mechanisms may reveal the involvement of multiple transport pathways in the hepatobiliary 
disposition of compounds(157).  
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Future Challenges 
Tools to Study Xenobiotic Transport 
 One of the complexities and challenges of studying drug transport is the overlapping substrate 
specificity and redundant transporter activity in a given tissue.  As a result, there remain no truly selective 
substrates or inhibitors to study the role of individual transporters in complex in vitro or in vivo models, 
including clinical DDI studies in humans(173). In addition, there is an urgent need for probes and 
methods to measure and characterize definitively the consequences of altered transport function on organ 
and tissue exposure of chemicals in vivo  in humans(173).  For these reasons, efforts must continue to 
further characterize existing and prospective probe substrates and inhibitors for their potential to interact 
with the panoply of transporters and mechanisms of regulation.   
In Vitro-In Vivo Correlations 
Scaling of in vitro transporter data into accurate in vivo predictions remains a significant 
challenge.  It is widely accepted that one of the primary gaps currently precluding successful 
extrapolation is knowledge concerning the quantitative differences in transport protein expression 
amongst the in vitro systems used to evaluate transport protein function, and between these in vitro 
models and whole tissue expression in vivo(194).  Mass spectrometry-based quantitative proteomics 
efforts are underway by a number of investigators to fill this gap for the major proteins involved in the 
hepatobiliary disposition of drugs.  These efforts have been advanced greatly by the work of Terasaki and 
colleagues(195-199) in an academic setting, as well as Lai and colleagues(177; 178; 200-202) in the 
pharmaceutical industry.  This work has focused primarily on whole-cell or -tissue expression(178; 198), 
often following isolation of crude membrane fractions(177; 202) in order to reduce background 
interference from the cell and tissue milieu.  These reports have proven useful to improve or confirm 
previous scaling efforts that used empirical approaches based on directly scaling transport activity of 
prototypical substrates between systems(51; 179; 180; 196; 200; 201; 203-208).  However, future efforts 
will continue to refine the quantitative proteomics methods to distinguish the transporter expression at the 
plasma membrane, which is believed to be the appropriate input to establish an accurate stoichiometric 
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relationship for single molecule-transporter interactions.  Further characterization might include 
subcellular transporter localization in the vesicular network, which may play a role in the cellular 
accumulation of some drugs and their ultimate excretion by vesicle trafficking and plasma membrane 
fusion, as discussed above.  Additionally, the role of post-translational modifications of transport proteins 
as they migrate through the antero- and retrograde vesicle pathways may be elucidated by the sensitive 
capabilities of mass spectrometry.  One of the challenges associated with characterizing the subcellular 
distribution of transporter expression is assessing and correcting for the efficiency of the methods used to 
isolate various subcellular components.  Although these methods have been established and incorporated 
into other quantitative proteomics efforts, the application of this technology to drug transporters remains 
in an early stage. 
Emerging transporters 
It is generally assumed that the transporters commonly involved in efflux of drugs and 
metabolites from hepatocytes into blood or bile have been identified.  However, transporters that were 
previously disregarded, or entirely unknown, continue to emerge as the field of drug transport moves 
forward.  One such example is the SLC47A, or Multidrug and Toxin Extrusion (MATE), family, which 
was first discovered in 1999 and cloned in 2005(209-212).  MATE1 has quickly come to prominence 
after reports describing its role in the renal handling of metformin and cisplatin, with associated 
alterations in efficacy and toxicity due to DDIs in humans and in knockout animals(213-215).  
Interestingly, MATE1 also is localized in the liver on the canalicular membrane, but the interactions 
observed in renal proximal cells do not appear to occur to an appreciable degree in hepatocytes.  The 
reasons for this remain unclear, but the understanding of MATE1 in the liver is likely to evolve.  
Similarly, the organic solute transporter (OSTα/β), SLC51, was discovered in 2001 and subsequently 
characterized in humans and rodents(216; 217).  Expression and localization of OST includes the 
basolateral membrane of the liver and small intestine, where it plays a significant role in bile acid 
transport and homeostasis(35).  Although known substrates of OST are limited currently to bile acids, 
steroid conjugates, eicosanoids and digoxin, additional drugs are likely to interact with this pathway(34-
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37).  These are just the latest transporters to be identified and characterized, but other proteins are likely 
to emerge as important players in hepatic efflux of xenobiotics.    
 
Conclusions 
The field of drug transport is evolving rapidly.  The growing body of knowledge, including substrates and 
inhibitors, has revealed a pattern of broad and overlapping substrate specificity for the various transport 
proteins.  While the majority of transport proteins mediating hepatic efflux have been identified and 
characterized with regard to tissue expression and localization, the interplay of multiple efflux 
transporters remains poorly understood and limits our ability to predict hepatocellular accumulation 
and/or routes of excretion when the function of one or more proteins is impaired, as outlined in the recent 
International Transporter Consortium White Paper(294). However, advances in quantitative proteomics, 
determination of intracellular concentrations, in vitro-in vivo extrapolation and pharmacokinetic modeling 
will continue to enable cutting-edge research in this critical area.  The ultimate goal is to improve the 
safety and efficacy of medications through a better understanding of hepatic efflux and its impact on the 
pharmacokinetics of drugs. 
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Table 1.1. Summary of hepatic efflux transporter expression changes in disease states. 
 
Transporter 
 PBC 
NAFLD/ 
NASH HCV 
HCV/ 
Cirrhosis 
HCC 
(mixed etiology) PFIC3 
ABCC1/MRP1       
mRNA (109) (31) (114)  (114)      (116; 117) (118)
Protein  (31)     
ABCC2/MRP2       
mRNA (108; 109) 
(31)  (114)  (114)      (116; 117)  
Protein  (107) (31)     (118)
ABCC3/MRP3       
mRNA (109) (31)    (113)     (114) 
 (114)    (109; 116)     
(117) 
 (118)
Protein (107) (31)     
ABCC4/MRP4       
mRNA  (107)           (31) 
 (113; 114)  (114)                  (116)  (118)
Protein  (107)  (31)   (114)   (118)
ABCB1/P-gp       
mRNA (109)  (31)  (113; 114)  (114)      (109; 116; 117) 
 (118)
Protein  (107)  (31)     
ABCG2/BCRP       
mRNA   (31)  (113; 114)  (114)         (116)   
Protein   (31)     
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Figure 1.1.  Localization of Human Transport Proteins Involved in Hepatocellular Disposition of Drugs. 
(Adapted from Chandra and Brouwer, Pharm Res, 21:719, 2004) 
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Figure 1.2. Fold change in exposure as a function of fe at various [I]/KI ratios as described by eq. 1. 
(Reprinted with permission from Zamek-Gliszczynski, et al. Drug Metab Dispos 37:386, 2009) 
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Figure 1.3.  Scheme depicting potential experimental uptake/efflux protocols in the sandwich-cultured 
hepatocyte (SCH) model.  Gray shading represents inclusion of substrate in the Hanks’ Balanced Salt 
Solution (HBSS) buffer during the uptake phase. 
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Figure 1.4.  Fluorescence intensity in bile networks observed following administration of 1 μM 
carboxydichlorofluorescein diacetate (CDFDA) according to the schemes depicted in Figure 1.4 for the 
uptake (A.) and efflux (B.) phase. 
 
A.  
 
B.  
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Project Rationale and Specific Aims 
The objective of this research project is to develop preclinical and clinical (translational) tools to assess 
hepatocellular exposure, identify the role of altered hepatic transport function, and explain the change(s) 
that would be expected.  This includes improving our mechanistic understanding of hepatobiliary drug 
disposition, specifically the role of overlapping substrate specificity (multiplicity of transport) and impact 
of impaired function of one or more transport proteins (due to genetic variation, drug interactions or disease 
states) on drug disposition.  In order to describe and predict hepatic exposure of drugs, including the effects 
of altered transport function, intracellular disposition of substrates and inhibitors must be better understood.   
In summary, the first aim of this research project was to administer 99mTc-mebrofenin (MEB) to 
human subjects, and measure changes in biliary excretion, as well as hepatic and systemic exposure, in 
order to elucidate the impact of ritonavir (RTV) coadministration, an inhibitor of multiple transport 
processes (Aim #1).  A second objective was to develop methods in the SCH model to evaluate 
intracellular disposition of a set of probe drugs, including the determination of unbound concentrations in 
total lysate and hepatic cytosol, and subcellular localization of each compound (Aim #2).   Finally, 
rosuvastatin (RSV) was used as a probe to estimate the relative contribution of basolateral vs. biliary 
excretion, and the impact of impaired transport function on hepatocellular accumulation and routes of 
excretion.  Candidate transporters that mediate basolateral efflux of RSV in humans were evaluated.  In 
vitro methods for estimating basolateral efflux in the SCH model system also were developed (Aim #3). 
Aim #1. Quantify the influence of hepatic transport protein modulation by ritonavir (RTV) on the 
hepatic exposure, systemic disposition and biliary excretion of 99mTechnetium-mebrofenin (MEB) in 
humans. 
Hypothesis: RTV modulates one or more canalicular and/or basolateral transport proteins responsible for 
MEB disposition.  This modulation can be measured in humans using a novel oral tube method for bile 
collection and noninvasive imaging technology to quantify tissue exposure in vivo.  Mechanistic 
understanding of the interaction can be gleaned using in vitro and in vivo data coupled with 
pharmacokinetic modeling/simulation.   
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1.a.  Quantify the effects of the transport protein inhibitor RTV on MEB hepatic exposure, biliary 
excretion and systemic disposition in vivo in healthy volunteers. 
1.b.  Characterize, in human SCH, the effects of RTV on MEB hepatocellular accumulation and excretion. 
1.c. Use in vitro and in vivo data (1.a.,b. and Aim #2) with PK modeling/simulation to gain a mechanistic 
understanding of the impact of RTV-mediated transporter modulation on MEB disposition in 
humans. 
Aim #2. Examine the utility of sandwich-cultured hepatocytes (SCH) to assess the role of intracellular 
binding/sequestration in the hepatic accumulation of probe drugs.  
Hypothesis: Intracellular binding/sequestration contributes to the hepatic accumulation of RTV and other 
drugs, and influences their ability to interact with enzyme systems (metabolism and transport) involved in 
their own hepatic disposition, and the disposition of other drugs (DDI potential). 
2.a.  Determine uptake, efflux and hepatocellular accumulation (including fraction unbound and 
subcellular localization) of probe drugs in rat SCH, and compare with available in vivo data and/or 
data generated in 2.b.   
2.b. Determine the hepatic accumulation, unbound fraction and subcellular localization of ritonavir in rat 
isolated perfused livers (IPLs), and compare results with data generated in 2.a. and available in vivo 
data. 
Aim #3. Evaluate the role of basolateral efflux in hepatocellular accumulation of rosuvastatin (RSV) 
in the setting of impaired biliary excretion. 
Hypothesis: Impaired biliary excretion will increase hepatocellular accumulation and shift excretory 
routes based on the relative involvement of basolateral efflux, which may be mediated by MRP3 and/or 
MRP4 in humans.  
3.a.  Define the role of basolateral and canalicular efflux in the hepatocellular disposition of RSV in SCH 
under conditions of impaired function of Mrp2 (TR- rats) and Bcrp (GF120918), alone and in 
combination, compared to control. 
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3.b. Define the role of basolateral and canalicular efflux in the hepatobiliary disposition of RSV using rat 
isolated perfused livers (IPLs), and establish scaling factors for clearance values determined in SCH 
(3.a.).  
3.c. Determine the potential of MRP3 and MRP4 to mediate basolateral efflux of RSV in human liver 
using the membrane vesicle system. 
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CHAPTER 2 
 
Effect of Ritonavir on 99mTechnetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling 
and In Vitro Approach to Predict Transporter-Mediated DDIs 
Introduction 
Transport proteins present in clearance organs, specifically liver and kidney, are a well-
recognized source of potential drug-drug interactions (DDIs)(1; 2).  Inhibition of uptake and/or efflux 
transporters in the polarized cells of clearance organs may alter drug exposure in the organ, in the 
systemic circulation, or in both, leading to changes in efficacy and/or toxicity(3; 4).  Changes in systemic 
exposure may be detected from the blood concentration-time curve, whereas organ exposure is more 
difficult to assess.  However, assessing organ drug exposure is important in order to understand, in a 
comprehensive manner, the effects of altered transport function and identify the specific site(s) and 
magnitude of DDIs.   
Scintigraphic imaging is a non-invasive technique that can be employed to determine organ 
exposure(5).  99mTechnetium (99mTc)-labeled compounds, coupled with gamma scintigraphy, have been 
used to estimate the hepatic exposure of drugs by assessing alterations in hepatic uptake and excretion(6; 
7), and to evaluate the involvement of specific transport proteins(8; 9).  Changes in systemic and organ 
exposure, as well as biliary excretion of 99mTc-labeled compounds, can be quantified using a previously 
validated method for bile collection, including a correction for gallbladder ejection fraction(10).  An 
integrated approach incorporating pharmacokinetic modeling and simulation of clinical data (biliary  
excretion, systemic and organ exposure) can then guide in vitro investigations to elucidate sites and 
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mechanisms of DDIs. 
In vitro systems are commonly used to evaluate transporter function, and predict or confirm 
DDIs(11). Membrane vesicles prepared from transfected cell lines are useful to characterize substrate 
specificity and inhibitory potential of a given transport protein in isolation, although the relative 
contribution of individual transport proteins to overall hepatic uptake or excretion is difficult to elucidate 
using these artificial systems.  A more representative, organ-specific, whole-cell system, such as 
sandwich-cultured hepatocytes (SCH), can be used to investigate the relative contribution of hepatic 
uptake and canalicular excretion processes to overall biliary clearance, and to estimate intracellular drug 
concentrations(11; 12). 
99mTc-Mebrofenin (Choletec®), a metabolically stable iminodiacetic acid (IDA) analogue, is an 
imaging agent utilized in nuclear medicine to diagnose structural and functional disorders of the 
hepatobiliary network and gallbladder(13-15).  The efficient vectorial transport of 99mTc-mebrofenin from 
blood into liver is mediated by the organic anion transporting polypeptides, OATP1B1 and OATP1B3(9; 
16; 17); 99mTc-mebrofenin is preferentially excreted into bile unchanged by the canalicular efflux 
transporter multidrug resistance protein 2 (MRP2)(9; 16; 18).  99mTc-Mebrofenin also can be excreted 
from hepatocytes back into blood by MRP3(9).  The important role of MRP2-mediated biliary excretion 
as the rate-limiting step for 99mTc-mebrofenin elimination in vivo is evidenced by increased and prolonged 
hepatic exposure of 99mTc-mebrofenin and other IDA analogues in preclinical species (TR- rats) and 
humans (Dubin-Johnson syndrome) with genetic impairment of Mrp2/MRP2(14; 18-21).  Probe 
substrates to assess transport function in vivo are a highly sought-after clinical tool; 99mTc-mebrofenin has 
been proposed as a probe substrate for MRP2(11) but has yet to be tested in a clinical DDI study. 
Ritonavir, an HIV protease inhibitor, is a typical component of anti-retroviral therapy.  Ritonavir 
is administered as a “boosting” agent in combination with other protease inhibitors to exploit the 
inhibition of intestinal P-gp transport and metabolic enzymes, thereby increasing the bioavailability of 
anti-retroviral medications administered concomitantly(22; 23).  Ritonavir is also a substrate and inhibitor 
of the biliary transporter MRP2(24; 25), with an IC50 reported as low as 50nM in teleost fish(26).  
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Consequently, we hypothesized that concomitant ritonavir administration would decrease the biliary 
excretion of 99mTc-mebrofenin, thereby increasing hepatic exposure.  Ritonavir also has been reported to 
inhibit hepatic OATPs/Oatps, with an IC50 ranging from 0.25-2.5µM(27; 28).  Therefore, at higher 
concentrations, ritonavir may inhibit 99mTc-mebrofenin hepatic uptake, thereby increasing systemic 
exposure.  
These studies employed 99mTc-mebrofenin as a probe for transport-mediated hepatobiliary 
clearance, with and without ritonavir as a “perpetrator” of DDIs.  The blood, liver and bile dataset was 
used to develop a semi-physiologically-based pharmacokinetic (semi-PBPK) model to describe 99mTc-
mebrofenin disposition in humans, including clearance pathways mediated by transport proteins, and to 
elucidate potential site(s) and mechanism(s) of the 99mTc-mebrofenin-ritonavir DDI.  In vitro studies were 
conducted using relevant model systems for hepatobiliary transport in humans to substantiate the results 
of pharmacokinetic modeling and simulation.  We report a translational approach and suggested 
framework for the use of 99mTc-mebrofenin as a clinical probe to evaluate DDIs in hepatobiliary transport. 
Results 
Effect of ritonavir on 99mTc-mebrofenin disposition in human subjects 
99mTc-Mebrofenin (mean ±SD) blood concentration-time curves are shown in Figure 2.1A, after 
administration of a 2.5mCi intravenous dose to 18 healthy volunteers either (a) alone (control; n=8), (b) 
2h after a single, 200mg oral ritonavir dose (n=7), or (c) following 300mg oral ritonavir doses 
administered at 14 and 2h prior to 99mTc-mebrofenin (n=3).  99mTc-Mebrofenin blood concentrations 
declined rapidly, with prompt distribution into the liver, followed by a slower terminal elimination phase.  
Pharmacokinetic parameters resulting from noncompartmental analysis are summarized in Table 2.1; area 
under the 99mTc-mebrofenin blood concentration-time curve (AUCblood,0-∞) was significantly greater, by 
approximately two-fold, in subjects treated with 2x300mg ritonavir compared to control.  Observed 
ritonavir plasma concentrations ranged from 236 to 16,100ng/mL (0.33 to 20μM; Table 2.1).  Ritonavir 
concentrations in plasma (and bile) were significantly greater in subjects pre-treated with 2x300mg 
ritonavir compared to a single 200mg dose (Table 2.1). 
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Biliary recovery of 99mTc-mebrofenin was corrected for gallbladder ejection fraction (EF), with an EF 
ranging from 8 to 96% (Table 2.1).  Biliary recovery was similar between treatment groups, at 75±12, 
59±11 and 72±2% of the administered dose in control, 200mg and 2x300mg ritonavir groups, respectively 
(Table 2.1).  Urinary recovery of 99mTc-mebrofenin (approximately 1% of the administered dose) was 
negligible and unaffected by ritonavir treatment. 
Hepatic imaging of 99mTc-mebrofenin over 180min revealed rapid uptake by the liver (Figure 2.1B).  
The time of maximum liver concentration (tmax,liver) was 11±3, 11±4, and 10±1min in control, 200mg and 
2x300mg ritonavir groups, respectively (Table 2.1).  This agrees well with the reported value of 
11min(14; 29).  The elimination half-life based on hepatic time-activity curves from the current study, 
determined from 30-60min by nonlinear regression, was 19±5, 19±5 and 18±1min in control, 200mg and 
2x300mg ritonavir groups, respectively (Table 2.1), compared to previous reports of ~15min(14; 29).  
Subjects greater than 20% of ideal body weight were excluded in the present study to minimize individual 
differences in body mass and composition, which could result in variable attenuation of the scintigraphic 
imaging data.  Activity at liver tmax was 1950±252, 2003±274 and 1890±508 counts per second in control, 
200mg and 2x300mg ritonavir groups, respectively (Figure 2.1B and Table 2.1).  There was no apparent 
difference in 99mTc-mebrofenin overall liver exposure in the presence or absence of ritonavir based on the 
mean liver activity profiles. 
The 99mTc-mebrofenin liver-to-blood ratio was calculated using blood sampling points and 
corresponding liver activity from scintigraphic imaging data (Figure 2.1C).  The peak at 40min and 
subsequent decline suggested more complicated disposition than a mammillary two-compartment model 
representing blood and liver with constant first-order transfer rates as previously described(9; 14; 29). 
Pharmacokinetic modeling 
A semi-PBPK model was developed to describe 99mTc-mebrofenin activity in blood, liver and bile 
(Figure 2.2).  The extrahepatic compartment in the semi-PBPK model represented a high-volume, slowly-
perfused tissue(s), with an apparent permeability-limited uptake and egress.  Parameters representing 
transport-mediated clearance mechanisms were obtained by fitting the model to data from the two 
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subjects with available individual attenuation-corrected liver scintigraphy data (Figure 2.2, Table 2.2; see 
Supplemental Materials for details).  A separate model fit and parameter set were obtained for the mean 
control group data (biliary recovery, blood and liver concentrations) because the “representative” control 
subject for which attenuation-corrected data was obtained exhibited the highest biliary recovery of all 
values observed.  Since liver data across all subjects was not corrected for attenuation, an attenuation 
correction factor was included as a parameter in the model and estimated to scale counts/sec data to 
activity in nCi/g liver (Table 2.2).    
Sensitivity Analysis 
Sensitivity analysis of parameter estimates on model output was conducted as described in 
Supplemental Material, with resulting changes in predicted blood and liver exposure and biliary excretion 
shown in Figure 2.3.  Blood exposure was most sensitive to inhibition of hepatic uptake.  However, 
impaired hepatic uptake also would be expected to decrease hepatic exposure and biliary excretion.  No 
single parameter change explained the observed increase in 99mTc-mebrofenin blood exposure in the 
absence of changes in hepatic exposure or biliary excretion, indicating that a combination of factors was 
necessary to describe the effect of ritonavir.  Hepatic exposure was particularly sensitive to impaired 
biliary clearance (hepatocyte-to-bile), which supports the conclusions from the clinical study that 
ritonavir did not significantly decrease 99mTc-mebrofenin biliary clearance.  In contrast, the model was 
relatively insensitive to changes in efflux from tissue (hepatic or extrahepatic) back into blood. 
Simulations 
Simulations were conducted to explore various scenarios representing the potential impact of 
ritonavir on 99mTc-mebrofenin disposition.  Decreased 99mTc-mebrofenin uptake and increased sinusoidal 
efflux only from the hepatic compartment (Figure 2.4, black dashed lines) adequately described blood and 
liver concentrations, but predicted a decrease in biliary excretion.  This decrease was not observed in the 
clinical study.  Decreased 99mTc-mebrofenin uptake and increased efflux back into blood from both the 
hepatic and extrahepatic compartments were required in simulations to describe the increase in 99mTc-
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mebrofenin systemic exposure observed in the presence of 2x300 mg ritonavir, with minimal impact on 
hepatic exposure and biliary recovery (Figure 2.4, gray dashed lines). 
In Vitro Studies 
The effect of ritonavir on ATP-dependent uptake of 99mTc-mebrofenin by membrane vesicles 
prepared from human embryonic kidney cells (HEK293) transiently transfected with MRP2 was 
determined, as reported previously(9).  Membrane vesicles were incubated for 3 min at 37°C with 
50μCi/mL 99mTc-mebrofenin in the presence of ritonavir.  Ritonavir 5 and 50μM inhibited ATP-
dependent uptake of 99mTc-mebrofenin into MRP2-expressing HEK293 membrane vesicles by 32±15 and 
60±2% of control, respectively (mean±SD in triplicate).  By comparison, 50μM MK571, a prototypical 
MRP inhibitor, reduced ATP-dependent transport of 99mTc-mebrofenin by 88±2%(9).   
 The effect of ritonavir on 99mTc-mebrofenin accumulation and biliary excretion in human 
sandwich-cultured hepatocytes (SCH) was determined (Figure 2.5).  Ritonavir inhibited 99mTc-mebrofenin 
accumulation in cells+bile and cells in a concentration-dependent manner (Figure 2.5A), with an IC50 of 
3.46 ±1.53μM on total uptake (cells+bile), based on the extracellular dosing concentration.  In contrast, 
ritonavir had no effect on the biliary excretion index (BEI) of 99mTc-mebrofenin in SCH, consistent with 
the clinical data and associated pharmacokinetic analysis suggesting that ritonavir did not affect 99mTc-
mebrofenin biliary clearance.  Intracellular ritonavir concentrations were estimated to facilitate 
comparison with membrane vesicle data.  Hepatocellular accumulation of ritonavir during the 10-min 
uptake study in human SCH was 5-10 fold higher than the dosing concentration (Figure 2.5B), based on 
estimates of cellular volume reported previously(30).  Based on total cellular accumulation of ritonavir 
(up to 100μM) in human SCH, and the estimated IC50 value (5-50μM) against MRP2-mediated 99mTc-
mebrofenin transport determined in membrane vesicles, ritonavir would be expected to inhibit 99mTc-
mebrofenin biliary excretion in SCH.  However, ritonavir was extensively bound in lysates from human 
hepatocytes (fu=0.024 ±0.006).  Thus, correcting for the intracellular unbound concentration revealed that 
the effective cellular concentration of ritonavir was lower than the concentration necessary to 
significantly inhibit MRP2. 
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Discussion 
This work highlights how in vitro and in silico approaches, including pharmacokinetic modeling 
and simulation, as well as transport studies conducted in relevant model systems, can be used to predict 
the site(s) and potential impact of hepatic transporter-mediated DDIs in humans in vivo.  Furthermore, 
this clinical study demonstrates the utility of 99mTc-mebrofenin as a model organic anion to evaluate DDIs 
in transporter-mediated hepatobiliary clearance.  To our knowledge, this is the first study that utilizes 
liver scintigraphy data to evaluate a hepatic DDI, and incorporates blood, bile and urine data in humans to 
develop a comprehensive pharmacokinetic model describing 99mTc-mebrofenin disposition.   
Previously published data involving administration of 99mTc-mebrofenin (and other IDA 
derivatives) in humans or animals focused on the time-activity data in blood and liver up to 60min(14; 31-
34).  A two-compartment model representing blood and liver reasonably approximated 0-60min time-
activity data in these studies(31; 32).  However, extending the time course of blood and liver observations 
to 180min clearly demonstrates more complex pharmacokinetic behaviour; the statistically-significant, 
two-fold increase in 99mTc-mebrofenin systemic exposure without accompanying changes in hepatic 
exposure or biliary recovery observed following ritonavir administration (2x300mg) is not consistent with 
a 2-compartment model.  99mTc-Mebrofenin did not accumulate in extrahepatic tissues within the gamma 
camera field-of-view, yet the liver-to-blood ratio and incomplete recovery of total activity in urine and 
bile suggested an extrahepatic component to 99mTc-mebrofenin disposition.  Therefore, a modeling and 
simulation approach was undertaken to describe 99mTc-mebrofenin disposition and elucidate the probable 
sites of the 99mTc-mebrofenin-ritonavir interaction. 
99mTc-Mebrofenin rapidly and extensively distributed to the liver.  The 99mTc-mebrofenin hepatic 
extraction ratio was 0.80±0.16 [(mean±SD), range 0.55-1]  in control subjects, based on the observed 
clearance from  noncompartmental analysis (Cltotal/Qh; Table 2.1).  In contrast to previous reports 
estimating hepatic extraction at nearly 100% (29), this suggests that 99mTc-mebrofenin hepatic clearance 
would be susceptible to changes in hepatic uptake.  This is consistent with the observed changes in 99mTc-
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mebrofenin disposition following ritonavir administration, which resulted from inhibition of uptake into 
both hepatic and extrahepatic sites of distribution.   
Total plasma concentrations of ritonavir, measured at the beginning and end of the 3-h study period (2 
and 5h following ritonavir administration) ranged from 236 to 16,100ng/mL (0.33 to 20μM).  Intestinal 
absorption of ritonavir was estimated to contribute ~12,000 and 18,000ng/mL (17 and 25μM) to the 
incoming portal blood for the 200 and 300mg doses, respectively, using the previously reported approach 
(ka●Dose●Fa/Qh, where ka represents the absorption rate constant and Fa represents the fraction 
absorbed)(35).  The maximum estimated portal vein concentration (up to 45μM) exceeded the IC50 for 
99mTc-mebrofenin uptake in human SCH (~3.5μM).  Even though ritonavir is highly protein bound 
(plasma fu0.01), unbound concentrations were predicted to be in the range of concentrations expected to 
inhibit hepatic uptake.  Human SCH data, correlated well with the clinical data and pharmacokinetic 
modeling indicating that ritonavir inhibited 99mTc-mebrofenin hepatic uptake, with no effects on biliary 
excretion.  The present study suggests that ritonavir may inhibit the hepatic uptake of other OATP 
substrates resulting in increased systemic exposure, similar to previous reports (25; 28; 36).  The 
magnitude of this increase and altered exposure in hepatic and extrahepatic tissues will depend on the 
substrate- and tissue-specific involvement of transport-mediated distribution and clearance, and the effect 
of ritonavir on these processes.  In addition to inhibition of uptake, parameter estimates (Table 2.2) 
suggest enhanced hepatic basolateral efflux (PSeff,h) , which may be explained by increased basolateral 
transporter expression (e.g. MRP3 or MRP4) and/or increased unbound fraction of 99mTc-mebrofenin  in 
the liver. 
Good agreement was found between observed CLtotal of 99mTc-mebrofenin (15.9±3.2 mL/min/kg in 
control group, Table 2.1) and predicted CLuptake based on in vitro uptake in human SCH (10.6±3.1 
mL/min/kg, Supplemental Material).  Similarly, predicted CLbiliary, based on data obtained in human SCH, 
was 4.4±1.5 mL/min/kg, compared to the observed CLbiliary of 12.5±2.5 mL/min/kg in control subjects.    
The in vitro intrinsic CLuptake was ~50-fold lower than the corresponding value (PSinf) estimated by the 
semi-PBPK model, which agrees well with reported scaling factors for hepatic uptake clearance in SCH 
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(37-39).  It should be noted that the in vitro CLuptake of 99mTc-mebrofenin in human SCH, along with the 
calculated IC50 value of ritonavir on 99mTc-mebrofenin accumulation, represents the net effect of all 
sinusoidal uptake and efflux transporters [e.g., at least OATP1B1, OATP1B3 and MRP3(9; 17)] involved 
in the hepatocellular disposition of 99mTc-mebrofenin. 
Impaired function of MRP2 in humans and Mrp2 in preclinical species has been reported to delay 
elimination of 99mTc-mebrofenin and other IDA derivatives from the liver, with a significant increase in 
hepatic exposure and time to half-maximal concentration(14; 18-21).  Sensitivity analysis and simulations 
using data from the current study also confirmed that hepatic exposure was highly sensitive to biliary 
clearance; even modest (2-fold) changes in this parameter should have an apparent effect on the slope of 
the liver time-activity curves.  These data imply that 99mTc-mebrofenin clearance from liver to bile in the 
current study was not influenced significantly by ritonavir, even though ritonavir is an MRP2 inhibitor.  
Previous reports of Mrp2/MRP2 inhibition by ritonavir utilizing a non-mammalian model system 
[killifish isolated proximal tubules(26)] and mammalian systems (rat and human SCH), confirmed 
species- and substrate-specific interaction potential(25).  Studies in human SCH, coupled with MRP2 
membrane vesicles and ritonavir binding to human hepatocyte lysates,  corroborate the lack of effect of 
ritonavir on 99mTc-mebrofenin biliary excretion observed in the clinical study, suggesting that the reported 
approach using complementary in vitro systems is useful to predict transporter-mediated DDIs in biliary 
excretion.  Although total ritonavir accumulation in SCH exceeded the estimated IC50 for 99mTc-
mebrofenin transport into MRP2-expressing membrane vesicles, extensive hepatic binding explains why 
intracellular ritonavir concentrations were insufficient to inhibit 99mTc-mebrofenin excretion into bile in 
humans.  These findings demonstrate the importance of correcting for the intracellular unbound 
concentration when translating between isolated expression systems and whole cell models or in vivo 
intracellular targets.  This study also emphasizes the importance of using appropriate in vitro systems and 
specific substrate-inhibitor combinations to accurately assess DDI potential. 
In the present study, decreased hepatic uptake of 99mTc-mebrofenin in the presence of ritonavir led to 
increased systemic exposure but did not result in altered hepatic exposure or biliary excretion.  These 
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findings are counter-intuitive until one considers the effect of 99mTc-mebrofenin extrahepatic distribution, 
which also is subject to alteration by ritonavir, based on the modeling and simulation results.  Inhibition 
of 99mTc-mebrofenin uptake in both hepatic and extrahepatic sites of distribution would collectively 
increase systemic exposure such that decreased uptake would yield little net change in tissue exposure 
(dXtissue/dt=Csystemic●CLuptake).  This concept recently was demonstrated for metformin in the setting of 
impaired transport function in liver and kidney(40).  The extrahepatic distribution of 99mTc-mebrofenin is 
not surprising; semi- or whole-body PBPK models have been applied to a number of large and/or anionic 
drugs(41-44).  An outstanding question from this clinical study is the identity of the extrahepatic site(s) of 
99mTc-mebrofenin distribution, accounting for ~10-40% of the administered dose at 180min.  Observed 
99mTc-mebrofenin activity was confined to the liver and gallbladder regions during the scintigraphic 
imaging, thereby excluding other tissues within the gamma camera field-of-view, which included the bulk 
of the torso and resident organ systems, as potential distribution sites.  Human skeletal muscle expresses 
transport proteins that have been implicated in drug distribution and toxicity(45; 46).  Further studies are 
required to confirm the identity of other tissue(s) involved in the extrahepatic distribution of 99mTc-
mebrofenin. 
The availability of quantitative (attenuation corrected) scintigraphy data in humans marks a major 
advance in the use of imaging agents to assess organ/tissue exposure.  Although the methods have existed 
for many years, they are under-utilized and provide a rich data set that is ideal for pharmacokinetic 
modeling.  The present clinical study has further characterized 99mTc-mebrofenin as a clinical probe of 
transporter-mediated hepatobiliary clearance, and demonstrated the need to quantify99mTc-mebrofenin  in 
blood and urine beyond 180min to further characterize the terminal elimination phase.  A semi-PBPK 
modeling and in vitro systems approach elucidated unforeseen mechanisms underlying a transporter-
mediated DDI at both hepatic and extrahepatic sites of 99mTc-mebrofenin distribution.  In vitro studies 
confirmed the conclusions from modeling and simulation that ritonavir inhibited 99mTc-mebrofenin 
hepatic uptake, but not biliary excretion, at clinically relevant concentrations.  This complimentary set of 
in vivo and in vitro studies demonstrates that reliable predictions of transporter-mediated hepatic DDIs 
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can be achieved when data from appropriate in vitro models (e.g., assessment of inhibitory potential in 
relevant systems; biliary excretion assessed in SCH) are integrated with knowledge regarding drug 
disposition (e.g., hepatic and extrahepatic distribution; plasma and intracellular binding) utilizing a 
quantitative systems approach. 
Methods 
Clinical Protocol 
A randomized, open-label, two arm, parallel study, approved by the University of North Carolina 
Institutional Review Board (IRB), was conducted in the Clinical and Translational Research Center.  
Written informed consent was obtained from all subjects prior to enrollment.  Healthy male and female 
subjects (19-29yrs of age), within 20% of ideal body weight (51-91kg), were admitted to the CTRC the 
evening before the procedure (see Supplemental Materials for detailed demographic information).  
A customized oroenteric tube was positioned in the upper small intestine, using the protocol 
described previously(10). Following tube placement, the balloon was inflated with 20mL of air, and then 
subjects were positioned under a gamma camera in the supine position.  A 2.5mCi intravenous bolus dose 
of 99mTc-mebrofenin was administered via an indwelling catheter placed in a forearm vein; subjects 
randomized to the ritonavir-treated group also swallowed two 100mg capsules of ritonavir before 
placement of the oroenteric tube, which occurred approximately 2hr prior to 99mTc-mebrofenin 
administration.  Blood samples were collected from a catheter placed in the arm opposite of 99mTc-
mebrofenin administration at baseline, and at designated time points up to 180min after administration of 
the 99mTc-mebrofenin dose.  Biliary secretions were aspirated continuously via the oroenteric catheter and 
pooled over predetermined intervals throughout the study.  Urine was collected at baseline and pooled 
over 180min.  Anterior and posterior scintigraphic images of the abdomen were acquired dynamically in 
the 99mTc window (140KeV ±15%) at 1-min intervals using a dual headed gamma camera.  Two hours 
after 99mTc-mebrofenin administration, 0.02μg/kg cholecystokinin octapeptide (CCK-8, Kinevac®) was 
administered as a 30-min intravenous infusion.  The gallbladder ejection fraction (EF) was calculated 
from the abdominal scintigraphy images and total biliary recovery of 99mTc-mebrofenin was corrected for 
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EF to minimize inter-subject variability associated with gallbladder response to CCK-8 as described 
previously(10).  Blood, bile and urine samples were analyzed for 99mTc-mebrofenin radioactivity with a 
sodium iodide well counter, and corrected for decay (99mTc t1/2=6.01 hr).  Bile samples associated with 
bulk gallbladder emptying following CCK-8 administration at 120min, as well as plasma samples at 0 and 
180min (approximately 120 and 300min post ritonavir dose) were analyzed for ritonavir by HPLC or LC-
MS/MS as described previously(47; 48).  99mTc-Mebrofenin activity was determined in counts/min (CPM) 
from the geometric mean of the anterior and posterior scintigraphic images, thereby normalizing for the 
abdominal thickness of the individual subject.  Liver time-activity curves were generated by scaling 
activity in a region of interest (ROI) over the right upper quadrant to activity in the whole liver based on 
the initial uptake phase, thereby excluding gallbladder interference from the 0-180min liver activity 
curve.   
Protocol Modifications  
Upon approval by the UNC IRB, the clinical protocol was modified to include an increased dose 
of ritonavir: 300mg (three, 100mg capsules) upon admission and before oroenteric tube placement 
(approximately 14 and 2hr, respectively, prior to 99mTc-mebrofenin administration).  The 2x300mg 
ritonavir regimen was intended to increase plasma ritonavir concentrations to a steady-state and reduce 
inter-subject variability observed in the group of subjects treated with the single 200mg dose regimen.  In 
addition, a transmission-emission acquisition was performed before injection of 99mTc-mebrofenin for the 
final control and ritonavir-treated subjects using a cobalt-57 flood source to determine the effect of 
photon attenuation, as described in Supplemental Materials. 
Pharmacokinetic Analysis 
 The area under the blood concentration-time curve (AUC) for 99mTc-mebrofenin was determined 
by noncompartmental analysis using WinNonlin Phoenix, v6.1 (St. Louis, MO).  AUC0-180 min and AUC0-∞ 
were calculated using the linear trapezoidal rule; extrapolation to infinity was determined by the slope 
from linear regression of the last 3-6 time points. 
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A semi-PBPK model was developed to describe 99mTc-mebrofenin distribution and elimination 
(Figure 2.2), consisting of a central (blood) compartment, 5-compartment liver representing the 
“dispersion” model of hepatic elimination, and extrahepatic tissue compartment.  Transfer between blood 
and tissue was denoted by transport-mediated clearance processes; passive diffusion was assumed to be 
negligible, based on data reported previously from in vitro systems(9; 17).  Differential equations 
describing the disposition of 99mTc-mebrofenin and the modeling procedures are detailed in Supplemental 
Materials. 
 In Vitro Studies 
 Hepatocytes were purchased from Celsis In Vitro Technologies (Baltimore, MD) or kindly 
provided by Life Technologies (Research Triangle Park, NC), and Triangle Research Labs (Research 
Triangle Park, NC) and plated on 24-well BiocoatTM plates and overlaid with MatrigelTM as described 
previously(12).  Hepatocyte donors consisted of two Caucasians and one African-American, ranging from 
46-59yrs of age, and BMI from 25.6-29.8kg/m2.  Cell cultures were maintained and  accumulation studies 
were conducted in SCH with 0.5μCi/mL 99mTc-mebrofenin in the presence or absence of ritonavir, as 
described previously(12), and further detailed in Supplemental Material.   
 Membrane vesicles were prepared from MRP2 over-expressing HEK293 cells and transport 
assays were carried out by a rapid filtration method as described previously(9; 49). 
 Human hepatocytes from two donors were used to determine the extent of ritonavir binding to 
cellular components by equilibrium dialysis as described previously(50).  Pellets containing ten million 
hepatocytes were diluted in 10 volumes of phosphate buffer and homogenized by probe sonication.  
Ritonavir was added to a concentration of 1μM, and aliquots (n=3) were loaded into a 96-well 
equilibrium dialysis apparatus (HTDialysis, LLC; Gales Ferry, CT)  and dialyzed against phosphate 
buffer for 6h with shaking at 37°C.  Ritonavir was quantitated by LC-MS/MS, and the unbound fraction 
was corrected for dilution as described previously(50): 
 
 
   1/D 1  - 1/fu
1/D fu  Undiluted
measured 

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Where D is the dilution factor. 
Statistical Analysis 
 Statistically significant differences in pharmacokinetic parameters across all three treatment 
groups were assessed by ANOVA on ranks, adjusted using Dunnett’s multiple comparisons test.  
Comparison of ritonavir concentrations between the two ritonavir-treated groups was performed using 
Wilcoxon Rank Sum.  The criterion for significance in all cases was p<0.05. 
Study Highlights 
Evaluation of altered intracellular drug concentrations due to hepatic transporter-mediated DDIs is limited 
due to lack of probes and methodology to assess hepatic exposure and hepatobiliary transport function in 
humans.  This novel approach utilized the hepatobiliary imaging agent 99mTc-mebrofenin as a probe to 
evaluate clinical DDIs in hepatic transport.  Modeling/simulation evaluated sites/mechanisms of the 
99mTc-mebrofenin-ritonavir DDI.  Quantitative scintigraphy data using imaging agents to assess tissue 
exposure provided a rich dataset for modeling, which revealed a novel 99mTc-mebrofenin extrahepatic 
distribution compartment.  Semi-PBPK simulations emphasized the impact of extrahepatic 99mTc-
mebrofenin distribution and transporter-mediated DDIs on systemic and tissue exposure.  In vitro data 
substantiated in vivo effects and modeling conclusions.  This work emphasized modeling, assessment of 
inhibitory potential in relevant in vitro systems, and intracellular unbound concentrations to predict 
complex hepatic DDIs.  We report a translational approach and suggested framework for use of 99mTc-
mebrofenin as a clinical probe to evaluate hepatobiliary transport DDIs. 
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Figure 2.1.  99mTc-Mebrofenin (A) blood concentration versus time curves; (B) liver scintigraphy versus 
time curves by treatment group (gray shaded area represents mean ±SD of control); (C) liver-to-plasma 
ratio versus time curves; mean data by treatment group.  Data are presented as group means [±SD in (A) 
and (B)]; gray = control group, open/dashed = 200mg ritonavir group, closed/solid = 2x300mg ritonavir 
group. 
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Figure 2.2.  Semi-PBPK model scheme (A) representing 99mTc-mebrofenin disposition in humans [Q 
denotes blood flow (mL/min), subscripts represent tissue or vascular compartments, as follows: liver (h), 
bile (bile), extrahepatic (“other”) tissue (o); clearance values are designated as CLuptake for influx from 
blood into tissue, CLefflux for efflux from tissue to blood, and CLbiliary for excretion from liver into bile].  
Simulations based on the semi-PBPK model and observed blood, liver and bile curves for 99mTc-
mebrofenin in subjects with quantitative scintigraphy data for (B) subject 8 (control), and (C) subject 17 
(2x300mg ritonavir).  Circles represent observed blood samples, solid lines represent simulated blood 
concentrations, + symbols represent observed liver concentrations from attenuation-corrected 
(quantitative) scintigraphy data of the liver ROI, dashed lines represent simulated liver concentrations, 
squares represent observed mass recovered in bile (corrected for gallbladder ejection fraction), and dotted 
lines represent simulated biliary excretion data. 
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Figure 2.3.  Sensitivity analysis of parameter estimates determined from the semi-PBPK model (Figure 
2.2; Table 2.2).  Parameters were altered 10-fold in either direction of the values estimated for mean 
control data (Table 2.2), and the fold-change in the predicted study endpoints [99mTc-mebrofenin central 
compartment (blood) exposure, hepatic exposure, and biliary excretion] were examined.  Solid lines 
represent influx clearance (CLuptake) from blood into tissue, dashed lines represent efflux clearance 
(CLefflux) from tissue to blood, and gray lines represent biliary excretion from liver into bile (CLbiliary). 
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Figure 2.4.  Simulations based on the 99mTc-mebrofenin semi-PBPK model scheme (Figure 2.2) for 
99mTc-mebrofenin (A) blood and (B) liver concentration-time data, and (C) cumulative % dose excreted in 
bile resulting from parameters describing mean control data (Table 2.2) and the following changes in 
transport-mediated processes, alone and in combination.  Mean control data (red); 1/3 CLuptake,h + 3x 
CLefflux,h (blue); 1/2 CLuptake,h and CLuptake,o + 2x CLefflux,h and CLefflux,o (dashed black); 1/2 CLbiliary (solid 
black); mean control data without extrahepatic compartment (gray). 
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Figure 2.5.  Human sandwich-cultured hepatocytes (SCH) were incubated for 10min at 37°C  with 
0.5μCi/mL 99mTc-mebrofenin in standard (cells+bile) or Ca+-free (cells) HBSS  (B-CLEAR®) alone and 
with various concentrations of ritonavir in SCH from 3 separate donors, in triplicate.  (A) 99mTc-
Mebrofenin accumulation and biliary excretion index (BEI) in cells+bile (closed bars) and cells (open 
bars) in the presence of increasing concentrations of extracellular ritonavir.  99mTc-Mebrofenin BEI values 
(above the bars) represent mean data.  (B) Ritonavir accumulation in hepatocytes (Ca2+-free HBSS) when 
co-administered with 99mTc-mebrofenin, represented as intracellular total concentration (Ccell,total), as 
described in Methods.  99mTc-Mebrofenin and ritonavir accumulation data are represented as 
mean±S.E.M. of 3 separate donors in triplicate (5μM data are mean±range of 2 donors, in triplicate). 
 
 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Ritonavir (M)
0 0.05 0.1 0.5 1 5 2099
m
Tc
-M
eb
ro
fe
ni
n 
Ac
cu
m
ul
at
io
n 
(%
 C
on
tro
l)
0
20
40
60
80
100
120
BEI 26±4 26±7 26±5 23±4 26±7 21±14 23±21
86 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Ritonavir (M)
0.01 0.1 1 10 100
R
ito
na
vi
r A
cc
um
ul
at
io
n
(C
ce
ll,
to
ta
l, 
 M
)
0.01
0.1
1
10
100
1000
87 
 
Table 2.1.  Pharmacokinetics of 99mTc-mebrofenin in control and ritonavir pre-treated subjects.  All 
parameters refer to 99mTc-mebrofenin, except as noted; data are expressed as geometric mean (mean±SD). 
 
 99mTc-Mebrofenin alone 
 1 2 3 4 5 6 7 8 GeoMean (Mean ±SD) 
Administered 
Dose (µCi) 2432 2279 2427 2372 2498 2245 2226 2719 
2395  
(2400 ±162) 
Ejection 
Fraction 0.67 0.78 0.94 0.54 0.86 0.88 0.96 0.54 
0.75 
(0.77 ±0.17) 
Biliary 
Recovery  
(% Dose) 
62 63 80 59 80 87 76 91 74 (75 ±12) 
Urinary 
Recovery  
(% Dose) 
0.9 0.8 1.0 0.7 0.3 0.0 0.0 0.7 NE (0.56 ±0.41) 
AUC0-180 
(nCi·min/mL) 1314 1806 1893 1726 1765 2182 1429 2190 
1763 
(1788 ±313) 
AUC0-∞  
(nCi·min/mL) 1473 2044 2022 1928 2071 2294 1576 2356 
1948 
(1970 ±311) 
Cltotal 
(mL/min/kg) 18.6 18.9 13.9 15.0 15.4 10.9 20.7 14.1 
15.6 
(15.9 ±3.2) 
Clbiliary 
(mL/min/kg) 12.8 13.4 11.8 9.93 14.3 9.87 17.4 13.8 
12.7 
(12.5 ±2.5) 
tmax,liver  
(min) 13 10 11 11 10 17 10 9 
11 
(11 ±3) 
t1/2,liver,30-60min 
(min) 23 13 18 20 17 30 15 16 
18 
(19 ±5) 
Xmax,liver 
(counts/sec) 1744 2432 1822 1926 1836 1698 1912 2227 
1936  
(1950 ±252) 
Cplasma,0min 
RTV (ng/mL) - - - - - - - - - 
Cplasma,180min 
RTV (ng/mL) - - - - - - - - - 
Cbile,120-140min 
RTV (ng/mL) - - - - - - - - - 
NE, not estimable; * p <0.05 compared to control, adjusted; † p <0.05, 200 mg vs. 2x300 mg ritonavir 
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200 mg Ritonavir  2x300 mg Ritonavir 
9 10 11 12 13 14 15 GeoMean (Mean ±SD) 
 
16 17 18 GeoMean (Mean ±SD) 
2317 2542 2450 2331 2404 2453 2484 2425 (2426 ±81) 
 
2472 2543 2369 2460 (2461 ±87) 
0.80 0.20 0.94 0.75 0.72 0.72 0.89 0.66 (0.72 ±0.24) 
 
0.61 0.08 0.90 0.35 (0.53 ±0.42) 
40 53 62 63 75 62 56 58 (59 ±11) 
 
74 70 73 72 (72 ±2) 
1.0 0.6 0.5 1.5 0.9 0.8 3.3 1.0 (1.2 ±1.0) 
 
1.0 1.0 1.5 1.1 (1.2 ±0.3) 
1611 3704 1545 2419 1529 3447 2728 2280 (2426 ±914) 
 
3516 5844 2247 3587 (3869 ±1825) 
1847 3947 1714 2662 1724 4189 3226 2587 (2759 ±1055) 
 
4090 6483 2819 4212* (4464 ±1861) 
13.8 8.62 20.6 17.3 17.8 8.41 13.3 13.6 (14.3 ±4.6) 
 
11.0 5.10 12.3 8.83 (9.46 ±3.8) 
6.30 4.83 14.3 12.0 15.1 6.30 8.86 8.89 (9.67 ±4.1) 
 
9.52 3.93 11.2 7.49 (8.23 ±3.8) 
9 10 20 8 12 10 9 11 (11 ±4) 
 
9 11 9 10 (10 ±1) 
30 21 13 17 15 22 18 19 (19 ±5) 
 
18 20 17 18 (18 ±1) 
1633 2145 2379 2195 2005 1663 1998 1986 (2003 ±274) 
 
2473 1548 1648 1848 (1890 ±508) 
837 1095 666 3338 `954 4234 265 1150 (1740 ±1630) 
 
6670 12100 6200 7940† (8320 ±3280) 
810 1361 475 1823 `469 4343 236 996 (1510 ±1500) 
 
4910 16100 3950 6780 (8320 ±6760) 
1858 2466 728 2232 1345 2319 1381 1640 (1760 ±640) 
 
18300 13700 33200 20300† (21700 ±10200) 
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Table 2.2.  Parameter estimates derived from the 99mTc-mebrofenin semi-PBPK model based on the 
scheme depicted in Figure 2.2A. 
 
Parameter* 
 Subject 8 
(Control)   
 Subject 17  
(2x300 mg Ritonavir) 
 Mean Data (Control 
Subjects) 
CLuptake,h  91  49  88 
CLefflux,h  1.2  7.4  1.7 
CLbiliary  3.3  2.5  2.2 
CLuptake,o  9.4  7.0  15 
CLefflux,o  6.7  3.0  2.3 
ACF†  9.1‡  9.8‡  10.6 
*Clearance values (L/min) are designated as CLuptake for influx from blood into 
tissue, CLefflux for efflux from tissue to blood, and CLbiliary for excretion from 
liver to bile. 
†ACF = Attenuation Correction Factor; ‡mean value over 180-min study 
period. 
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Supplemental Material 
Materials and Methods 
Attenuation Correction 
A transmission-emission acquisition was performed before injection of 99mTc-mebrofenin for the 
final control and ritonavir-treated subjects using a cobalt-57 flood source (Isotope Products Laboratories, 
Burbank, CA) positioned posteriorly, and gamma rays were detected in the cobalt window 
(122KeV±15%) for 10min on the anterior detector in the absence and presence of the subject.  A subject-
specific correction matrix was obtained as the quotient of the two-dimensional transmission-emission 
acquisition of the cobalt-57 flood source without (Io) and with the subject (I), as described previously (51; 
52).  The geometric mean of the anterior and posterior 99mTc-mebrofenin gamma scintigraphy images was 
multiplied by the subject-specific correction matrix.  Time-activity curves (in counts per second) were 
generated for the liver (excluding the gall bladder) using Syngo MI applications version 6.5.9.19 
(Siemens, New York, NY).  The generated time-activity curves were converted from CPM to μCi 
99mTechnetium using a factor of 854 CPM/μCi based on standards and pilot experiments with an 
anthropomorphic torso phantomTM (Data Spectrum Corporation, Hillsborough, NC). 
Semi-PBPK Model Development 
A semi-PBPK model was developed to describe the distribution and elimination of 99mTc-
mebrofenin (Figure 2.2).  This model consisted of a central compartment describing the blood 
concentration-time curve after an intravenous bolus dose, as well as hepatic and extrahepatic tissue 
compartments linked to the central compartment by blood flow and a tissue-specific vascular space.  
Transfer between blood and tissue, as well as biliary excretion, were denoted by clearance parameters 
representing transport-mediated processes.  Passive diffusion was assumed to be negligible, based on data 
reported previously from in vitro systems(9, 17).  The following differential equations described 99mTc-
mebrofenin disposition: 
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dXb/dt = Qh•[Xi,5/(Vi/5)] + Qo• (Xb,o/Vb.o) - (Xb/Vb) • (Qh+Qo)  Xb° = dose 
dXi1/dt = Qh• (Xb/Vb) + fh• (CLefflux,h/5) • [Xh1/(Vh/5)] - Qh• (Xi /Vi) – fb• (CLuptake,h•/5) • (Xi/Vi) 
dXi,n/dt = Qh• [Xi,n-1/(Vi/5)] + fh• (CLefflux,h/5) • [Xh,1/(Vh/5)] - [Xi,n/(Vi/5)] • [Qh + fb• (CLuptake,h•/5)] 
dXh,n/dt = fb• [Xi,n/(Vi/5)] • (CLuptake,h/5) - fh• [Xh,n/(Vh/5)] •[ (CLefflux,h/5)+(CLbiliary/5)] 
dXbile,n/dt = fh• [Xh,n/(Vh/5)] • (CLbiliary/5) 
dXb,o/dt = Qo• (Xb/Vb) + CLefflux,o•fo• (Xo/Vo) - Qo• (Xb,o/Vb.o) - CLuptake,o•fb• (Xb,o/Vb.o) 
dXo/dt = CLuptake,o•fb• (Xb,o/Vb.o) - CLefflux,o•fo• (Xo/Vo) 
 
Where Q denotes blood flow (mL/min), V represents tissue volume (mL), X and f the mass (nCi) 
and unbound fraction of 99mTc-mebrofenin, respectively.  Subscripts represent tissue or vascular 
compartments, as follows: blood (b), liver (h), liver vascular (inlet) component (i), bile (bile), liver sub-
compartment (n), extrahepatic (“other”) tissue (o), and extrahepatic vascular (blood) component (b,o).  
Clearance values are designated as CLuptake for influx from blood into tissue, CLefflux for efflux from tissue 
to blood, and CLbiliary for excretion from liver into bile.  Physiological parameters for tissue volumes (V) 
and blood flows (Q) were obtained from the literature (53; 54) and summarized in Table 2.4.   
The unbound fraction of 99mTc-mebrofenin in blood (fb) was determined by ultrafiltration using 
40-60 min plasma samples to allow for protein binding equilibration and ensure that 99mTc-mebrofenin 
activity in the ultrafiltrate exceeded the minimum sensitivity of the detector.  The plasma samples were 
centrifuged at 600xg for 10min at room temperature.  The plasma was placed in Centrifree® 
micropartition devices and centrifuged in a fixed angle rotor at 1380xg at room temperature for 5 min to 
pass <10% of the original volume through the filter.  Samples of plasma (total concentration in the 
presence of protein) and ultrafiltrate (unbound concentration) were collected post-centrifugation and 
analyzed with a sodium iodide well counter.  99mTc-Mebrofenin fb of 0.03 was determined as the product 
of the unbound fraction and total concentration in the plasma, divided by the total concentration in the 
blood.  The unbound fraction of 99mTc-mebrofenin in all other tissues was assumed to be the same as 
blood.  
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Differential equations describing the disposition of 99mTc-mebrofenin in each of the 
compartments were fit simultaneously to the blood, bile, and liver quantitative scintigraphy data using 
WinNonlin Phoenix, v6.3 (Pharsight, St. Louis, MO) to obtain estimated parameters representing 
transport-mediated clearance processes.  All processes were assumed to be linear under the present 
experimental conditions [trace amounts of 99mTc-mebrofenin were administered (2.5mCi=~194nmol)] and 
therefore, only first-order rate constants were included in the model.  Liver data was reduced to 2, 4, 6, 8, 
10, 15, 20, 30, 40, 50, 60, 80, 100, 120, 140, 160, 175 min to reflect a similar sampling intensity as the 
blood compartment.  The model also was fit to mean control data to obtain parameter estimates 
representing average biliary recovery and extrahepatic distribution.  In order to account for the semi-
quantitative mean liver scintigraphy data, an extra term was added to the function input representing an in 
silico attenuation correction factor (ACF).  The in silico ACF represents the time-averaged effect of the 
two-dimensional correction matrix on total liver counts; the resulting parameter estimate was in good 
agreement with the value obtained from the two subjects with attenuation-corrected scintigraphy data 
using the cobalt-57 flood source. 
Sensitivity analysis of parameter estimates on model output (blood, liver and bile time-activity 
profiles) was conducted in Berkeley-Madonna v.8.3.11.  Parameters representing transport-mediated 
clearance processes were adjusted in isolation up to 10-fold in either direction of the values describing 
mean control data (Table 2.2), with resulting changes in predicted blood and liver exposure and biliary 
excretion (t=0-180min) shown in Figure 2.3.  Sensitivity of one or more model output (blood, liver, bile) 
to a given parameter indicates relative confidence in the parameter value estimate.  In contrast, poor 
confidence is implicated when sensitivity analysis reveals the parameter could take on a range of values 
with little or no change in relevant model results.   
Simulation experiments were conducted in Berkeley Madonna to explore various scenarios 
representing the potential impact of ritonavir on 99mTc-mebrofenin disposition.  In addition, simulations 
provide a comparison of the full 180-min profiles versus the time-averaged parameters (AUCs) and 
cumulative biliary recovery represented in the sensitivity analysis.  The specifc combinations and 
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magnitude of parameter changes were selected to represent the potential impact of ritonavir on 99mTc-
mebrofenin disposition based on results of sensitivity analysis (Figure 2.3) and semi-PBPK model fit and 
parameter estimates (Table 2.2). 
Human SCH Studies 
[3H]Taurocholate and [3H]rosuvastatin (1μM; ~100nCi/mL)  were used as positive controls to ensure 
functional uptake and biliary excretion of each SCH preparation (Table 2.5).  Samples were quantified 
using a sodium iodide well counter for 99mTc-mebrofenin activity, LC-MS/MS analysis for ritonavir, and 
liquid scintillation counting for [3H]taurocholate and [3H]rosuvastatin.  Transport function was 
normalized to the protein content of each preparation, and intracellular ritonavir concentrations were 
calculated using a value of 7.5μL/mg protein(29).  The inhibitory effect of ritonavir on 99mTc-mebrofenin 
accumulation was evaluated using GraphPad Prism to calculate the IC50 in each hepatocyte preparation, 
fixing the initial (no inhibitor) and maximal effect at 100 and 0%, respectively.  99mTc-Mebrofenin in vitro 
biliary clearance (CLbiliary) and biliary excretion index (BEI) were calculated using B-CLEAR 
technology(55).  In vitro uptake clearance (CLuptake) was calculated based on total accumulation in 
standard HBSS, as described previously(12).  In vitro clearance values (μL/min/mg protein) were scaled 
to kilograms of body weight using the following conversions: 0.85 mg protein/million cells(29), 100 
million cells/g liver, and 25.7 g liver/kg body weight(12). Predicted in vivo clearance values were 
estimated according to the well-stirred model of hepatic disposition (Table 2.6).   
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Table 2.3. Demographic information for clinical study participants. 
 
 99mTc-Mebrofenin alone 
 1 2 3 4 5 6 7 8* 
Age (yrs) 23 21 20 19 20 23 21 29 
Weight (kg) 88.6 59.0 86.5 82.0 78.6 90.2 68.2 81.9 
Gender M M M M M M M M 
Ethnicity† O C O C L B C C 
 
*Subjects for which quantitative scintigraphy data were obtained using the cobalt-57 flood source. 
†Self-Identified Race/Ethnicity: A – Asian, B – Black/African-American, C – Caucasian, L – Latino/-a, O 
- Other 
 
 
 
200 mg Ritonavir  2x300 mg Ritonavir 
9 10 11 12 13 14 15  16 17* 18 
23 20 24 24 26 20 20  24 21 21 
90.9 74.7 69.3 50.6 78.4 69.6 57.8  54.8 76.9 68.6 
M M M F M M F  F M F 
O B C A C C B  A C C 
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Table 2.4.  Physiologic parameters for semi-PBPK model (53; 54) 
 
Physiologic Parameters Value 
Volume: g or mL/kg body weight 
Blood (total) 75 
Liver 26 
Extrahepatic 400 
Tissue vascular space:  
Liver 7 
Extrahepatic 0.75 
  
Blood Flow: mL/min/kg 
Liver 20 
Extrahepatic (remaining cardiac output) 55 
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Table 2.5.  Total accumulation (cells+bile, standard HBSS) and BEI of [3H]taurocholate and 
[3H]rosuvastatin (1μM; ~100nCi/mL) in 24-well human SCH.   Accumulation data represent mean ± SD 
of n=3 human liver donors. 
 
Compound Total Accumulation BEI In Vitro CLuptake In Vitro CLbiliary 
 pmol/mg P % mL/min/kg 
[3H]Taurocholate 131.5 ± 29.5 77.4 ± 15.6 29.3 ± 6.6 22.6 ± 6.8 
[3H]Rosuvastatin 68.8 ± 19.6 30.5 ± 7.7 15.3 ± 4.4 4.7 ± 2.0 
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Table 2.6. 99mTc-Mebrofenin in vitro intrinsic clearance values and predicted in vivo clearance from data 
generated in human SCH.  Data represent mean ± SD of n=3 human liver donors. 
 
Clearance Value In Vitro Intrinsic Clearance 
Predicted In Vivo 
Clearance 
 mL/min/kg 
CLuptake 23.7 ± 12.1 10.6 ± 3.1 
CLbiliary 5.8 ± 2.4 4.4 ± 1.5 
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CHAPTER 3 
 
Determination of Intracellular Unbound Concentrations and Subcellular Localization of Drugs in 
Rat Sandwich-Cultured Hepatocytes Compared to Liver Tissue 
Introduction 
The impact of drugs on intracellular targets of efficacy and/or toxicity, as well as routes of 
elimination, is driven by local unbound concentrations (Cunbound) according to the “free drug hypothesis”(1).  
Prediction of clinical efficacy, toxicity and drug-drug interactions (DDIs) could be improved by accounting 
for Cunbound in vitro and in vivo(2-4).  Furthermore, subcellular drug distribution may aid prediction and/or 
correlation of efficacy and/or toxicity and risk assessment for drugs(5-7).  Measurement of blood or plasma 
Cunbound is convenient and may correlate with tissue concentrations for compounds with sufficient passive 
permeability.  However, for hydrophilic compounds (highly polar or ionized at physiologic pH) that rely 
on uptake/efflux transporters for distribution and do not readily cross membrane barriers, the ratio of 
intracellular and extracellular (blood or plasma) Cunbound (Kpu,u) may be highly disparate. 
Kpu,u has been used extensively in CNS pharmacokinetics-pharmacodynamics (PK/PD) to 
elucidate the role of blood-brain barrier penetration and transport(8), as well as correlate in vivo effects 
with in vitro potency(9-11).  Figure 3.1 illustrates the concept of Kpu,u as it applies to hepatobiliary drug 
disposition.  The important role of the organic anion transporting polypeptides (OATPs) has been 
recognized in recent years, highlighting the need to elucidate the role of active uptake in the hepatic 
accumulation of drugs(12; 13).  Compounds that are taken up efficiently into hepatocytes may exhibit a  
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Kpu,u>>1(12; 14).  Indeed, any situation in which the net rate of appearance exceeds elimination under 
steady-state conditions might result in a Kpu,u>>1; this would include formation of  metabolites, which are 
often polar, poorly permeable compounds that rely on active transport for elimination.  Kpu,u<<1 in the 
liver indicates that the net effects of elimination (efflux, metabolism) outweigh appearance in the 
tissue/cellular compartment (low passive permeability and/or rate-limited influx).  While a Kpu,u<<1 is 
common in the context of CNS exposure, where net efflux processes often dominate drug disposition as a 
mechanism of tissue protection/exclusion,  a Kpu,u>>1 is expected to be more common in the liver due to 
its major role in drug elimination (biotransformation, biliary excretion), which is driven by 
(hepato)cellular concentrations.   
Hepatic intracellular Cunbound, Kpu,u and subcellular localization information has improved 
predictions and/or explained seemingly discrepant PK/PD relationships with a variety of endpoints 
including efficacy(12), toxicity(15), and drug disposition, including drug transport(16), metabolism(17-20), 
and related DDIs(15; 21-23).  Intracellular Cunbound in the relevant compartment(s) and subcellular 
localization of drugs are challenging to accurately measure, and our understanding of intracellular drug 
disposition in the liver remains rudimentary.  A versatile and reliable method to determine these parameters 
in a relevant hepatic in vitro model would be of value in order to differentiate the contribution of active 
uptake vs. binding/sequestration as mechanisms of hepatocellular accumulation, and to assess routes and 
rates of elimination (e.g., metabolism, biliary excretion)(2; 13; 24; 25). 
Isolated perfused livers (IPLs) are considered the “gold standard” for studying the hepatobiliary 
system in isolation, without the influence of extrahepatic components(26).  Unfortunately, the IPL system 
has a number of drawbacks, including a limited experimental period (≤~2 h), the time- and labor-intensive 
nature of the procedure, and limited applicability to non-rodent species including humans.  Sandwich-
cultured hepatocytes (SCH) are a common in vitro model used to assess the role of hepatic uptake and 
excretory function, including DDIs and transporter-metabolism interplay(27).  Methods to estimate 
subcellular distribution and intracellular Cunbound in the SCH model have not been developed. 
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The objective of this work was to determine the intracellular Cunbound and subcellular localization 
of drugs in SCH compared to liver tissue from IPLs. A set of probe drugs with distinct mechanisms of 
hepatocellular uptake and accumulation was selected for investigation.  Ritonavir inhibits drug transport 
and metabolism in vitro and in vivo, and accumulates in liver tissue(28). Surprisingly, the mechanism(s) 
underlying the cellular uptake and accumulation of ritonavir, and the intracellular Cunbound for prediction of 
DDIs, have not been reported(29).  Rosuvastatin, an HMG-CoA reductase inhibitor with a primary site of 
action in hepatocytes, is efficiently taken up by OATPs and accumulates within hepatocytes, with an 
expected Kpu,u>1.    Pafuramidine, the prodrug of furamidine, is the only orally-active agent that has shown 
efficacy in clinical trials for the treatment of first-stage (hemolymphatic) human African 
trypanosomiasis(30).  Furamidine is formed in the liver via sequential metabolism, and must be excreted 
from hepatocytes into the systemic circulation to exert antiparasitic activity.  This set of drugs provided a 
useful range of tissue accumulation, hepatic unbound fraction (fu), subcellular distribution, and Kpu,u values 
for comparison of methods to determine hepatocellular Cunbound. 
Materials and Methods 
Materials 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.  
Rosuvastatin(31) and the deuterated internal standard were purchased from Moravek Biochemicals (Brea, 
CA).  Ritonavir(28) was purchased from Toronto Research Chemicals (Toronto, ON, Canada.  Furamidine, 
the prodrug pafuramidine, and internal standard (deuterium-labeled furamdine) were synthesized in the 
laboratory of Dr. David W. Boykin, as reported previously(32).  
Tissue Accumulation.  
Male Wistar rats (Charles River Labs, Wilmington, MA) were used for IPL studies.  Rats were 
allowed free access to water and food, and acclimated for a minimum of 1 week prior to experimentation.  
All animal procedures complied with the guidelines of the Institutional Animal Care and Use Committee 
(University of North Carolina, Chapel Hill, NC).  All procedures were performed under full anesthesia with 
ketamine/xylazine (140/8mg/kg i.p.).  Livers were perfused in a single-pass manner (30 mL/min continually 
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oxygenated Krebs-Ringer bicarbonate buffer in the presence of 5 μM taurocholate to maintain bile flow); 
following a 15-min equilibration period, ritonavir (1 μM) or rosuvastatin (1 μM) was included in the 
perfusate for 30-min, and then the livers were flushed briefly with blank buffer.  Pafuramidine (10 μM) was 
perfused in a recirculating liver system for 120 min as reported previously(32).  Livers were harvested and 
stored whole at -80°C until homogenization and analysis. 
Rat hepatocytes were seeded in 6-well BioCoat plates (BD Biosciences, San Jose, CA) and overlaid 
with Matrigel basement membrane matrix (BD Biosciences, San Jose, CA) in a sandwich-cultured 
configuration and maintained as described previously(27).  Day 4 rat SCH were pre-incubated for 10 min 
in Ca2+-free Hanks Balanced Salt Solution (HBSS; B-CLEAR® technology) to open tight junctions and 
prevent accumulation in bile canalicular spaces, and then  treated with 1 μM ritonavir or [3H]rosuvastatin 
(100 nCi/mL; American Radiolabeled Chemicals, Inc., St. Louis, MO) for 10 min at 37°C as described 
previously(27).  Starting on day 3, pafuramidine was incubated for 24 h at 10 μM to allow complete 
formation and equilibration of furamidine, as previously reported(32), followed by a 5-min incubation in 
Ca2+-free HBSS.  In all cases, incubation medium was collected at the end of the incubation period, and 
cells were washed three times in ice-cold HBSS.  
Fractionation.  
Liver tissue was homogenized in 3-5 volumes of fractionation buffer (250 mM sucrose, 10 mM 
HEPES, 10 mM KCl, 1 mM EDTA, 1.5 mM MgCl2, 1 mM DTT, Roche cOmplete Protease Inhibitor 
Cocktail) using a Potter-Elvehjem homogenizer.  Following treatment with the drug of interest, all wells of 
the 6-well SCH plate were harvested and pooled by scraping each well sequentially into 1 mL fractionation 
buffer.  Collected cells in buffer were homogenized by passing 10 times through a 27g needle, resting 10 
min on ice, followed by an additional 10 passes.  Following homogenization to disrupt cell membranes, the 
resulting crude lysates (liver and SCH) were sampled and reserved to perform analysis for total and unbound 
drug concentrations, protein content and enzyme activity assays.  The remaining lysate was subjected to 
stepwise differential centrifugation as published previously(33) to separate the following cellular 
components: 10 min at 600xg (nuclei and cellular debris), 10,000xg (mitochondria), 35,000xg (lysosomes 
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and other medium-sized membrane-bound bodies), 60 min at 100,000xg (microsomes, membrane fraction) 
with the resulting supernatant representing the cytosolic fraction.  All spins <100,000xg were repeated after 
resuspending the pellet in 5 (liver) or 0.2 (SCH) mL of fractionation buffer; resulting supernatants were 
pooled before moving on to subsequent centrifugation steps.  Pellets were resuspended in fractionation 
buffer [10 mL for liver tissue and 0.3 (600xg) or 0.15 (>600xg) mL for SCH] for analysis of drug and 
protein content and enzyme activities.   
Protein content of each fraction was determined using the Pierce BCA Protein Assay (Thermo 
Fisher Scientific Inc, Rockford, IL).  Separation and recovery of subcellular fractions was assessed by 
measuring lactate dehydrogenase (LDH) activity as a cytosolic marker using a Cytotoxicity Detection kit 
(Roche Diagnostics, Indianapolis, IN), and acid phosphatase activity as a lysosomal marker using an Acid 
Phosphatase kit (Sigma, St. Louis, MO).  Succinate dehydrogenase activity was measured to assess the 
presence of mitochondria as described previously(34), adapted to a microplate format as follows: 5 μL 
sample volume was combined with 60 μL 10 mM sodium succinate in 50 mM phosphate buffer and 
incubated for 60 min at 37°C, followed by the addition of 20 μL 2.5 mg/mL p-iodonitrotetrazolium and 
incubation for another 15 min.  The reaction was quenched by the addition of 0.2 mL of 5:5:1 (v/v/w) 
ethanol/ethyl acetate/trichloroacetic acid and absorbance was determined at 492 nm on a plate-based 
spectrophotometer (BioTek PowerWave HT, Winooski, VT).  Similarly, glucose-6-phosphatase activity 
was measured to assess the presence of microsomes as described previously(35), adapted to a microplate 
format as follows: 10 μL sample volume was plated in duplicate and combined with 10 μL 20 mM Tris-
HCl, pH 7.3, with and without 50 mM glucose-6-phosphate (Na+ salt, Sigma, St. Louis, MO) and incubated 
for 30 min at 37°C.  Inorganic phosphate standards were prepared from 0.1-2 mM and added to the plate 
(20 μL) at the end of the incubation.  The reaction was terminated by the addition of 200 μL detection 
reagent [3:1 1 mg/mL malachite green (oxalate salt, Sigma, St. Louis, MO) in 1 N HCl/4.2% (w/v) 
ammonium molybdate in 5 N HCl] to samples and standards, followed immediately by the addition of 10 
μL 0.05% (v/v) Tween-20.  The reaction mixture was shaken briefly and allowed to equilibrate for 10-15 
min, and absorbance was determined at 660 nm on a plate-based spectrophotometer.  Phosphate formation 
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was calculated as the difference between samples incubated with and without glucose-6-phosphate substrate 
to correct for endogenous phosphate content in the samples.  Recovery of each fraction was calculated as 
the percentage of the total organelle-specific enzyme activity detected in each subfraction compared to the 
whole lysate.  
Binding.  
Binding was determined in whole tissue lysates and cytosolic fractions by equilibrium dialysis.  
Initial studies were performed to determine the time to equilibrium and test for protein leakage or potential 
volume shifts with whole liver tissue (data not shown).  Aliquots were loaded into a 96-well equilibrium 
dialysis apparatus (HTDialysis, LLC; Gales Ferry, CT) and dialyzed against phosphate buffer for 6 h with 
shaking at 37°C.  Binding replicates (n=3) consisted of 3-fold dilutions of each sample (1-, 3-, and 9-fold 
original sample).  The unbound fraction (fu) was back-extrapolated to account for dilution during the 
homogenization/fractionation process, as well as subsequent dilutions, as described previously(36): 
 
  
This approach provides the best precision in the linear range, and that precision is lost when the measured 
unbound fraction becomes high (fu,measured is >80%).  Where fu,measured was >80% at the lowest dilution, the 
value is reported as “greater than” the undiluted fu calculated according to the equation above.   
Sample Analysis 
Ritonavir, rosuvastatin and furamidine were quantified by LC-MS/MS as described previously; 
rosuvastatin was quantified by liquid scintillation counting for SCH studies.(37-40)  Total cellular 
concentrations in SCH were calculated by dividing the quantified substrate mass in the whole lysate by 7.4 
μL/mg protein in SCH, the estimated hepatocellular volume determined by [3H]3-O-methyl-D-glucose.(40) 
Data Analysis.   
The observed partition coefficient (Kpobserved) was calculated as the total tissue concentration (liver 
or SCH) divided by the perfusate (IPL) or buffer (SCH) total concentration, respectively.  The predicted 
partition coefficient (Kppredicted) was calculated as the reciprocal of the unbound fraction, including the 
   1/D 1  - 1/fu
1/D fu  Undiluted
measured 

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subcellular distribution in the case of the cytosolic fraction  [1/fu or 1/(fcytosolxfu,cytosol)], where fcytosol 
represents the fraction of the total drug mass in the tissue recovered in the cytosol.  The unbound tissue 
concentration was calculated as the product of the total tissue concentration and the unbound fraction 
determined in whole lysate (Cunbound=fu•Ctissue), including the subcellular distribution in the case of the 
cytosolic fraction (Cunbound=fcytosol•fu,cytosol•Ctissue).  The ratio of intracellular and extracellular Cunbound (Kpu,u) 
was calculated as the unbound tissue concentration divided by the unbound concentration in perfusate or 
buffer (fu,buffer was assumed to be 1 in the absence of protein in both systems). 
Results 
In order to characterize the subcellular distribution of the probe compounds, differential 
centrifugation was performed on lysates from whole liver tissue and SCH following drug treatment.  Marker 
enzyme activities specific to mitochondria, lysosomes, endoplasmic reticulum (microsomes) and cytosol 
were examined in tissue lysate and subfractions to assess the purity and recovery of the various fractions.  
The distribution of these organelles in subfractions of whole liver tissue and SCH is shown in Figure 3.2.  
Using whole liver tissue, separation of subfractions was demonstrated, with organelle-specific enzyme 
activity detected in the expected fractions.  Following fractionation of SCH lysates, the majority of 
membrane-bound organelles (including mitochondria and microsomes) were recovered in the initial low-
speed spin (600 xg).  Cytosolic separation and recovery was efficient and successful, as shown in Figure 
3.2.D with ~90% of the total LDH activity in the crude lysate recovered in the cytosolic fraction of SCH 
lysates. 
Recovery of the probe drugs in all fractions was compared to the total mass in the whole lysate 
prior to fractionation.  Recovery of probe drugs after fractionation of whole liver tissue and SCH was 
approximately 100% (±10%).  The average subcellular distribution of each drug in whole tissue and SCH 
is shown in Figure 3.3.  In all cases, the coefficient of variation was less than 20% when at least 10% of 
the drug was recovered in a given fraction. In whole liver tissue, approximately 36% of the ritonavir was 
found in the cytosolic fraction, 31% in the microsomal fraction, and 18% in the mitochondrial fraction, 
with the remainder distributed fairly evenly among the remaining fractions.  In SCH lysates, cytosolic 
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recovery of ritonavir was similar to that in whole liver tissue (43%).  The remaining ritonavir was 
recovered primarily in the initial low-speed spin, consistent with binding/sequestration to organelles 
(including microsomes), which were difficult to separate in SCH lysates.  Rosuvastatin distribution was 
confined primarily to the cytosol, with recovery of 72% in the cytosolic fraction of whole liver tissue, and 
88% in SCH lysates.  Rosuvastatin distribution to specific organelles was minimal (<11%).  Furamidine 
was localized in the mitochondrial (43%), nuclear (18%) and lysosomal (15%) fractions of tissue lysate 
from the rat IPL; the remaining material was recovered in the cytosolic fraction, with minimal localization 
in the microsomal fraction.  Furamidine was recovered predominantly (85%) in the initial low-speed spin 
(600 xg) following fractionation of SCH lysates, with minor recovery in the remaining fractions, 
including cytosol (3%).  This is consistent with extensive binding and/or sequestration within membrane-
bound organelles (including mitochondria), which were recovered in the 600 xg pellet following initial 
centrifugation of SCH lysates.   
Concentrations of probe drugs in tissue, along with binding data and calculated concentration 
ratios (Kp and Kpu,u) are listed in Table 3.1.  Total tissue accumulation (Kp) ranged over three orders of 
magnitude in the compound set selected for investigation.  Ritonavir binding was extensive in whole liver 
tissue and SCH (fu of 1.0±0.1% and 3.0±1.0%, respectively).  Predicted accumulation (Kppredicted) of 
ritonavir based on binding and subcellular distribution (91-100 in IPL, 22-35 in SCH) was in good 
agreement with observed accumulation (Kpobserved; 110 and 33 in IPL and SCH, respectively).  The 
estimated intracellular Cunbound approximated the extracellular concentration, resulting in a Kpu,u of ~1, 
suggesting that binding to cellular components can explain the observed tissue accumulation.  
Rosuvastatin displayed moderate accumulation in liver tissue and SCH (Kpobserved of 33 and 17 
respectively) in the absence of extensive binding and/or sequestration.  Kppredicted (~3-4 in IPL and SCH) 
underestimated the observed accumulation, as might be expected for a compound that is a substrate for 
hepatic uptake transporters.  The estimated intracellular Cunbound and resulting Kpu,u (~8-11) suggested 
accumulation of unbound rosuvastatin within the liver.  Calculation of a precise Kpu,u in SCH was 
complicated by the low degree of binding in diluted SCH lysate and cytosolic fraction, but accumulation 
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of unbound drug was evident based on a Kpu,u value >5-6.  Furamidine accumulation was extensive in 
whole liver tissue and SCH (Kp of 8400 and 6900, respectively).  While furamidine also was extensively 
bound or sequestered, Kppredicted underestimated the observed accumulation by more than 10-fold.  The 
estimated intracellular Cunbound and resulting Kpu,u (>16) confirmed accumulation of unbound drug within 
hepatocytes.   
Discussion 
The present study evaluated the use of an organ-specific in vitro model system to estimate 
Cunbound, and predict cellular partitioning and accumulation of drugs.  The SCH system exhibits properly 
localized and functional transport proteins, metabolic and regulatory machinery.  This system may be able 
to recapitulate the relevant cellular disposition of drugs whose distribution is influenced by the interplay 
of these processes in hepatocytes in vivo.    
Total accumulation (Kpobserved) in whole tissue was well predicted by the SCH model (within 2-3 
fold) for the limited compound set selected for investigation.  A system that enables accurate estimates of 
hepatic Kp values would be a valuable addition to physiologically-based pharmacokinetic (PBPK) 
modeling efforts.  Although tissue partitioning can be predicted using physicochemical properties, such as 
the method of Rodgers and Rowland(41; 42), exceptions and inaccuracies inevitably exist, particularly for 
compounds that may rely on active processes, such as transport and/or metabolism. 
 While the Kp value is useful for estimating overall tissue, it does not provide information on the 
mechanism(s) of tissue accumulation.  For mechanistic information, one must assess tissue binding and 
subcellular distribution.  In the case where binding does not explain the observed tissue accumulation, 
Kpu,u is an  informative parameter for describing the potential role of active uptake.  However, a Kpu,u ≈ 1 
does not necessarily imply that passive processes (e.g., diffusion) are solely responsible for hepatocellular 
distribution.  While it is tempting to dismiss the potential contribution of active transport for such 
compounds, it is possible that a net balance exists between uptake and efflux processes.  In such a case, 
impaired transport function (e.g., DDIs, genetic variation, and/or disease states) may result in altered 
hepatic and/or systemic exposure, with corresponding implications for changes in efficacy, toxicity, and 
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DDI potential.  For example, ritonavir undergoes active hepatic transport even though the calculated Kpu,u 
is ~1.  Although the role of active uptake in the hepatobiliary disposition of ritonavir has not been 
reported conclusively, ritonavir is a competitive inhibitor of OATP-mediated uptake, as well as P-gp and 
MRP-mediated efflux in vitro(43-45).  Despite the fact that ritonavir accumulates in the liver (reported 
literature ranges from 10-100 fold(28)) and is excreted into bile in rats, dogs and humans(28), we recently 
demonstrated that ritonavir did not inhibit MRP2-mediated biliary excretion of the imaging agent, 99mTc-
mebrofenin in humans(23).  This apparent in vitro-in vivo disconnect was reconciled by accounting for 
the Cunbound of ritonavir in hepatocytes relative to its inhibitory potency against MRP2(23).   
Rosuvastatin accumulation in whole liver (Kpobserved = 33) and SCH (Kpobserved = 17)  was in good 
agreement with the previously reported range of 18- to 45-fold up to 8 h after oral administration in 
rats(31).  Although rosuvastatin binding did account for a portion of tissue accumulation (Kppredicted ~3-4), 
the majority of accumulation was due to unbound drug (Kpu,u of 8 to 11), consistent with efficient hepatic 
uptake and rate-limited efflux as described previously(31; 46).  Rosuvastatin binding data in SCH 
demonstrated a limitation of the required dilution of small tissue samples when performing these studies 
in in vitro systems.  For compounds that are not extensively bound (fu,measured >80%), dilution of SCH 
samples resulted in observed binding data that were difficult to extrapolate accurately.  Therefore, the 
resulting Kpu,u value is a conservative minimum and potentially underestimates the true value by up to 2-
3-fold.  Rosuvastatin was selected as a model drug that is efficiently taken up by OATPs, which drives 
accumulation of unbound drug within hepatocytes, with an expected Kpu,u significantly greater than 1.   
As previously reported, extensive and prolonged hepatic accumulation of the active metabolite, 
furamidine, was observed in both rat IPLs and SCH(32).  Previous studies using differential 
centrifugation to separate fractions revealed that furamidine was localized primarily in the mitochondrial 
fraction of the liver and kidney(47).  Similarly, furamidine was localized primarily in the mitochondrial 
fraction (43%) following subcellular fractionation of tissue lysate from the rat IPL.  Despite extensive 
binding and sequestration, these processes underpredict the observed accumulation in liver tissue.  
Accumulation of unbound furamidine (Kpu,u) was predicted to be >16-fold, suggesting permeability-
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limited efflux of this charged metabolite formed in the hepatocyte.  The extensive hepatic 
binding/sequestration may limit the systemic exposure to furamidine; in contrast, a structural analogue 
had a 5-fold greater hepatic fu, which could contribute, in part, to the enhanced systemic exposure of this 
agent compared to furamidine(32). 
Subcellular fractionation has not been reported previously in SCH.  Similar to partitioning, it 
would be useful to determine subcellular localization and sequestration in a relevant in vitro system.  This 
is particularly true of the liver, where drug-induced liver injury via idiosyncratic hepatocellular injury is 
the most frequent cause of regulatory action on drugs, including failure to approve, labeling changes, and 
withdrawal from the market(48).  Hepatotoxic drugs are known to cause hepatocellular injury through 
diverse pathways, including organelle-specific sequestration and toxicity, such as phopholipidosis 
(lysosomes)(5) and  mitochondrial disruption/dysfunction(6; 49), among others(7).  Although isolation of 
subcellular fractions consisting of membrane-bound organelles proved challenging in SCH, cell lysis, 
release and isolation of soluble cytosolic proteins and contents was successful, as determined by LDH 
activity and rosuvastatin recovery.  Enzyme markers of subcellular components were recovered primarily 
in the initial, low-speed centrifugation step from SCH lysates, indicating that these organelles were 
retained in large, dense conglomerates.  It is possible that the collagen matrix, indispensible to the 
sandwich configuration, prevented the plasma membrane from separating enough to release larger, 
membrane-bound bodies.  This limitation may provide an advantage for rapid isolation of the cytosolic 
fraction in SCH. These data suggest that a single, low-speed (600xg) spin, which can be performed on any 
benchtop microcentrifuge, will reliably exclude cellular organelles from the resulting supernatant of SCH 
lysate.  This single step method has the additional advantage of minimizing potential redistribution of 
drugs during multiple centrifugation steps and associated dilutions.  Although the specific site(s) of 
subcellular sequestration would remain unknown, extensive distribution/recovery of drug in the pellet 
could indicate the need to consider intracellular pharmacokinetics.  Meanwhile, the cytosolic fraction 
would contain the unbound drug content in the tissue (fcytosol), which could be assessed formally by 
determining the extent of binding to cytosolic protein (fu,cytosol), as reported in the present studies. 
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A number of potential limitations are associated with the subcellular fractionation approach, 
including: a) Some degree of cross-contamination among isolated cellular fractions.  This can be assessed 
primarily by recovery of marker enzyme activity specific for each organelle, but adds significant time- 
and labor-intensive efforts to sample analysis.  b) Potential disruption of binding equilibrium between 
cellular compartments during the fractionation process.  Tissue homogenization and fractionation 
inherently involve dilution, which can shift binding equilibrium.  Despite the potential limitations of the 
reported method, assessment of intracellular Cunbound and mechanisms of hepatic accumulation is 
challenging and in vitro methods are needed for general application to compounds that are not amenable 
to visualization, such as fluorescence.  Other methods are rarely used and not without limitations, such as 
assessment of cellular accumulation at 4 versus 37°C(12).  The assumption of the latter method is that all 
active processes are inert at 4°C, and that cellular accumulation represents passive equilibration of 
unbound drug.  However, the effect of temperature and potential artifacts on non-specific binding(50-52) 
and membrane fluidity and partitioning(53-55) are well-established. 
 Hepatic intracellular Cunbound, Kpu,u and subcellular localization can be used to improve prediction 
of clinical efficacy, toxicity and drug-drug interactions (DDIs).  A straightforward in vitro method was 
developed to determine hepatocellular accumulation of total and unbound drug in the SCH model.  This 
method was used successfully to differentiate the contribution of active transport vs. 
binding/sequestration as mechanisms of hepatocellular accumulation for a set of probe drugs with distinct 
mechanisms of hepatocellular uptake and accumulation. 
  
 
Table 3.1.  Total tissue concentrations, unbound fraction and calculated tissue-to-medium or -perfusate partition coefficients (Kp and Kpu,u). 
Outcome 
Ritonavir  Rosuvastatin  Furamidine 
IPL SCH  IPL SCH  IPL SCH 
Ctissue (μM) 56 15±2  18 17±3  24b 1500±500 
Cmedium (μM) 0.49 0.47±0.12  0.54 1  0.0032c 0.27±.19 
Kpobserved 110 33  33 17  8400c 6900 
Whole lysate:a         
fu (%) 1.0±0.1 3.0±1.0  23±1 >36d  0.3±0.1b 0.9±0.2 
Kppredicted 100 35  4.3 <2.8  330 110 
Cu,tissue (μM) 0.56 0.46±0.16  4.1 >6.1  0.073 14±6 
Kpu,u 1.1 1.1  7.9 >6.1  23 53 
Cytosol:a         
fu (%) 3.3±0.2 11±1  46±8 >34d  6.2±1.2b 11±4 
Kppredicted 91 22  3.3 <3.4  81 330 
Cu,tissue (μM) 0.62 0.76±0.31  5.9 >5.0  0.30 4.3±1.6 
Kpu,u 1.3 1.7  11 >5.0  93 16 
a Kppredicted and Cu,tissue calculated for lysate and cytosol as described in Methods. 
b From Yan, et al.(32) 
c Taking into account fu of 44% in perfusate, containing 20% whole blood. 
d Undiluted fu and subsequent calculations represented by inequalities when fu,measured >80%, as described in Methods. 
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Figure 3.1.  The tissue-to-plasma unbound concentration ratio (Kpu,u) applied to hepatobiliary drug 
disposition. 
 
 
 
 
  
117 
 
Figure 3.2.  Distribution and recovery of organelle-specific marker enzyme activity following differential 
centrifugation of whole liver tissue (A) and SCH (B). Data are expressed as % total activity in the initial 
lysate, mean±SD of n=3 (whole liver) or n=9 (SCH). 
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Figure 3.3.  Subcellular distribution and recovery of ritonavir, rosuvastatin and furamidine  following 
differential centrifugation of whole liver tissue and SCH. Data are presented as % recovery of total material 
in lysate.  Open = 600xg pellet, light gray = 10,000xg pellet, mid-gray = 35,000xg pellet, dark gray = 
100,000xg pellet, black = 100,000xg supernatant. 
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CHAPTER 4 
 
Basolateral Efflux Transporters Contribute Significantly to the Excretion of Rosuvastatin in Rat 
and Human Hepatocytes: Characterization of Basolateral vs. Biliary Clearance Using a Novel 
Protocol in Sandwich-Cultured Hepatocytes 
 
Introduction 
Hepatic transport plays an important role in the pharmacokinetics and pharmacodynamics of 
rosuvastatin (RSV), with the liver serving as the primary organ of efficacy and elimination.  Hepatic 
clearance accounts for 72% of total RSV clearance following an intravenous dose in humans.(1)  A 
number of transport proteins mediating RSV disposition in the liver have been characterized.  Active 
uptake into hepatocytes is mediated by multiple OATP isoforms; NTCP also has been reported to play a 
role (2-4).  MRP2 and BCRP are the major canalicular proteins responsible for the biliary excretion of 
RSV (2; 5-8).  The role of basolateral transport proteins in the efflux of RSV from hepatocytes back into 
sinusoidal blood has not been examined.  This is clinically relevant because impaired hepatic transport 
due to drug-drug interactions (DDIs) and genetic polymorphisms has been shown to alter the 
pharmacokinetics of RSV (2; 5; 7; 9-12).  Some of these changes have been associated with altered 
efficacy (LDL-lowering) of RSV (13; 14), while increased systemic exposure has been associated  
with the life-threatening rhabdomyolysis related to statin use in general (15; 16).  Candidate basolateral 
efflux transporters for RSV include MRP3 and MRP4, which have been shown to mediate basolateral 
excretion of drugs and metabolites, particularly as a compensatory route of excretion under cholestatic  
 
 
1This work has been presented, in part, at the AAPS Workshop on Drug Transporter in ADME, N. Bethesda, MD, 
March 18-20, 2013 and will be submitted to Journal of Pharmacology and Experimental Therapeutics. 
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conditions (17-20).  SLC51 (polyspecific organic solute carrier, OSTα/β), is localized at the basolateral 
membrane of the liver and small intestine, where it plays a role in bile acid transport; the ability of 
OSTα/β to efflux drugs such as RSV has not been investigated(21). 
Many transport proteins involved in the hepatobiliary disposition of RSV are also present in the 
small intestine.  Thus, the effects of impaired transport function on oral absorption vs. hepatic elimination 
can be challenging to deconvolve.  For example, the ~2-fold increase in RSV systemic exposure in 
individuals carrying a BCRP polymorphism associated with decreased transport function has been 
attributed to the effects of intestinal BCRP and a resulting increase in oral absorption (7; 11).  However, a 
similar increase in RSV systemic exposure was observed in Mrp2- and Bcrp-deficient animal models 
following intravenous administration (2).  This could be attributed to translocation of RSV from the 
hepatocyte back into the systemic circulation in the setting of impaired biliary excretion.  The role of the 
basolateral efflux pathway in mediating altered hepatic vs. systemic exposure in the setting of impaired 
biliary excretion has not been characterized thoroughly.   
The quantitative impact of excretory transport modulation on the hepatic, systemic, and biliary 
exposure to xenobiotics and derived metabolites was formalized recently by our research team (22).  
Experimental data and theoretical relationships indicated that the fold change in exposure is governed by 
the relationship, 1/(1 – fe), where fe is the fraction excreted by a particular transport protein.  Loss-of-
function of a transport pathway associated with a fe < 0.5 will have minimal consequences on exposure, 
but substantial changes can be expected in response to loss-of-function of one or more transport pathways 
with fe > 0.5.  It should be noted that the impact of fe on exposure depends on the compartment of interest 
(systemic, hepatic or bile), the directionality of the impaired efflux pathway (canalicular or sinusoidal), 
and the existence of an alternative route of excretion.  When a transport protein is impaired, the increased 
excretion in the alternative direction is a function of the fraction of total hepatocellular clearance 
mediated by the impaired pathway.  For example, in the case of impaired (') biliary clearance (CLBile) the 
resulting increase in basolateral (BL) excretion and systemic exposure can be estimated from Δfe,BL = 
(CLBile – CLBile') / (CLBile + CLBL), where (CLBile + CLBL) is the baseline (pre-impairment) total cellular 
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excretory clearance (CLTotal).  The increase in hepatocellular exposure resulting from impaired efflux can 
be estimated from Δfe,Total = (CLTotal – CLTotal') / CLTotal, assuming that there are no compensatory changes 
in uptake or metabolism.  Therefore, accurate predictions of altered hepatic and systemic exposure in the 
setting of impaired excretory transport require an understanding of the contributions of basolateral and 
biliary clearance. 
 The present experiments were designed to quantify the contribution of the basolateral efflux 
pathway to the hepatocellular elimination of RSV.  The role of basolateral efflux was investigated in 
single-pass rat isolated perfused livers (IPLs) and an uptake/efflux protocol was developed in rat and 
human sandwich-cultured hepatocytes (SCH).  This novel protocol allowed tight junction modulation and 
measurement of RSV accumulation in cells+bile and cells throughout the experimental time course 
without compromising cell viability or function as a result of prolonged exposure to –Ca2+ conditions; 
quantification of RSV cellular efflux after the loading phase can be measured directly using this protocol.  
The ability of the basolateral efflux proteins MRP3 and MRP4 to transport RSV in humans was evaluated 
in membrane vesicles prepared from overexpressing HEK293 cells.  These methods, combined with 
pharmacokinetic (PK) modeling, revealed that basolateral and biliary clearance represent alternative 
elimination routes with a quantitatively similar contribution to the overall hepatocellular excretion of 
RSV in rat and human hepatocytes. 
Materials and Methods 
Materials 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.  Non-
radiolabeled RSV and the deuterated internal standard (d6-RSV) were purchased from Moravek 
Biochemicals (Brea, CA).  [3H]Estradiol-17-β-D-glucuronide (E217G) and [3H]dehydroepiandrosterone 
sulfate (DHEAS) were purchased from Perkin Elmer (Waltham, MA); [3H]RSV was purchased from 
American Radiolabeled Chemicals, Inc. (St. Louis, MO).  GF120918 (elacridar) was a generous gift from 
GlaxoSmithKline (Research Triangle Park, NC). 
Animals 
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Male Wistar wild-type (WT) rats (250-350 g) from Charles River Labs (Wilmington, MA) or male 
Mrp2-deficient (TR-) rats bred at the University of North Carolina (250—350 g; breeding stock obtained 
from Dr. Mary Vore, University of Kentucky, Lexington, KY) were used as donors for hepatocyte and 
isolated perfused liver (IPL) studies.  Rats were allowed free access to water and food, and acclimated for 
a minimum of 1 week prior to experimentation.  All animal procedures complied with the guidelines of the 
Institutional Animal Care and Use Committee (University of North Carolina, Chapel Hill, NC).  All 
procedures were performed under full anesthesia with ketamine/xylazine (140/8 mg/kg i.p.).   
Sandwich-cultured Hepatocytes (SCH) 
Freshly isolated rat and human hepatocytes were seeded in 24-well BioCoat plates (BD 
Biosciences, San Jose, CA) at a density of 0.35×106 cells/well (WT rat and human) or 0.2×106 cells/well 
(TR- rat)  and overlaid with Matrigel basement membrane matrix (BD Biosciences, San Jose, CA) in a 
sandwich configuration and maintained as described previously (23).  Human hepatocytes were kindly 
provided by Life Technologies (Research Triangle Park, NC) from a 55 year old female Caucasian donor 
with a BMI 30.8 kg/m2.  On day 4 (rat) or day 7 (human), SCH were pre-incubated for 10 min in 0.5 
mL/well standard (Ca2+-containing) or Ca2+-free Hanks Balanced Salt Solution (HBSS) to maintain or open 
tight junctions, respectively (B-CLEAR® technology, Qualyst Transporter Solutions, Research Triangle 
Park, NC).  Subsequently, SCH were treated with 0.1 or 1 μM [3H]RSV (100 nCi/mL) in the absence or 
presence of GF120918 (0.5 μM ), in standard HBSS for 20 min at 37°C.  After the 20-min uptake phase, 
buffers containing RSV were removed, cells were washed twice with 37°C standard or Ca2+-free HBSS 
buffer without RSV, and the third application of buffer was added to SCH for the 15-min efflux phase (Fig. 
4.1A).  For conditions in the presence of inhibitor, 0.5 μM GF120918 was maintained in the incubation 
buffer for the duration of the experiment (pre-incubation, uptake and efflux phases).   Preliminary studies 
indicated that 0.5 µM GF120918 was sufficient to inhibit RSV biliary excretion in SCH with minimal 
impact on uptake.  RSV accumulation in cells+bile, cells, and medium (standard HBSS or Ca2+-free HBSS 
buffer) during uptake (2, 5, 10, and 20 min) and efflux (2, 5, 10, and 15 min) phases were determined by 
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terminal sampling of n=3 wells at each time point.  In all cases, incubation medium was collected at the 
end of the incubation period, and cells were washed twice in ice-cold HBSS.  Cells were solubilized in 0.3 
mL 0.5% Triton X-100 and radioactivity in cell lysates and buffer samples was quantified by liquid 
scintillation counting (Packard TriCarb, Perkin-Elmer, Waltham, MA).  Preliminary studies were 
performed to confirm that cell viability and tight junction modulation were maintained throughout the 
experimental uptake/efflux protocol described above and in Fig. 4.1 using 1 μM carboxydichlorofluorescein 
diacetate (CDFDA).  The fluorescence intensity in bile networks was observed by serial imaging using a 
Zeiss Axiovert 100TV inverted fluorescent microscope (Carl Zeiss Inc., Thornwood, NY).  Leakage of 
lactate dehydrogenase (LDH) into buffer during the uptake/efflux protocol was determined using the LDH 
Cytotoxicity Detection Kit (Roche Diagnostics, Indianapolic, IN).  LDH release was evaluated as a 
percentage of total cellular LDH content, represented by values measured after complete cell lysis using 
0.5% Triton X-100.   
Isolated Perfused Livers (IPLs) 
WT and TR- rat livers were perfused in a single-pass manner as described previously (24; 25).  
Briefly, following cannulation of the portal vein and bile duct, livers were perfused in situ with 
continuously-oxygenated Krebs-Ringer bicarbonate buffer (35 mL/min) in the presence of 5 μM 
taurocholate to maintain bile flow.  Livers were removed from the body cavity and placed in a humidified 
perfusion chamber heated to maintain liver temperature at 37°C.  After a 15-min equilibration period, the 
perfusate for the 60-min loading phase contained RSV (0.5 μM); at 60 min, the perfusate was switched 
back to RSV-free, and was continued for an additional 30 min.  For conditions in the presence of inhibitor, 
the inflow perfusate contained 0.5 μM GF120918 for the duration of the experiment (15-min equilibration 
period followed by a 90-min perfusion).  The concentration of GF120918 was based on preliminary studies 
in SCH (see above).  Liver viability was assessed by monitoring inflow perfusion pressure (<15 mm H2O), 
gross morphology, and maintenance of bile flow (within 30% of the baseline rate during the equilibration 
period).  Bile and perfusate were collected over 5-min intervals, and bile volume was determined 
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gravimetrically in pre-weighed tubes.  After perfusion, livers were blotted dry, weighed, and stored at -
80°C until analysis. 
Membrane Vesicles 
Human MRP3 plasmid (pcNDA3.1(-)-MRP3) and MRP4 plasmid (pcDNA3.1(-)-MRP4) were 
kindly provided by Dr. Susan Cole (Queen’s University, Kingston, Canada) and Dr. Dietrich Keppler 
(German Cancer Research Center, Heidelberg, Germany), respectively.  Transiently transfected HEK293T 
cells were generated and membrane vesicles were prepared as described previously (26).  Transport 
experiments were carried out by a rapid filtration assay as described previously (27).  Briefly, membrane 
vesicles (10 μg protein) were incubated at 37°C with test compound in Tris-sucrose buffer (TSB; 50 mM 
Tris-HCl, 250 mM sucrose, 10 mM MgCl2, 10 mM creatine phosphate, 100 μg/mL creatine kinase, 4 mM 
ATP or AMP) and 20 μM [3H]E217βG (0.4 μCi/mL) for MRP3, 2 μM [3H]DHEAS (0.7 μCi/mL) for MRP4, 
or 0.1-100 μM [3H]RSV (0.5 μCi/mL),  in a volume of 50 μL.  After incubation for 10 min, the reaction 
was stopped by the addition of 0.45 mL ice-cold TSB and immediately applied to a glass fiber filter (type 
A/E, Pall Corp., Port Washington, NY) and washed twice with 2 mL ice-cold TSB.  Filters were mixed by 
vortex in 5 mL of scintillation fluid and radioactivity was quantified by liquid scintillation counting 
(Packard TriCarb, Perkin-Elmer, Waltham, MA).  The ATP-dependent uptake of substrate was calculated 
by subtracting substrate uptake in the presence of AMP from substrate uptake in the presence of ATP.  
Membrane vesicles from non-transfected (NT) cells were used to demonstrate the potential endogenous 
ATP-dependent uptake of probe substrates.  Inhibition data are presented as the percentage of the 
prototypical substrate (E217βG or DHEAS) uptake in membrane vesicles prepared from cells 
overexpressing MRP3 or MRP4.  Transport of RSV by MRP4 is presented as ATP-dependent uptake, after 
subtracting endogenous ATP-dependent uptake in NT vesicles.  All data are expressed as mean ±SD of 
triplicate determinations in a single experiment.   
Bioanalysis 
RSV was quantified by LC-MS/MS as described previously for samples derived from IPL studies; 
[3H]RSV was quantified by liquid scintillation counting for SCH studies (4).  The RSV calibration curve 
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was constructed over a standard range of 1-1000 nM based on peak area ratios of analyte and internal 
standard.  The pentanoic acid metabolite of RSV was identified by high resolution LC-MS/MS (TOF/TOF) 
using an ABSciex API5600 TripleTOF mass spectrometer (Fig. 4.3).  Although absolute quantification of 
the pentanoic acid derivative of RSV was not possible due to the lack of an analytical standard, relative 
changes in this metabolite were determined by normalizing the peak area of the extracted (TOF) parent ion 
chromatogram with the extracted (TOF) parent ion of the internal standard.  The concentration of RSV 
pentanoic acid was estimated by the calibration curve generated using the peak area of RSV normalized by 
the peak area of the internal standard under the assumption that RSV and the pentanoic acid metabolite of 
RSV have similar ionization efficiencies.   
Pharmacokinetic Modeling 
 Pharmacokinetic modeling and simulation were used to evaluate RSV disposition in rat SCH and 
IPLs, and to determine the effects of GF120918 and loss of Mrp2 function on RSV hepatobiliary 
disposition.  Models incorporating various combinations of linear and/or non-linear parameters governing 
RSV flux were fit to mass (SCH) or rate (IPL) versus time data from individual experiments (Fig. 4.4).  The 
model fitting was performed with WinNonlin Phoenix, v6.1 (St. Louis, MO) using the stiff estimation 
method and a mixed (additive and proportional) model to estimate residual error.  The following differential 
equations, which were developed based on the model scheme depicted in Fig. 4.1B, were fit simultaneously 
to data generated in SCH in the presence of intact and disrupted bile canaliculi: 
Mass in buffer (Standard HBSS):  
dXBuffer൅
dt 	ൌ	CLBLൈCCell
൅ 	൅	KFluxൈXBile െ CLUptakeൈCBuffer൅ െ KWashൈXBufferା 																				XBuffer൅								° ൌ Xdose				 
Mass in buffer (Ca2+-free HBSS):   
dXBufferି
dt 	ൌ	ሺCLBL൅	CLBileሻൈCCell
ି െ CLUptakeൈCBufferି െ KWashൈXBufferି 																								XBufferି								° ൌ Xdose 
Mass in cells:  
dXCell൅orି
dt 	ൌ	CLUptakeൈCBuffer
൅orି 	െ	ሺCLBL൅	CLBileሻൈCCell൅orି																				XCell൅orି	° ൌ 0 
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Mass in bile (Standard HBSS):  
dXBile
dt 	ൌ	CLBileൈCCell	
ା െ	KFluxൈXBile																				XBile							° ൌ 0 
Mass in cells+bile (Standard HBSS):  
dXCells൅Bile
dt 	ൌ	
dXBile
dt ൅	
dXCellା
dt  
where variables and parameters are defined as in Fig. 4.2A.  In order to account for removal of the RSV 
dose from the buffer compartment during wash step, Kwash was activated for 1.5 minutes at the end of the 
20-min uptake phase and fixed at 1x104 min-1 based on simulations.  CCell represents the intracellular 
concentration, calculated as XCell/VCell, where cellular volume (VCell) was estimated based on the protein 
content of each preparation, using a value of 7.4 μL/mg protein.(28)   CBuffer represents the buffer 
concentration, calculated as XBuffer/VBuffer where the buffer volume (VBuffer) was constant (0.5 mL).  Initial 
parameter estimates were obtained from noncompartmental analysis of SCH data, where CLUptake was 
estimated from the initial (2 min) uptake data, CLUptake = (dXcells+bile/dt)/CBuffer, and CLBL and CLBile were 
estimated from efflux phase data under calcium-free conditions, where (CLBL + CLBile) = X-Buffer,0-
15min/AUCcells,0-15min.  KFlux , which represents the flux of substrate out of bile networks in standard HBSS 
conditions, was estimated initially from simulations using Berkeley-Madonna. 
 The model scheme depicting the single-pass IPL system (Fig. 4.2) consisted of an extracellular 
(sinusoidal/perfusate) compartment, liver tissue, and a bile compartment, each divided into 5 
subcompartments in the semiphysiologically-based approximation of the dispersion model, as reported by 
Watanabe et al.(29)  The model was fit simultaneously to biliary excretion rate and appearance in outflow 
perfusate rate versus time data, as well as terminal recovery of RSV and the pentanoic acid metabolite in 
liver tissue.  Differential equations describing the model scheme in Fig. 4.2 are as follows: 
Extracellular liver 1:  
dXEC,1
dt ൌQൈCin	൅	
CLBL
5 ൈCu,L1 െ	
CLUptake
5 ൈCEC,1 െ QൈCEC,1 
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Extracellular liver 2-5:  
dXEC,n
dt 	ൌ	QൈCEC,n‐1	൅	
CLBL
5 ൈCu,L,n െ	
CLUptake
5 ൈCEC,n െ 	QൈCEC,n 
Intracellular liver 1-5: 
dXLiver,n
dt 	ൌ	
CLUptake
5 ൈ ൤൬
CLBL
5 ൰൅ ൬
CLMet
5 ൰൅ ൬
CLOther
5 ൰൨ൈCu,L,n െ	
Cu,L,nൈሺVmax/5ሻ
൫Km	൅	Cu,L,n൯  
Bile 1-5: 
dXBile,n
dt 	ൌ	
Cu,L,nൈሺVmax/5ሻ
൫Km	൅	Cu,L,n൯  
where variables and parameters are defined as in Fig. 4.2 with further explanation as follows.  CEC is the 
extracellular concentration, calculated as XEC,n/(VEC/5) and VEC is the extracellular volume of the liver, 
which was assumed to be in equilibration with the sinusoidal space and estimated at 20% of the total liver 
mass, as reported previously (5; 29).  Q is the perfusate flow rate of 35 mL/min, and Cin is the concentration 
of RSV in the perfusate, measured for each preparation; binding of RSV to the perfusion tubing and 
apparatus was <10% and not considered further.  Cu,L is the unbound intracellular concentration of RSV in 
the liver based on binding of RSV to rat liver tissue, which was determined by equilibrium dialysis with an 
unbound fraction of 0.25, corrected for dilution.  The total intracellular liver concentration was calculated 
as Xliver,n/(VL/5) where VL is the intracellular volume, calculated as total liver mass minus the VEC.  The 
RSV concentration resulting in half-maximal biliary excretion (Km) was set to 10 μM based on the reported 
affinity of RSV for Mrp2 and Bcrp in isolated expression systems (8; 30).  The CEC5×Q was fit to the 
observed appearance rate in outflow perfusate, while the sum of the excretion rate in bile (dXbile/dt) for liver 
subcompartments 1-5 was fit to the observed biliary excretion rate.  Initial parameter estimates were 
obtained from a combination of direct extrapolation of IPL data and simulations in Berkeley-Madonna.  
Vmax was estimated initially as the steady-state excretion rate in bile based on unbound liver concentrations 
from mass balance of ~3-5 times the Km for biliary excretion process (10 µM).  CLUptake was estimated 
initially from the observed hepatic extraction (Eh) at the initial time point in outflow perfusate (0-15 min), 
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and subsequently extrapolated using the well-stirred model, assuming hepatic intrinsic clearance represents 
uptake clearance, according to the following equations: 
Eh = (Cin-Cout)/Cin 
Eh = CLint/(Q+CLint)  
CLUptake = CLint = Eh×Q/(1-Eh)   
Based on two independent reports of RSV uptake in freshly-isolated, suspended WT rat hepatocytes, 
CLUptake was fixed at 40 mL/min/g liver (31; 32), which was very close to the CLUptake estimated from TR- 
liver preparations in the current study (50 mL/min/g liver).  Metabolic clearance to the pentanoic acid 
derivative (CLMet) and other potential metabolites (CLOther) were estimated initially from simulations in 
Berkeley-Madonna. 
Transporter-mediated clearance values (CLUptake, CLBL and CLBile) estimated from pharmacokinetic 
modeling of RSV SCH and IPL data were compared and scaling factors were reported for the WT Control 
conditions.  The scaling factors represent the respective clearance value in IPL divided by the corresponding 
value in SCH.  
Data Analysis 
The effect of Mrp2 status (WT or TR-) and GF120918 on RSV disposition in SCH and IPL 
experiments was determined by one-way ANOVA with Tukey’s post-hoc test.  The effect of Mrp2 status 
was evaluated at each level of inhibitor (absent or present) and the effect of GF120918 was evaluated at 
each level of Mrp2 status (WT or TR-). 
Results 
SCH 
 Preliminary studies were conducted to establish that the novel uptake/efflux protocol described in 
Fig. 4.1A maintained tight junction modulation in the absence of Ca2+ throughout the experimental time 
course without compromising cell viability.  Following carboxydichlorofluorescein diacetate (CDFDA) 
administration, fluorescence microscopy confirmed that CDF did not accumulate in bile networks during 
the 20-min uptake phase following preincubation in Ca2+-free HBSS.  Less than 5% of total cellular LDH 
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content was released over the experimental time course (data not shown).  The mass-time profiles of RSV 
in cells+bile, cells and buffer during the uptake/efflux protocol are plotted in Fig. 4.4.  RSV accumulation 
in cells+bile and cells increased during the uptake phase and decreased during the efflux phase, while 
appearance in the buffer increased during the efflux phase.  RSV accumulation in bile networks (the 
difference between accumulation in cells+bile and cells) was reduced in Mrp2-deficient TR- SCH, and 
biliary excretion nearly was ablated in TR- SCH in the presence of GF120918.  Parameter estimates 
recovered from fitting the differential equations based on the model scheme in Fig. 4.1B to these data are 
listed in Table 4.1.  CLBile was significantly different between groups (F-value 38.2, p<0.0001).  The 
effect of Mrp2 status (WT vs. TR-) was statistically significant in the absence and presence of GF120918, 
while the effect of GF120918 was statistically significant in WT hepatocytes but not in the TR- 
hepatocytes.  The CLBL term was significantly different between groups (F-value=3.92, p<0.048).  
However, the individual effect of animal and GF120918 failed to reach significance after correcting for 
multiple comparisons.  There was a trend toward decreased CLUptake and increased CLBL in TR- compared 
to WT hepatocytes in both the absence and presence of GF120918.  Interestingly, GF120918 tended to 
decrease both CLUptake and CLBL in WT and TR- SCH.  The KFlux term was significantly different between 
groups (F-value=7.22, p<0.01); KFlux was significantly increased in TR- SCH in the absence of 
GF120918.  The effect of GF120918 was statistically significant in TR- but not WT SCH.  Importantly, 
parameter estimates revealed that CLBL and CLBile have a similar contribution to the total cellular 
excretion of RSV in WT SCH in the absence of GF120918.   
 Uptake of 1 µM RSV and subsequent efflux was examined in SCH from one human liver (Fig. 
4.5).  Parameter estimates recovered from fitting the differential equations based on the model scheme 
depicted in Fig. 4.1B to these data are listed in Table 4.1.  CLUptake was at least an order of magnitude 
greater than the efflux pathways (CLBL and CLBile)), which were of similar magnitude; CLBL was 
approximately 2-fold greater than CLBile.  KFlux was similar to the value observed in rat SCH. 
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IPLs 
Outflow perfusate concentrations of RSV ranged from 0.003 to 0.23 µM in WT and TR- IPLs. The 
rates of RSV appearance in bile and outflow perfusate are plotted in Fig. 4.6; recovery of RSV and the 
pentanoic acid metabolite at the end of the perfusion are summarized in Fig. 4.7.  Interestingly, the initial 
appearance rate of RSV in the outflow perfusate was reduced in TR- IPLs (Fig 4.6.C and D).  Addition of 
GF120918 did not reduce further the appearance rate of RSV in outflow perfusate of TR- IPLs.  The 
recovery of RSV in perfusate tended to be reduced in TR- compared to WT livers in the absence of 
GF120918, and also by GF120918 in WT livers (F-value=5.54, p=0.039).  However, the individual effects 
of Mrp2 status and GF120918 failed to reach significance after correcting for multiple comparisons.  Biliary 
excretion of RSV was not affected by GF120918 in WT livers, while the effect of GF120918 on reduced 
biliary recovery in TR- IPLs was statistically significant.  The effect of Mrp2 status on RSV biliary excretion 
was statistically significant in the presence of GF120918, but not in the absence of GF120918.  The recovery 
of RSV in liver tissue at the end of the 90-min perfusion was significantly greater in TR- compared to WT 
livers in the absence and presence of GF120918 (Fig. 4.7).  Total recovery of the dose in perfusate, bile and 
liver tissue at the end of the 90-min studies was nearly complete following perfusion of WT livers, and 
reduced significantly in TR- livers in the absence and presence of GF120918. This reduction in total 
recovery was offset, in part, by the presence of the pentanoic acid metabolite in TR- liver tissue.  
Concentrations of the pentanoic acid metabolite were low in perfusate and bile samples, representing <2% 
of the total dose over the course of the study.  As such, the pentanoic acid metabolite was reported only in 
the liver tissue.  The pentanoic acid derivative comprised approximately 40% of total RSV content in TR- 
liver tissue, or 16% of the administered RSV, at the end of the perfusion; no other specific metabolites were 
identified by LC-MS/MS.   
Parameter estimates recovered from fitting the differential equations based on the model scheme 
depicted in Fig. 4.2 to the data are listed in Table 4.2.  The estimated maximal velocity (Vmax) of the 
biliary excretion process and resulting biliary clearance of RSV (CLBile = Vmax/Km) were significantly 
reduced in TR- compared to WT IPLs in the absence and presence of GF120918.  GF120918 reduced 
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Vmax significantly in TR- but not WT IPLs.  CLBL was significantly greater in WT compared to TR- livers 
in the absence of GF120918.   GF120918 tended to reduce CLBL in WT IPLs, with no additional effect in 
TR- IPLs.  The CLMet and CLOther tended to be increased in TR- compared to WT IPLs, and the presence of 
GF120918 also tended to increase the metabolic clearance (F=5.62, p=0.023 and F=4.57, p=0.038, for 
CLMet and CLOther, respectively; differences failed to reach significance after correcting for multiple 
comparisons).  Comparing transport-mediated clearance rates between WT (Control) SCH and IPL data 
(Tables 4.1 and 4.2)  resulted in empirical scaling factors of 4.2 for CLUptake (40 mL/min/g liver in IPL vs. 
9.5 mL/min/g liver in SCH), 6.4 for CLBL (0.21 vs. 1.4 mL/min/g liver in SCH compared to IPLs), and 
1.1 [0.23 mL/min/g liver in SCH vs. 0.26 mL/min/g liver (Vmax/Km) in IPLs] for CLBile. 
MRP3- and MRP4-Mediated Transport in Membrane Vesicles 
 The inhibitory potential and substrate specificity of RSV for MRP3 and MRP4 was evaluated 
using membrane vesicles prepared from non-transfected (NT) and MRP-overexpressing HEK293 cells.  
Pilot studies confirmed ATP-dependent uptake was linear up to 5 and 2 min for the prototypical MRP3 
and MRP4 probe substrates, E217G and DHEAS, respectively (data not shown).  ATP-dependent uptake 
determined at 1 min was concentration-dependent with a Km and Vmax of 23±5 µM and 1700±200 
pmol/min/mg protein, respectively, for E217G, and 2.9±0.2 µM and 390±40 pmol/min/mg protein, 
respectively, for DHEAS (mean±SD).  Co-incubation with 50 µM RSV inhibited ATP-dependent 
transport of the prototypical MRP3 and MRP4 probe substrates, E217G (20 µM) and DHEAS (2 µM), by 
76 and 88%, respectively (Fig. 4.8A and B).  By comparison, ATP-dependent transport of E217G (20 µM) 
and DHEAS (2 µM) was 77 and 88% lower in NT membrane vesicles, and decreased by 98 and 105% in 
the presence of the potent pan-MRP inhibitor, MK571 (50 µM, Fig. 4.8A and B).  ATP-dependent 
transport of 0.1 µM RSV was linear up to ~1 min, and was greater in membrane vesicles from HEK293 
cells overexpressing MRP4 and MRP3 compared to NT cells (Fig. 4.8C).  Uptake of RSV at 1 min in 
membrane vesicles from MRP4-overexpressing cells was concentration-dependent with a Km and Vmax of 
21±7 µM and 1140±210 pmol/min/mg protein for MRP4 (Fig. 4.8D).  Despite inhibition of MRP3-
mediated E217G transport by 50 µM RSV (Fig. 4.8A) and apparent MRP3-dependent RSV uptake at low 
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concentrations (Fig. 4.8C), ATP-dependent uptake of RSV over a range of concentrations in membrane 
vesicles from MRP3-overexpressing cells was not significantly greater than uptake into vesicles prepared 
from NT cells (data not shown). 
Discussion 
 The present studies suggest for the first time a significant role for basolateral efflux in the 
hepatobiliary disposition of RSV in rat and human hepatocytes.  Uptake and efflux profiles observed in 
SCH with tight junction modulation extended over 35 min, and the behavior of the system under these 
conditions, also has not been reported previously.  The novel uptake and efflux protocol in SCH, 
combined with pharmacokinetic modeling, revealed that CLBL and CLBile represent alternative pathways 
with a quantitatively similar contribution to the total hepatocellular excretion of RSV under normal 
conditions in rat and human SCH.  The effects of modulating Mrp2 and Bcrp function using TR- SCH and 
GF120918, respectively, were consistent with IPL data and previous reports suggesting that each 
transporter contributes to a similar degree, and together comprise approximately 90-95% of RSV biliary 
excretion in rats.  GF120918 tended to inhibit both CLUptake and CLBL in rat SCH experiments, consistent 
with the promiscuous nature, or overlap in affinity, of transporter substrates and inhibitors.  In TR- rat 
SCH, CLUptake tended to decrease and CLBL tended to increase, consistent with the hepatoprotective 
compensatory changes that would be expected in the setting of impaired biliary excretion.  Indeed, it has 
been shown that Ntcp expression is downregulated and Mrp3 upregulated in TR- compared to WT livers 
(33).   
It is clear that differences exist in the handling of RSV by WT and TR- livers beyond the expected 
decrease in biliary excretion rate resulting from loss of Mrp2 function (Figs. 4.6 and 4.7, Table 4.2).  In 
particular, there is a delay in the attainment of steady-state appearance rate of RSV in the outflow 
perfusate of TR- livers during the loading phase.  Qualitatively, this would be expected assuming RSV 
accumulation in the liver and saturation of the biliary excretion capacity, as represented by the model 
structure and resulting parameter estimates (Fig. 4.2, Table 4.2).  Quantitatively, it is curious that the 
excretion rate in the outflow perfusate remains lower in TR- compared to WT throughout the loading 
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phase despite increased hepatocellular concentrations driving the efflux process(es).  This finding is 
consistent with the hypothesis that the basolateral efflux of RSV may be impaired in TR- livers.  Indeed, 
the CLBL was significantly reduced in TR- compared to WT livers in the absence of GF120918.  
Basolateral efflux is regarded commonly as a compensatory route of elimination to protect hepatocytes in 
the setting of cholestasis or otherwise impaired biliary excretion (17-20).  Proteins that have been 
suggested to have compensatory/hepatoprotective roles in this manner include Mrp3 and Mrp4, which are 
known to be upregulated in animals with impaired biliary excretion; Mrp3 exhibits increased expression  
in TR- rat livers, and Mrp4 expression is increased following bile duct ligation (33; 34).  Therefore, it 
would be expected that basolateral efflux and resulting outflow perfusate rates would be greater in TR- 
livers.  Impaired basolateral efflux of RSV in TR- IPLs could be attributed to accumulation of endogenous 
anions (e.g., bilirubin glucuronides, glutathione, and bile acids) resulting from loss-of-function of Mrp2 
(35); these anions would be expected to compete with RSV for basolateral excretion(36).  The absence of 
impaired basolateral efflux in TR- SCH may be due to decreased accumulation of endogenous anions in 
vitro.  Although the SCH system retains much of the synthetic function of the liver in vivo, bile acids and 
bilirubin are extensively recycled from the intestine, which is absent in the SCH model (37; 38).  
Exogenous bile acid administration in SCH has been reported to amplify the toxicity of known BSEP 
inhibitors (39).  Scaling of transporter-mediated RSV clearance values between SCH and IPLs was 
confined to the WT Control conditions because of the differences observed between SCH and IPLs in the 
effect of Mrp2 status on CLBL.  CLBL was decreased ~6-fold (0.21 vs. 1.4 mL/min/g liver) in SCH 
compared to IPLs, suggesting a corresponding decrease in expression of the transporter(s) mediating 
basolateral efflux of RSV; available data suggest that Mrp4 protein expression remains constant or is 
decreased over days in culture(23).  The ~4-fold decrease in CLUptake in SCH  compared to IPLs (9.5 vs. 
40 mL/min/g liver) corresponds with reduced Oatp expression over days in culture in rat SCH(40).  
Interestingly, the CLBile translated almost directly [0.23 mL/min/g liver in SCH vs. 0.26 mL/min/g liver 
(Vmax/Km) in IPLs].  Although Bcrp and Mrp2 protein expression have been reported to increase and 
140 
 
decrease, respectively (~2-3 fold) in SCH over days in culture, these changes may offset each other with 
respect to RSV biliary clearance(41; 42).   
Following i.v. administration of RSV to healthy humans, approximately 72% of the dose was 
eliminated by the liver, with an estimated hepatic extraction (Eh) of 0.63 (1).  Similarly, the mean Eh 
observed at steady-state (30-60 min) in WT rat IPLs without GF120918 in the current studies was 0.66.   
However, perfusate outflow profiles in the current studies using WT and TR- rat IPLs clearly indicated 
that RSV is almost completely extracted by the liver in a single-pass, and that appearance in outflow 
perfusate is a result of basolateral efflux.  This is evident from the low initial appearance rate of RSV in 
outflow perfusate, especially from the TR- IPLs, and the absence of a “drop-off” in outflow perfusate 
upon switching to blank buffer for the 30-min efflux phase in single-pass IPL studies(25; 43).  As evident 
from the disparate initial appearance rate in outflow perfusate, initial estimates of CLUptake were up to 5-
fold greater in TR- compared to WT rat liver preparations.  Uptake in TR- livers would not be expected to 
be greater than WT; if anything, uptake mechanisms (e.g., Ntcp) are known to be downregulated in a 
compensatory/hepatoprotective manner in relation to loss-of-function of Mrp2 (33).  Rather, it was 
assumed that rapid attainment of steady-state in the outflow perfusate of WT liver preparations precluded 
accurate estimation of the initial uptake rate.  These studies demonstrate for the first time the important 
role of hepatic basolateral efflux in mediating systemic exposure of RSV.  The importance of basolateral 
efflux of RSV is further documented by inhibition of this efflux pathway, either by GF120918 in WT 
IPLs, or in TR- compared to WT IPLs.   
RSV is not metabolized extensively in humans; approximately 90% of the dose was recovered as 
parent drug (44).  The primary metabolite is N-desmethyl-RSV, formed by CYP2C9.  In rats, RSV 
metabolism plays a larger role, with metabolites accounting for ~50% of plasma and liver content(2; 45).  
Biotransformation of RSV in rats is not mediated extensively by Cyps.  Rather, the primary metabolite is 
the pentanoic acid derivative, presumably formed by β-oxidation of the fatty acid chain (45).  Results of 
the present study confirmed the presence of RSV pentanoic acid as the primary metabolite, contributing 
~40% of total content in both WT and TR- livers, consistent with previous reports (2; 45).  Measurement 
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of total radioactivity in SCH experiments precluded comparisons between IPL and in vitro studies. 
However, the increase in hepatic accumulation of RSV and the pentanoic acid metabolite of RSV in TR- 
compared to WT IPLs is consistent with impaired RSV excretion and “shunting” to the metabolic 
pathway(s); alternatively, excretion of RSV pentanoic acid may be impaired in TR- rat hepatocytes.  A 
similar effect of increased hepatic exposure was observed for erythromycin and its N-desmethyl 
metabolite when co-administered with GF120918 in cultured hepatocytes and whole animals (46).   
Interestingly, in a whole animal study with WT Sprague-Dawley and Mrp2-deficient Eisai 
hyperbilirubinemic rats (EHBR), liver concentrations of RSV were not significantly increased in EHBR 
animals (2).  Biliary clearance (liver-to-bile) was decreased, and systemic exposure was increased more 
than 3-fold.  While this may suggest efficient hepatic basolateral efflux of RSV in the setting of impaired 
biliary excretion, decreased renal elimination in EHBR rats may contribute to the increased systemic 
exposure.  An important advantage of the IPL model is that the role of hepatic processes can be evaluated 
in isolation from other organ systems.  RSV disposition was reported recently in recirculating perfused 
WT and TR- IPLs (5).  Increased tissue accumulation was observed in TR- compared to WT livers, similar 
to the present study.  However, the role of basolateral excretion was not considered.  Indeed, the 
pharmacokinetic model used to analyze and interpret the data did not allow for translocation of RSV from 
liver tissue back into perfusate.  The single-pass IPL system used in the present study allows for direct 
evaluation of basolateral excretion from liver to perfusate. 
Finally, two candidate transporters that could be responsible for the basolateral excretion of RSV 
were examined in the membrane vesicle system.  RSV (50 µM) inhibited the transport of protypical 
substrates, E217βG and DHEAS, in membrane vesicles from HEK293 cells overexpressing MRP3 and 
MRP4, respectively, at a similar level as the prototypical pan-MRP inhibitor MK-571 (Figs. 4.8A and B).  
Further studies were performed to evaluate RSV as a substrate, showing that time- and ATP-dependent 
uptake in membrane vesicles prepared from MRP3- and MRP4-overexpressing cells was greater than in 
vesicles from non-transfected (NT) cells (Fig. 4.8C).  Based on kinetic analysis, RSV was transported by 
MRP4 with a Km ~20 µM.  Unbound RSV concentrations in human liver are likely to be below this Km 
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value, despite efficient hepatic uptake and accumulation.  The mean steady-state RSV total plasma Cmax is 
~50 ng/mL (0.1 µM) following an 80 mg daily oral dose (47; 48), while accumulation of total RSV (Kp) 
in human and rat hepatocytes in vitro is ~20-fold in this and other reports (31), and accumulation in rat 
liver in vivo is ~20-45 fold (45).   The involvement of other transport proteins cannot be ruled out.  In 
fact, SCH and IPL data in the present studies suggest that ~50% of basolateral efflux in rat liver is 
mediated by mechanism(s) unaffected by GF120918 or intracellular accumulation of endogenous anions 
in TR- rat hepatocytes. 
A novel uptake and efflux protocol was developed in SCH that revealed the significant 
contribution of basolateral efflux to the hepatocellular excretion of RSV in rat and human hepatocytes.  
When combined with a modeling approach, this experimental paradigm can be used to elucidate the 
relative contribution of basolateral efflux clearance as well as biliary clearance.  As shown in SCH and 
IPLs, basolateral efflux of RSV is altered by co-administration with GF120918, and in TR- hepatocytes.  
RSV is a substrate for human MRP4, which likely contributes to the basolateral efflux of RSV in human 
liver.  MRP4-mediated efflux of RSV may be impaired due to patient-specific factors such as DDIs, 
genetic variation and/or disease states.  Altered function may lead to changes in systemic and hepatic 
exposure of RSV, with implications for the pharmacologic effect and safety of this commonly-used drug.  
  
143 
 
Table 4.1. Summary of recovered parameter estimates based on the model scheme depicted in Figure 
4.1B describing rosuvastatin disposition in rat wild-type (WT) and Mrp2-deficient (TR-) sandwich-
cultured hepatocytes (SCH) in the absence (Control) or presence of GF120918, and rosuvastatin 
disposition in human SCH. 
 
 CLUptake  CLBL  CLBile  KFlux 
Conditions: (mL/min/g liver)  (mL/min/g liver)  (mL/min/g liver)  (min-1) 
WT SCH        
Control  9.5 ± 2.7    0.21 ± 0.07†   0.23 ± 0.04†‡  0.057 ± 0.029*† 
+GF120918 7.9 ± 1.0    0.16 ± 0.03†   0.079 ± 0.017††  0.046 ± 0.007†* 
TR- SCH        
Control 7.6 ± 1.2      0.34 ± 0.09*†   0.089 ± 0.025*  0.093 ± 0.008*† 
+GF120918 6.6 ± 1.6      0.27 ± 0.06*†   0.018 ± 0.015*  0.049 ± 0.027†* 
        
Human SCH 1.8 ± 0.1   0.095 ± 0.013  0.053 ± 0.010  0.042 ± 0.008*† 
Data are presented as mean ± SD of individual fits from n=3-4 rat SCH preparations, or ± SD 
of the parameter estimate from a single preparation of human SCH 
* p<0.05, adjusted: Effect of Mrp2 status (WT vs. TR-) is statistically significant within the same level of 
inhibitor (+ or –GF120918); †p<0.05, adjusted: Effect of GF120918 (absence vs, presence) is statistically 
significant within the same level of Mrp2 status (WT or TR-). 
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Table 4.2. Summary of recovered parameter estimates based on the model scheme depicted in Figure 4.2 
describing rosuvastatin disposition in wild-type (WT) and Mrp2-deficient (TR-) isolated perfused livers  
in the absence (Control) or presence of GF120918. 
 
 CLBL  Vmax  CLMet  CLOther 
Conditions: (mL/min/g liver)  (nmol/min/g liver)  (µL/min/g liver)  (µL/min/g liver) 
WT        
Control 1.4 ± 0.3   2.6 ± 1.2  0.83 ± 0.25  16 ± 22 
+GF120918   0.83 ± 0.29*   3.2 ± 0.7   1.3 ± 0.5†  24 ± 34 
TR-        
Control    0.55 ± 0.19*†     1.3 ± 0.1*  3.2 ± 1.5  46 ± 13 
+GF120918    0.51 ± 0.13*†      0.26 ± 0.08*†   4.2 ± 1.7  85 ± 27 
Mean ± SD of n=3 livers; 
CLUptake was fixed at 40 mL/min/g liver (Nezasa et al., 2003,Yabe et al., 2011); 
Km was fixed at 10 μM based on the reported affinity of RSV for Mrp2 and Bcrp (Deng et al., 
2008,Huang et al., 2006). 
*p<0.05, adjusted: Effect of Mrp2 status (WT vs. TR-) is statistically significant within the same level of 
inhibitor (+ or –GF120918); † p<0.05, adjusted: Effect of GF120918 (absence vs, presence) is statistically 
significant within the same level of Mrp2 status (WT or TR-),. 
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Figure 4.1. A. Scheme depicting uptake/efflux protocol in sandwich-cultured hepatocytes (SCH).  Gray 
shading represents inclusion of substrate in the Hanks’ Balanced Salt Solution (HBSS) buffer during the 
uptake phase.    B. Model schemes depicting the disposition of rosuvastatin in SCH studies.  X denotes 
mass of rosuvastatin, V denotes compartmental volume, C denotes compartmental concentration; 
subscripts on mass, bile and concentration terms denote the corresponding compartment in the model 
scheme;  superscripts represent the presence (+; intact tight junctions, cells+bile) and absence (-; 
modulated tight juntions, cells) of Ca2+ in the incubation buffer; clearance values are designated as 
CLUptake for uptake from buffer into hepatocytes, CLBL for efflux from hepatocytes into buffer, CLBile for 
efflux from hepatpocytes into bile spaces, and KFlux for flux from bile spaces into buffer. 
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Figure 4.2. A.  Scheme depicting the experimental protocol in isolated perfused livers (IPLs).  B. Model 
scheme depicting the disposition of rosuvastatin in rat IPL studies.   Q denotes the flow rate of perfusate, 
X denotes mass of RSV, V denotes compartmental volume, C denotes compartmental concentration; 
subscripts on mass, bile and concentration terms denote the corresponding compartment in the model 
scheme, as follows: inflow perfusate (in), outflow perfusate (out), extracellular compartment (EC, 
assumed to be in rapid equilibration with the perfusate), intracellular liver compartment (L), and bile 
(Bile); clearance values are designated as CLUptake for RSV uptake from the extracellular to intracellular 
liver compartment, CLBL for RSV efflux from the intracellular to extracellular liver compartment, CLMet 
for conversion from RSV to the pentanoic acid metabolite, and CLOther for RSV conversion to metabolites 
other than the pentanoic acid derivative; Vmax is the maximum velocity of RSV biliary excretion, Km is the 
RSV concentration resulting in half-maximal biliary excretion. 
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Figure 4.3. A. Extracted ion current (XIC) chromatograph of rosuvastatin (blue, 482.2 0.05 amu), 
rosuvastatin pentanoic acid (purple, 422.20 0.05 amu), and d6-rosuvastatin (internal standard, red, 488.20 
0.05 amu) in TR- Control liver tissue compared to blank liver tissue (inset). B. High resolution product 
ion spectra of rosuvastatin (top), d6-rosuvastatin (middle), and rosuvastatin pentanoic acid (bottom). Note 
the expected Δ6 amu between the products of rosuvastatin and its internal standard (258.14/264.17, 
300.15/306.19, 314.14/320.20, 378.12/384.16, 404.19/410.23, 422.15/428.19 and 446.15/452.19).  
Common product ions formed from rosuvastatin and the pentanoic acid metabolite (242.10, 256.12 and 
270.17 amu) are independent of the changes within the carboxylic acid side chain.  Additionally, the 
paired product ions, 402.19/404.19 for rosuvastatin and 342.17/344.17 for the metabolite, represent loss 
of CH4O2S while maintaining the Δ60 amu (C2H4O2) between rosuvastatin and the pentanoic acid 
metabolite. 
A. 
 
B. 
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Figure 4.4. [3H]Rosuvastatin (RSV) mass versus time data in wild-type (WT) and Mrp2-deficient (TR-) 
rat SCH in the absence (Control) or presence of GF120918 during the uptake and efflux phase.  Closed 
symbols/solid lines represent [3H]RSV in cells+bile (standard HBSS) and open symbols/dashed lines 
represent [3H]RSV in cells (-Ca2+ HBSS).  The simulated mass-time profiles were generated from the 
relevant equations based on the model scheme depicted in Figure 4.1B and the final parameter estimates 
reported in Table 4.1.  Data (pmol/well) are reported as mean±SEM (n=3-4 SCH preparations in triplicate 
per group). 
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Figure 4.5. [3H]Rosuvastatin (RSV) mass versus time data in human SCH during the uptake and efflux 
phase. Closed symbols/solid lines represent [3H]RSV mass in cells+bile (standard HBSS) and open 
symbols/dashed lines represent [3H]RSV mass in cells (-Ca2+ HBSS).  The simulated mass-time profiles 
were generated from the relevant equations based on the model scheme depicted in Figure 4.1B and the 
final parameter estimates reported in Table 4.1.  Data (pmol/well) are reported as mean±SD (n=1 human 
SCH preparation, in triplicate). 
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Figure 4.6. Rosuvastatin (RSV) biliary excretion (A. and B.) and outflow perfusate (C. and D.) rate 
versus time data in isolated perfused livers from wild-type (WT: A. and C.) and Mrp2-deficient (TR-: B. 
and D.) rats in the absence (open symbols; dashed line) or presence (closed symbols; solid line) of 
GF120918.  The simulated excretion rate-time profiles were generated from the relevant equations based 
on the model scheme in Figure 4.2 and the final parameter estimates reported in Table 4.2. Data are 
presented as mean±SD (n=3 livers). 
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Figure 4.7. Recovery of rosuvastatin (solid bars) and rosuvastatin pentanoic acid (gray bars) in perfusate, 
liver and bile, as well as total recovery from wild-type (WT) and Mrp2-deficient (TR-) isolated perfused 
livers in the absence or presence of GF120918.  Data are reported as the mean percentage ± SD based on 
the total dose administered to each liver (n=3 per group) recovered at the end of the 90-min perfusion.  
For recovery of parent drug: *p<0.05, adjusted: Effect of Mrp2 status (WT vs. TR-) is statistically 
significant within the same level of inhibitor (+ or –GF120918),; † p<0.05, adjusted: Effect of GF120918 
(absence vs, presence) is statistically significant within the same level of Mrp2 status (WT or TR-).  For 
recovery of the metabolite: ‡p<0.05, adjusted: Effect of Mrp2 status (WT vs. TR-) is statistically 
significant within the same level of inhibitor (+ or –GF120918). 
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Figure 4.8. ATP-dependent uptake of (A) 20 μM [3H]E217G (MRP3) or (B) 2 μM [3H]DHEAS (MRP4) 
in membrane vesicles from non-transfected (NT) and MRP3- or MRP4-overexpressing (control) HEK293 
cells, respectively, and inhibition by 50 μM rosuvastatin (RSV) and MK571.  (C) Time-dependent 
transport of [3H]RSV in membrane vesicles from NT (●) MRP3- (▲) and MRP4-transfected (■) cells.  
(D) Concentration-dependent transport of RSV in membrane vesicles from MRP4-transfected HEK293 
cells, and corresponding Vmax and Km values obtained from nonlinear regression analysis.  In all cases, 
data represent mean ± SD of triplicate measurements in a single experiment. 
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CHAPTER 5 
 
Summary and Future Directions 
The general focus of this dissertation research has been the study and characterization of 
hepatobiliary clearance of drugs in humans and preclinical species.  The contribution of multiple transport 
proteins in mediating altered hepatic and/or systemic exposure in the setting of impaired transport 
function remains poorly characterized.  To address this knowledge gap, a series of experiments was 
designed and conducted using a variety of model systems, ranging from membrane vesicles that allowed 
the investigation of single transport proteins in isolation, to sandwich-cultured hepatocytes (SCH) 
containing the full complement of transport mechanisms expected in vivo, scaling up to isolated perfused 
rat livers, and finally in vivo studies in human subjects; a truly translational approach.  A number of probe 
drugs were employed to evaluate transporter function in these experimental systems.  This research has 
focused primarily on three drugs: 99mTechnetium-mebrofenin (Choletec®), ritonavir (Norvir®), and 
rosuvastatin (Crestor®).   
99mTc-Mebrofenin (MEB) is a metabolically stable iminodiacetic acid (IDA) analogue and 
imaging agent, used to diagnose structural and functional disorders of the hepatobiliary network and 
gallbladder(1-3).  The efficient vectorial transport of MEB from blood into liver is mediated by the 
organic anion transporting polypeptides, OATP1B1 and OATP1B3(4-6) and the canalicular efflux 
transporter multidrug resistance protein 2 (MRP2)(4; 5; 7).  Ritonavir (RTV) was developed as an HIV 
protease inhibitor, but its extensive clinical use as a component of anti-retroviral therapy is to “boost” 
concentrations of other protease inhibitors by exploiting its ability to inhibit metabolic enzymes and 
intestinal p-glycoprotein (P-gp), thereby increasing the bioavailability of medications administered 
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concomitantly(8; 9).  RTV also has been reported to inhibit hepatic OATP-/Oatp-(10; 11) and MRP-
mediated transport in vitro(8; 11; 12), accumulate in liver tissue(13) and undergo biliary excretion in rats, 
dogs and humans(13).  Hepatic transport plays an important role in the pharmacokinetics and 
pharmacodynamics of rosuvastatin (RSV), an HMG-CoA reductase inhibitor, with the liver serving as the 
primary organ of pharmacologic action and elimination.  Hepatic uptake of RSV is mediated by multiple 
OATP isoforms, and reportedly by the sodium-taurocholate cotransporting polypeptide (NTCP)(14-16), 
while MRP2 and breast cancer resistance protein (BCRP) are primarily responsible for the biliary 
excretion of RSV(14; 17-20).  Impaired function of these transporters via drug-drug interactions (DDIs) 
and genetic polymorphisms has been shown to have important consequences for the pharmacokinetics 
(14; 17; 19; 21-24) and pharmacodynamics (LDL-lowering)(25; 26) of RSV. 
 This research project has made a number of valuable contributions and advances to current and 
longstanding issues in the field of drug transport and pharmacokinetics.  As with any scientific 
investigation at the doctoral level, this research has generated at least as many questions as it has answers.  
The following is a summary of the contributions and opportunities for further exploration based on the 
original aims of this research project. 
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Effect of Ritonavir on 99mTechnetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling 
and In Vitro Approach to Predict Transporter-Mediated DDIs (Chapter 2) 
Probe substrates to assess transport function and organ exposure in vivo are a highly sought-after 
clinical tool; MEB has been proposed as a probe substrate for MRP2(27) but had not been tested in a 
clinical DDI study prior to this work.  This was the first study that utilized liver scintigraphy data to 
evaluate a hepatic DDI in humans, while incorporating blood, bile and urine data to develop a 
comprehensive pharmacokinetic model describing MEB disposition.  The objective of using MEB as a 
probe substrate and “victim” of a transporter-mediated DDI at the level of biliary excretion was to 
demonstrate that such interactions can lead to elevated liver concentrations, with implications for safety 
and efficacy of drugs.  Instead, coadministration of RTV led to a statistically-significant, two-fold 
increase in MEB systemic exposure without accompanying changes in hepatic exposure or biliary 
recovery.  This finding was unexpected, but led to a number of novel discoveries. 
This work has further characterized MEB as a clinical probe of transporter-mediated 
hepatobiliary clearance.  Previous reports of MEB (or other IDA derivative) administration in humans or 
animals was limited to ≤60 min(2; 28-31), in which a two-compartment model representing blood and 
liver reasonably approximated time-activity data(28; 29).  However, results of the present study, in which 
a statistically-significant, two-fold increase in MEB systemic exposure was observed without 
accompanying changes in hepatic exposure or biliary recovery following RTV administration (2x300mg), 
cannot be described by a 2-compartment model.  A semi-PBPK modeling and in vitro systems 
translational approach suggested a transporter-mediated DDI involving tissue uptake at both hepatic and 
extrahepatic sites of MEB distribution.  Rather than a specific MRP2 probe, this clinical study 
demonstrated the utility of MEB as a model organic anion to evaluate DDIs in overall (uptake and efflux) 
transporter-mediated hepatobiliary clearance.   
Estimated unbound hepatic portal vein concentrations of RTV achieved in the clinical study (0.2-
0.5 µM) were in the range that would be expected to inhibit OATP-mediated uptake (0.25-2.5µM)(10; 
11).  Studies in human SCH predicted the clinical study result that RTV was a more potent inhibitor of 
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hepatic uptake, as compared to biliary excretion, of MEB.  Inhibition of MRP2-mediated MEB transport 
by RTV in a membrane vesicle assay suggested that the IC50 was between 5-50 µM, instead of the 
reported value of 50 nM in teleost fish(12).  Despite this discrepancy, RTV accumulation within human 
SCH, and estimated total cellular concentrations (up to 100 µM), predicted that RTV would impair the 
biliary excretion of MEB.  By assessing nonspecific binding of RTV to cell lysates (fu ~0.02) and 
incorporating the estimated intracellular unbound concentration (2 µM maximum), we were able to 
translate data between in vitro systems, which predicted the in vivo results.  This research contributed 
specific data to the literature regarding the use of RTV as an inhibitor of hepatic transport processes. 
More importantly, these high-impact studies outlined an overall paradigm for reliable predictions of 
transporter-mediated hepatic DDIs using data from appropriate in vitro models (e.g., assessment of 
inhibitory potential in relevant systems; biliary excretion assessed in SCH) integrated with knowledge 
regarding drug disposition (e.g., hepatic and extrahepatic distribution; plasma and intracellular binding). 
 The experimental paradigm described in the current work - using in vitro human systems and 
accounting for intracellular unbound inhibitor concentrations - can be used to identify a substrate/inhibitor 
combination and target concentrations to design subsequent clinical studies.  This approach is being 
pursued in collaboration with the Health and Environmental Sciences Institute (HESI) liver imaging 
group, as demonstrated by the recent report by Slizgi, et al(32).  In addition to MEB, other probe 
substrates are being considered, including gadoxetate and PET agents such as fluorine-labeled bile acids.  
Potential inhibitors include rifampicin, diclofenac, ketoprofen, and fusidate.  All are known to inhibit 
MRP2, and are being evaluated for their effects on hepatic uptake.  The ideal inhibitor would demonstrate 
selective inhibition of biliary excretion and basolateral efflux, with a minimal impact on hepatic uptake. 
As noted in the current work: “The availability of quantitative (attenuation corrected) scintigraphy 
data in humans marks a major advance in the use of imaging agents to assess organ/tissue exposure.  
Although the methods have existed for many years, they are under-utilized and provide a rich data set that 
is ideal for pharmacokinetic modeling.”  In addition to this key methodological advance, other 
improvements could be made in future studies to improve the robustness of generated data.  One addition 
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would be to obtain the liver volume for individual subjects using a brief CT scan.  Determination of 
hepatic blood flow for individual subjects also would be ideal; however, accurate and reliable methods for 
this assessment are not readily available.  Such measurements could improve the PBPK modeling 
approach by reducing the uncertainty in these parameters, which are currently estimated based on weight-
based (allometric) scaling of reported population distributions.  This would reduce inter-subject 
variability in the parameter estimates obtained for the clearance values of interest (e.g., hepatic uptake, 
biliary excretion). 
One of the novel findings of the PBPK modeling approach was the proposed extrahepatic distribution 
of MEB.  An outstanding question from this clinical study is the identity of the extrahepatic site(s) of 
MEB distribution, which accounted for approximately 10-40% of the administered dose at 180 min.  
MEB activity was confined to the liver and gallbladder in scintigraphic imaging data, thereby excluding 
other tissues and organs within the gamma camera field-of-view as potential sites of distribution, 
including the bulk of the torso and resident organ systems.  Interestingly, parallel changes in the hepatic 
and extrahepatic compartments (impaired uptake and enhanced efflux) were required to explain altered 
MEB disposition following pre-treatment with 2x300 mg RTV.  This suggested that similar mechanisms 
may mediate hepatic and extrahepatic MEB distribution.  Human skeletal muscle has been shown to 
express a number of uptake and efflux transport proteins involved in drug disposition, including OAT1, 
OAT3, OATP2B1 and MRP1, -4 and -5 (33; 34).  The presence of transport proteins, in particular 
OATP2B1, may play a role in accumulation of MEB in muscle tissue.  In addition, the large relative 
volume of muscle tissue (~40% body weight) makes muscle a plausible target tissue for distribution.  
However, further studies are required to confirm that muscle or other tissue(s) account for the 
extrahepatic distribution of MEB.  Whole-body gamma scintigraphic imaging of animal models (rat or 
mouse) and/or tissue collection and analysis would be a logical place to start with respect to identifying 
the potential extraheptic site(s) of MEB distribution.   
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Determination of Intracellular Unbound Concentrations and Subcellular Localization of Drugs in 
Rat Sandwich-Cultured Hepatocytes Compared to Liver Tissue (Chapter 3) 
The methods applied in Aim 1 to estimate the intracellular unbound concentration of RTV in 
human SCH were further developed in Aim 2 using rat SCH and whole liver tissue.  A set of probe drugs 
with diverse mechanisms of hepatocellular accumulation and disposition were employed.  In addition to 
RTV and RSV, which have been described above, these studies evaluated furamidine, which is formed in 
the liver from the prodrug, pafuramidine, via sequential metabolism.  Furamidine is excreted from 
hepatocytes into the systemic circulation to exert antiparasitic activity(35).  This set of drugs provided a 
diverse range of tissue accumulation, hepatic unbound fraction (fu), subcellular distribution, and ratio of 
intracellular and extracellular unbound concentration (Kpu,u) values for comparison of methods to 
determine hepatocellular unbound concentrations (Cunbound).  A novel application of classic approaches 
used to determine whole tissue distribution (differential centrifugation, equilibrium dialysis) was 
investigated in the SCH model system.  The current work highlights the finding that total tissue 
accumulation and intracellular unbound concentration can be reasonably predicted using the SCH model.  
Importantly, the reported methods and resulting parameters, particularly the hepatic fu and Kpu,u, can be 
used to elucidate the relative contribution of active transport vs. binding/sequestration as potential 
mechanisms of hepatocellular accumulation, while providing a straightforward approach to estimate these 
parameters, which are needed for accurate in vitro-in vivo extrapolations. 
For example, the estimated intracellular Cunbound approximated the extracellular concentration of 
RTV, resulting in a Kpu,u of ~1, suggesting that binding to cellular components can explain the observed 
tissue accumulation.  Although RSV binding did account for a portion of tissue accumulation (Kppredicted 
~3-4), the majority of accumulation was due to unbound drug (Kpu,u of 8 to 11), consistent with efficient 
hepatic uptake and rate-limited efflux.  RSV was selected as a model drug that is efficiently taken up by 
OATPs, which drive accumulation of unbound drug within hepatocytes, and has an expected Kpu,u 
significantly greater than one.  In addition to extensive binding and sequestration, accumulation of 
unbound furamidine (Kpu,u) was >16-fold, suggesting permeability-limited efflux of this charged 
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metabolite formed in the hepatocyte.  It remains to be seen whether the similarity between predicted Kp, 
Kpu,u and Cunbound values generated in SCH and whole liver tissue for these probe drugs would be observed 
for additional drugs that exhibit a  wide range of physicochemical properties. 
Subcellular fractionation has not been reported previously in SCH.  Although isolation of 
subcellular fractions consisting of membrane-bound organelles proved challenging in SCH, cell lysis, 
release and isolation of soluble cytosolic proteins and contents was successful.  Enzyme markers of 
subcellular components were recovered primarily in the initial, low-speed centrifugation step from SCH 
lysates, indicating that these organelles were retained in large, dense conglomerates.  This limitation may 
provide an advantage for rapid isolation of the cytosolic fraction in SCH.  These data suggest that a 
single, low-speed (600xg) spin, which can be performed on any benchtop microcentrifuge, will reliably 
exclude cellular organelles from the resulting supernatant of SCH lysate.  This single-step method has the 
additional advantage of minimizing potential redistribution of drugs during multiple centrifugation steps 
and associated dilutions.  Although the specific site(s) of subcellular sequestration would remain 
unknown, extensive distribution/recovery of drug in the pellet would indicate the need to consider 
intracellular pharmacokinetics.   
One postulated reason for difficulty in isolating subcellular fractions in SCH may be the collagen 
matrix, which may prevent dissociation of the plasma membrane required to release larger, membrane-
bound organelles.  This could be tested by treating the collected (scraped) SCH cell pellet with 
collagenase prior to lysis, followed bydifferential centrifugation.  While this approach may allow 
successful separation of subcellular fractions, the utility following drug treatment may be limited.  
Treated SCH are washed and kept on ice for subsequent handling (lysis, fractionation) in part to minimize 
transport, metabolism and other potential mechanisms of altered cellular distribution.  However, 
collagenase treatment would require an incubation period at elevated temperatures under which these 
processes would again become active, likely resulting in an undesired redistribution of drugs. 
Given the challenge in isolating subcellular fractions in SCH, another direction for future work is 
to investigate mechanisms of hepatocellular accumulation and localization in SCH using techniques other 
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than differential centrifugation.  For example, the sequestration of cationic drugs in lysosomes vs. 
mitochondria is an area of considerable interest in drug discovery.   Cationic drug accumulation is 
commonly attributed to ion trapping due to the lysosomal pH and/or mitochondrial electrochemical 
gradients(36-41).  While it is true that physicochemical properties are predictive of cationic 
sequestration/accumulation to a certain extent(36; 41), even advanced pharmacophore models often fail to 
successfully predict drug sequestration over diverse chemical space within a single organelle (lysosomes 
or mitochondria), let alone mitochondrial versus lysosomal(36-38; 40; 41).  Therefore, empiric 
experimental methods are still needed to predict and explain subcellular distribution and related 
implications for drug safety, efficacy and disposition. 
This could be explored using a method analogous to the B-CLEAR® technology, where the 
presence and absence of Ca2+ in the incubation buffer is used to evaluate the difference between 
accumulation in cells+bile and cells, respectively.  Similarly, one could use chemicals that are known to 
abolish the pH gradient in lysosomes and/or the electrochemical gradient in mitochondria.  Examples of 
compounds that abolish the lysosomal pH gradient include ammonium chloride, concanamycin A and 
monensin(39; 41), while uncoupling agents that disrupt the inner mitochondrial membrane 
electrochemical potential include 2,4-dinitrophenol and FCCP (carbonylcyanide-p-
trifluoromethoxyphenylhydrazone) (41).  Experiments might involve pre-incubating SCH in the presence 
and absence of the modulating agent, followed by incubation with the compound of interest.  The 
difference in cellular accumulation at steady-state in the presence and absence of the lysosomal or 
mitochondrial modulator would indicate the extent of accumulation that can be attributed to the organelle 
or mechanism(s) being modulated.  This should be performed ideally under conditions in which the tight 
junctions have been disrupted (-Ca2+ conditions) so that only cellular content/accumulation is being 
evaluated.  However, caution should be exercised in modulating mitochondrial electrochemical or 
lysosomal pH gradients.  Care should be taken to carefully evaluate and characterize the SCH system 
under these conditions, including measures of cell viability (e.g., LDH) and function (e.g., prototypical 
transport substrates such as taurocholate and/or rosuvastatin).   
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Similarly, subcellular disposition of anionic drugs might be explored with respect to 
accumulation and transport within the vesicle network.  As integral membrane proteins, transporters are 
inserted immediately upon synthesis (under normal circumstances), and transferred to the plasma 
membrane through dynamic and complex vesicle trafficking pathways(42-46).  Similarly, plasma 
membrane regions and their contents are continuously cycled on and off the membrane, leading to 
intracellular pools of transporter-containing vesicles(47; 48).  As a result, substrates for efflux 
transporters constantly are accumulating within these vesicles.  This has been shown with fluorescent 
substrates, where characteristic punctate vesicular structures have been observed that are absent in Mrp2-
deficient cells and sensitive to known MRP2 inhibitors, such as cyclosporine A(47; 49; 50).  This 
pathway has been shown for a number of substrates, including taurocholate(48; 51).  Vesicle trafficking 
in hepatocytes is known to be altered by a number of disease states (including TR- rat liver as a model of 
Dubin-Johnson syndrome in humans) and drugs (e.g., monensin, colchicine, taurocholate) by both 
cytoskeletal-(actin/myosin) dependent and independent mechanisms(47; 51-56).  Vesicle trafficking also 
may play a role in taurocholate disposition in rat SCH(57).  Our ability to ascertain the contribution of the 
vesicle trafficking process and subcellular space to total cellular drug content and excretion may improve 
our understanding and prediction of drug interactions.  For example, the observed biliary excretion rate 
may be a combination of terminal release (efflux) of accumulated drug from fusion of subapical vesicles 
with the canalicular membrane and direct transporter-mediated efflux across the canalicular 
membrane(47; 56).  Vesicular fusion and direct transporter flux may occur at very different rates across 
the canalicular membrane.  One could modulate this pathway in SCH using known inhibitors of the 
vesicle trafficking process, such as monensin or colchicine.  Again, care must be taken to characterize the 
SCH system under these conditions.  Visual techniques such as microscopy using fluorescent compounds 
such as carboxydichlorofluorescein diacetate (CDFDA), bile acid derivatives (e.g., CGamF) or other 
compounds also may be effective in determining the potential for these types of modulatory effects in 
SCH. 
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Basolateral Efflux Contributes Significantly to the Hepatocellular Excretion of Rosuvastatin: 
Characterization of Basolateral vs. Biliary Clearance Using a Novel Protocol in Rat and Human 
Sandwich-Cultured Hepatocytes (Chapter 4) 
Transport proteins mediating the hepatic uptake and biliary excretion of RSV have been fairly 
well-characterized(14-20).  Less well-known is the role of basolateral efflux of RSV from hepatocytes 
back into sinusoidal blood.  Wild-type (WT) and Mrp2-deficient (TR-) rat livers were perfused in a 
single-pass manner with RSV in the presence and absence of the dual P-gp/Bcrp inhibitor, GF120918 
(elacridar), for a 60-min loading phase, followed by a 30-min washout phase to determine the degree of 
basolateral and biliary efflux of RSV; a pharmacokinetic model was fit to the resulting data.  As expected, 
the biliary clearance (CLBile) of RSV was reduced in TR- compared to WT livers, and GF120918 further 
reduced CLBile and biliary recovery in TR- livers.  Interestingly, the appearance rate of RSV in outflow 
perfusate and the resulting basolateral clearance (CLBL) estimate were reduced by GF120918 in WT 
livers, and also in TR- compared to WT livers.  These data, along with the lack of an immediate drop-off 
in RSV perfusate concentrations upon switching from the loading to the efflux phase, indicated that RSV 
is almost completely taken up by hepatocytes and that appearance of RSV in outflow perfusate is due 
almost exclusively to basolateral efflux.  In fact, modeling results suggested that CLBL and CLBile 
represent alternative pathways with a similar contribution to the total hepatocellular excretion of RSV.  
This is a novel finding, and suggests that hepatic exposure of RSV is unlikely to be elevated greatly in the 
setting of impaired biliary efflux, unless basolateral efflux is also impaired.  Serendipitously, data in TR- 
livers appeared to represent the case of impaired basolateral and biliary efflux, resulting in significantly 
elevated (~4-fold) hepatic exposure of RSV.  In addition to RSV, hepatic concentrations and recovery of 
the pentanoic acid metabolite of RSV were significantly greater (>5-fold) in TR- compared to WT livers.   
Although RSV is not reported to be extensively metabolized in humans(58), metabolism plays a 
larger role in rats, with ~50% of plasma and liver content accounted for by metabolites.(14; 59)  These 
studies confirmed the presence of RSV pentanoic acid as the primary metabolite, contributing ~40% of 
total RSV content in both WT and TR- livers, consistent with previous reports(14; 59).  This is the first 
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study to corroborate the structural identity of the pentanoic acid metabolite of RSV by mass spectrometry; 
previous reports suggested the identity of the metabolite by thin-layer chromatography of the pure 
standard co-spotted with blood, liver and bile samples from rats administered radiolabeled RSV.  
Increased hepatic accumulation of RSV and the pentanoic acid metabolite in TR- compared to WT livers 
was consistent with impaired excretion and “shunting” to the metabolic pathway(s).   
A novel uptake and efflux protocol, coupled with pharmacokinetic modeling, was developed in 
order to elucidate the relative contribution of CLBL and CLBile to the hepatocellular elimination of the 
model drug, RSV, in the SCH model.  Although several strategies using the SCH model have been 
published to assess efflux by preloading the cells and quantifying substrate in cells+bile, cells, and/or 
buffer during an efflux phase(5; 18), the system remains poorly characterized under these conditions.  A 
major contribution of the present work was to characterize the behavior of the SCH system under various 
uptake/efflux scenarios and differentiate the contributions of CLBL and CLBile from flux out of bile spaces 
(KFlux) in the presence of Ca2+ (cells+bile) (60-64) using a modeling approach.  Based on this approach, 
RSV disposition in rat SCH was in agreement with perfused liver data, demonstrating that CLBL and 
CLBile represent alternative pathways with a quantitatively similar contribution to total hepatocellular 
excretion of RSV.   
In order to translate the relevance of these findings from rat to humans, RSV transport was 
evaluated in human SCH and membrane vesicles prepared from HEK293 cells overexpressing human 
MRP3 and MRP4.  Results of these studies revealed, for the first time, that RSV is an inhibitor of MRP3 
and MRP4, and an efficient substrate of MRP4 (Km = 21±7 µM), which likely contributes to the 
basolateral efflux of RSV from hepatocytes in humans.  A pilot study in human SCH using the novel 
uptake/efflux protocol, coupled with pharmacokinetic modeling, revealed that, as in rats, CLBL and CLBile 
represent alternative pathways for hepatocellular excretion of RSV; in human SCH, CLBL was nearly 2-
fold CLBile. 
One limitation of the novel uptake/efflux protocol and pharmacokinetic modeling approach is that 
the resulting parameter estimates for sinusoidal uptake and efflux clearance represent net uptake and 
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efflux, respectively.  Addition of a passive diffusion term to the current model scheme results in 
parameter identifiability/covariance issues without additional experimental conditions under which active 
transport processes are rendered inoperable.  While no conditions exist that are ideal for isolating the 
passive diffusion component of transporter substrates, this is an area that may explored in the future.  The 
best possible approach may be to coadminister one or more inhibitors of transport mechanisms (e.g., 
rifamycin, rifampicin, CsA).  Other approaches, such as ATP depletion and incubations on ice, are less 
attractive due to limitations including compromised cell viability (ATP depletion) and temperature effects 
on non-specific binding(65-67), membrane fluidity and partitioning(68-70). 
Evidence of the role of transport in the basolateral efflux pathway of RSV can be strengthened by 
demonstrating that modulation of basolateral efflux results in altered hepatic and/or systemic exposure of 
drugs.  Recent efforts in the Brouwer lab have included screening drugs for inhibitory potential against 
MRP4(71).  One of the identified, potent inhibitors could be coadministered with RSV in SCH and/or 
IPLs to demonstrate the effect of a known MRP4 inhibitor on hepatobiliary disposition of RSV.  
However, the impact of an MRP4 inhibitor on overall cellular exposure would depend on the relative 
contribution of the impaired pathway to total excretory clearance (CLBL+CLBile).  For RSV, you would 
need to impair Mrp2 & Bcrp in addition to Mrp4 in order to detect a change in cellular exposure in rat 
SCH, since CLBile represents approximately one-half of total efflux clearance based on the data generated 
in this dissertation research.  Inhibition of Mrp4 alone would not be expected to result in significant 
alterations in cellular exposure, because the MRP4-mediated portion of total excretory clearance is 
approximately one-fourth of total efflux clearance.  Kynuremic acid recently was reported as a potent 
substrate and inhibitor of BCRP and MRP4 using membrane vesicle systems(72).  This would seem to be 
an ideal compound to coadminister with RSV, similar to the current work that used GF120918 as an 
inhibitor of BCRP and P-gp.  One caveat is that kynuremic acid must be able to enter the hepatocyte in 
order to inhibit efflux mechanisms.  While this compound is likely a substrate for OAT2 and/or OATPs, 
the uptake/accumulation of kynuremic acid would need to be verified in hepatocytes.  Even though it 
might inhibit hepatic uptake, the novel uptake/efflux protocol and modeling approach developed in this 
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aim should be able to deconvolute the resulting SCH data successfully.  Finally, kynuremic acid is highly 
bound to plasma proteins, so it may bind extensively to cellular components; preliminary experiments 
such as those developed in Aim 2 should be conducted to determine the feasibility of this inhibitor based 
on the intracellular Cunbound that is determined to inhibit hepatocellular efflux processes. 
 
This dissertation focused on two general themes involving hepatobiliary drug disposition: 
hepatocellular exposure and multiplicity of transport.  MEB, RTV and RSV were characterized further as 
probes with respect to their hepatocellular exposure and interaction with multiple hepatic transport 
proteins.  This research has resulted in a number of important and novel contributions that have advanced 
both preclinical and clinical (translational) tools available to study hepatic drug transport.  These 
developments will significantly enhance the ability to assess and predict altered hepatobiliary drug 
disposition due to drug interactions, disease states, or other patient-specific factors, and will ultimately 
lead to improved safety and efficacy of medications. 
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Figure 2.5 
A.   
Ritaonvir 
Dose (µM) 
MEB Accumulation (%Control) 
+Ca -Ca 
Mean SEM Mean SEM 
0 (Control) 100  74.4 4.1 
0.05 99.1 8.6 73.1 1.0 
0.1 99.7 8.9 72.8 3.9 
0.5 91.2 13.4 67.0 5.6 
1 83.1 17.8 64.1 13.3 
5 37.2 3.5 29.2 2.4 
20 17.4 3.7 14.8 7.0 
 
B.   
Ritonavir 
Dose (µM) 
ATP-Dependent Uptake  
(Ccell,total, µM) 
Mean SD 
0.05 0.288 0.186 
0.1 0.481 0.359 
0.5 3.26 2.14 
1 7.31 2.88 
5 42.7 28.7 
20 87.8 34.0 
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Figure 3.2 
A.  Whole Liver Tissue   
 Enzyme Activity (% Total in Whole Lysate) 
Centrifugation 
Step (x g) 
Succinate 
Dehydrogenase Acid Phosphatase 
Glucose-6-
Phosphatase 
Lactate  
Dehydrogenase 
 Mean SD Mean SD Mean SD Mean SD 
600 19 8 5.7 1.1 11 8 5.6 0.8 
10,000  39 13 14 4 18 1 4.5 4.2 
35,000  20 10 16 8 11 1 8.8 7.5 
100,000  11 11 19 8 51 15 8.6 2.6 
super  12 10 45 3 9.6 6.7 72 6 
 
B.  Sandwich-cultured Hepatocytes (SCH) 
 Enzyme Activity (% Total in Whole Lysate) 
 Succinate 
Dehydrogenase Acid Phosphatase 
Glucose-6-
Phosphatase 
Lactate  
Dehydrogenase 
 Mean SD Mean SD Mean SD Mean SD 
600 82 8 51 9 76 6 3.4 1.5 
10,000  11 5 8.1 2.2 11 6 2.1 1.0 
100,000  5.9 5.4 3.9 1.8 4.4 3.2 3.7 1.1 
super  1.2 1.7 36 7 9.0 5.5 91 3 
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Figure 3.3   
IPL: 
 Recovery of Probe Drug (% Total in Whole Lysate) 
Centrifugation 
Step (x g) Ritonavir Rosuvastatin Furamidine 
600 19 7.3 18 
10,000  39 11 43 
35,000  20 2.1 15 
100,000  11 7.9 4 
super  12 72 20 
 
SCH: 
 Recovery of Probe Drug (% Total in Whole Lysate) 
Centrifugation 
Step (x g) Ritonavir Rosuvastatin Furamidine 
 Mean SD Mean SD Mean SD 
600 45 8 8.3 0.5 85 1 
10,000  5.3 5.2 2.8 0.3 7.3 1.4 
100,000  6.5 3.6 1.0 0.1 4.9 1.6 
super  43 8 88 1 2.9 0.9 
 
 
 
 
 
 
 
Figure 4.4   
0.1 µM [3H]Rosuvastatin, WT (Control) 
 [3H]Rosuvastatin Accumulation (pmol/well) 
Lysate Buffer 
Study 
Phase 
Time (min) +Ca2+ -Ca2+ +Ca2+ -Ca2+ 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2 1.36 0.26 1.04 0.23     
5 5 2.59 0.31 1.43 0.13     
10 10 4.13 0.80 1.62 0.10     
20 20 6.06 1.25 1.87 0.36     
Efflux 
2 23.5 4.66 0.49 0.77 0.13 0.99 0.41 0.83 0.23 
5  26.5 4.24 0.59 0.38 0.17 1.82 0.64 1.31 0.49 
10  31.5 3.03 0.59 0.11 0.04 2.83 0.69 1.57 0.37 
15  36.5 2.66 0.32 0.07 0.07 3.60 1.32 1.74 0.73 
 
1 µM [3H]Rosuvastatin, WT (Control) 
 [3H]Rosuvastatin Accumulation (pmol/well) 
Lysate Buffer 
Study 
Phase 
Time (min) +Ca2+ -Ca2+ +Ca2+ -Ca2+ 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2 12.49 1.89 8.55 1.38     
5 5 21.87 2.58 13.24 1.65     
10 10 30.51 3.59 15.12 2.51     
20 20 43.05 4.24 18.29 2.38     
Efflux 
2 23.5 35.75 6.85 7.59 1.86 7.68 0.93 7.07 0.85 
5  26.5 29.59 5.92 4.00 1.69 14.73 3.27 11.42 2.15 
10  31.5 23.46 5.87 1.56 1.27 23.67 5.99 15.09 3.21 
15  36.5 21.46 4.28 0.47 0.47 28.58 9.01 14.09 2.81 
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0.1 µM [3H]Rosuvastatin, WT (+GF120918) 
 [3H]Rosuvastatin Accumulation (pmol/well) 
Lysate Buffer 
Study 
Phase 
Time (min) +Ca2+ -Ca2+ +Ca2+ -Ca2+ 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2 1.21  1.35      
5 5 2.29  2.02      
10 10 3.48  2.65      
20 20 4.99  3.27      
Efflux 
2 23.5 3.21  1.71  0.64  0.53  
5  26.5 2.92  1.30  1.23  1.01  
10  31.5 1.75  0.53  2.01  1.52  
15  36.5 1.66  0.36  2.48  1.84  
 
1 µM [3H]Rosuvastatin, WT (+GF120918) 
 [3H]Rosuvastatin Accumulation (pmol/well) 
Lysate Buffer 
Study 
Phase 
Time (min) +Ca2+ -Ca2+ +Ca2+ -Ca2+ 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2              
5 5 19.98 2.59 15.57 1.72     
10 10 29.03 6.17 19.55 4.03     
20 20 42.85 6.55 27.25 6.16     
Efflux 
2 23.5 32.95 8.87 13.96 2.91 7.91 0.87 7.68 1.04 
5  26.5 28.73 6.91 10.91 1.57 14.34 1.88 12.92 1.93 
10  31.5 20.43 6.98 5.33 1.86 23.03 3.63 18.94 2.99 
15  36.5         
 
 
  
 
 
0.1 µM [3H]Rosuvastatin, TR- (Control) 
 [3H]Rosuvastatin Accumulation (pmol/well) 
Lysate Buffer 
Study 
Phase 
Time (min) +Ca2+ -Ca2+ +Ca2+ -Ca2+ 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2 0.87 0.35 0.85 0.29     
5 5 1.43 0.45 1.14 0.32     
10 10 2.15 1.08 1.38 0.53     
20 20 2.26 0.86 1.33 0.47     
Efflux 
2 23.5 1.59 1.15 0.55 0.44 0.92 0.10 0.62 0.16 
5  26.5 1.10 0.78 0.29 0.22 1.24 0.32 0.84 0.35 
10  31.5 0.48 0.25 0.13 0.10 1.52 0.26 1.09 0.19 
15  36.5 0.38 0.30 0.07 0.08 1.83 0.45 1.19 0.37 
 
1 µM [3H]Rosuvastatin, TR- (Control) 
 [3H]Rosuvastatin Accumulation (pmol/well) 
Lysate Buffer 
Study 
Phase 
Time (min) +Ca2+ -Ca2+ +Ca2+ -Ca2+ 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2 6.69 2.20 6.33 1.94     
5 5 10.34 3.55 8.65 3.08     
10 10 16.47 7.39 10.99 5.54     
20 20 18.00 7.56 11.08 4.70     
Efflux 
2 23.5 11.23 5.65 3.54 2.22 5.72 1.99 3.86 1.71 
5  26.5 7.60 4.26 1.94 1.41 8.96 3.25 6.34 3.24 
10  31.5 5.36 3.90 0.88 0.79 12.52 5.90 7.40 3.89 
15  36.5 3.90 2.55 0.46 0.47 14.86 5.85 8.80 4.81 
 
 
  
 
 
0.1 µM [3H]Rosuvastatin, TR- (+GF120918) 
 [3H]Rosuvastatin Accumulation (pmol/well) 
Lysate Buffer 
Study 
Phase 
Time (min) +Ca2+ -Ca2+ +Ca2+ -Ca2+ 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2 0.84 0.31 0.90 0.37     
5 5 1.25 0.56 1.27 0.55     
10 10 1.91 1.01 1.74 0.88     
20 20 2.18 1.23 1.88 1.07     
Efflux 
2 23.5 1.36 1.09 0.93 0.61 0.83 0.19 0.72 0.11 
5  26.5 0.98 0.76 0.64 0.39 1.19 0.16 1.04 0.20 
10  31.5 0.68 0.70 0.42 0.38 1.70 0.37 1.46 0.33 
15  36.5 0.26 0.17 0.18 0.13 1.56 0.38 1.59 0.20 
 
1 µM [3H]Rosuvastatin, TR- (+GF120918) 
 [3H]Rosuvastatin Accumulation (pmol/well) 
Lysate Buffer 
Study 
Phase 
Time (min) +Ca2+ -Ca2+ +Ca2+ -Ca2+ 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2 6.98 2.53 7.08 2.62     
5 5 9.92 3.75 9.27 3.10     
10 10 14.94 7.34 13.38 6.06     
20 20 19.54 11.21 15.67 9.08     
Efflux 
2 23.5 12.39 9.23 7.43 4.62 5.68 1.56 5.90 1.36 
5  26.5 9.79 8.86 5.75 4.50 9.38 2.81 8.66 2.77 
10  31.5 5.49 6.04 2.46 2.46 12.48 5.93 10.04 4.36 
15  36.5 4.09 5.06 1.83 2.00 14.12 6.77 12.18 6.44 
 
 
  
 
 
Figure 4.5   
1 µM [3H]Rosuvastatin, human SCH 
 [3H]Rosuvastatin Accumulation (pmol/well) 
Lysate Buffer 
Study 
Phase 
Time (min) +Ca2+ -Ca2+ +Ca2+ -Ca2+ 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2 4.58 2.89 3.23 3.18     
5 5 8.28 2.29 5.67 2.15     
10 10 11.49 2.69 8.41 3.06     
20 20 15.05 3.31 10.20 1.44     
Efflux 
5 26.5 7.55 1.78 5.34 1.98 3.34 0.24 1.97 0.44 
10  31.5 4.77 1.31 2.27 1.45 5.24 0.43 3.37 0.52 
15  36.5 4.21 1.38 1.29 0.84 6.71 0.44 4.35 0.99 
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Figure 4.6   
Wild-Type (WT) 
 Rosuvastatin Appearance Rate (nmol/min) 
 Bile Perfusate 
Time 
(min) 
Control +GF120918 Control +GF120918 
Mean SD Mean SD Mean SD Mean SD 
5-15 4.15 1.00 5.60 2.80 4.22 0.98 2.40 1.87 
15-30  8.40 1.91 12.2 4.6 6.98 0.86 2.79 1.75 
30-45  11.2 2.6 14.3 3.3 6.11 1.73 3.24 1.83 
45-60  11.3 4.3 13.8 4.2 6.16 2.18 3.36 1.94 
60-70  16.1 9.9 14.4 2.6 4.60 1.92 2.17 1.21 
70-75  4.92 1.75 6.14 3.54 2.87 1.43 1.39 0.86 
75-80  2.44 0.96 4.75 1.60 2.45 1.59 1.06 0.68 
80-90  1.65 0.69 2.68 0.74 1.52 1.18 0.627 0.333 
 
Mrp2-Deficient (TR-) 
 Rosuvastatin Appearance Rate (nmol/min) 
 Bile Perfusate 
Time 
(min) 
Control +GF120918 Control +GF120918 
Mean SD Mean SD Mean SD Mean SD 
5-15 1.20 1.53 0.559 0.437 0.471 0.349 0.346 0.196 
15-30  5.17 1.30 1.42 0.49 1.20 0.75 1.41 0.92 
30-45  5.86 1.28 1.67 0.71 2.05 1.01 1.78 0.44 
45-60  5.92 1.16 1.63 0.52 2.78 1.23 3.05 0.84 
60-70  6.44 0.59 1.82 0.55 2.60 0.96 2.93 0.67 
70-75  4.05 1.28 1.25 0.33 2.43 1.05 2.66 0.29 
75-80  3.58 1.12 0.979 0.392 2.02 0.48 2.58 0.41 
80-90  2.92 1.14 0.743 0.473 1.52 0.37 1.91 0.48 
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Figure 4.7   
 Recovery (% Administered Dose) 
WT (Control) WT +GF120918 TR- (Control) TR- +GF120918 
Mean SD Mean SD Mean SD Mean SD 
Rosuvastatin: 
Perfusate 34.1 8.4 16.3 9.8 14.3 4.7 16.5 6.3 
Liver  4.9 4.2 6.5 2.0 20.2 9.2 29.0 5.4 
Bile  57.1 20.2 65.0 17.3 36.7 11.4 10.4 2.9 
Total  96.2 9.4 93.7 12.6 71.1 3.9 55.9 6.9 
Rosuvastatin Pentanoic Acid: 
Liver, Total  2.1 0.6 3.3 2.0 13.3 6.1 18.7 5.3 
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Figure 4.8 
A.  20 μM [3H]E217G 
 ATP-Dependent Uptake  
(% MRP Control) 
 Mean SD 
Non-Transfected (NT) 22.6 3.2 
Control (MRP3) 100 9.8 
+50 µM RSV 24.2 2.0 
+50 µM MK-571 1.9 2.1 
 
B.  2 μM [3H]DHEAS 
 ATP-Dependent Uptake  
(% MRP Control) 
 Mean SD 
Non-Transfected (NT) 12.2 4.7 
Control (MRP4) 100 4.0 
+50 µM RSV 12.4 4.6 
+50 µM MK-571 -5.3 2.7 
 
C.  Time-dependent transport of [3H]Rosuvastatin 
 ATP-Dependent [3H]Rosuvastatin Uptake (pmol/mg P) 
Time 
(min) 
Non-Transfected (NT) MRP3 MRP4 
Mean SD Mean SD Mean SD 
0.5 0.150 0.042 0.255 0.086 1.00 0.15 
1 0.285 0.075 0.566 0.032 1.50 0.09 
2 0.294 0.092 0.823 0.018 1.68 0.11 
5 0.342 0.084 0.999 0.153 1.87 0.10 
 
D.  Concentration-dependent transport of [3H]Rosuvastatin 
 MRP4-Dependent Uptake  
(pmol/min/mg P) 
[3H]Rosvustatin 
Concentration 
(µM) 
Mean SD 
1 49 1 
5 203 12 
10 379 23 
20 577 55 
50 786 174 
 
